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Abstract  
The profiling of hormones is an important requirement in sports dope testing and it is 
increasingly being used for clinical applications. The screening of samples for the detection 
of steroids is usually undertaken in urine and these analyses present many challenges. 
Issues related to the complexity of the matrix, the separation of exogenous from 
endogenous species and the very low detection limits have placed increasing demands on 
clinical and International Olympic Commission accredited laboratories. Whilst liquid 
chromatography (LC) systems provide a highly sensitive detection method for targeted 
species, gas chromatography, especially when coupled to mass spectrometry, is considered 
preferable for the screening of a wider range of target and unknown species. Existing 
chromatography methods are not without their limitations, not least the difficulty in 
reproducibly derivatising the wide range of steroids that can be exogenously administered, 
in particular the so called ‘designer steroids’ which deliberately hinder this process.   
Initially, a pilot study was conducted to investigate whether aptamer-coated magnetic beads 
could provide a simple, low cost method for the extraction of estradiol from urine, prior to 
its detection and quantification with mass spectrometry.  In reality, the process necessitated 
the use of additional solvent extraction steps to the standard method applied previously.  
These additional steps added complexity and were not without issue and the limit of 
detection was not found to be adequate for the proposed clinical purpose.  
The project explored the application of comprehensive gas chromatography/mass 
spectrometry (GC x GC/MS) coupled to bespoke molecular imprinted polymers (MIPS) as 
an alternative solution to the problem of the screening of multiple steroids in urine. Twelve 
structurally similar and commercially relevant steroids were used to develop the 
chromatographic method. Once optimised, these compounds were then extracted from 
synthetic urine using a MIP templated with testosterone and developed during the project.  
Significant improvements compared to commercially available C-18 materials were found. 
All the steroids were identified and detected when spiked at the 10 ng/ml level, as required 
by World Anti-Doping Agency (WADA) at the time. The method was further validated and 
then successfully applied to the extraction of designer steroids from synthetic urine, in the 
presence of the original steroids. Epistane, which has a different structure to testosterone, 
was not detected indicating the efficacy of the templating process.  
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Nomenclature 
1D  one dimension 
2D  two dimensions 
1D-GC one dimensional gas chromatography 
g  micrograms 
L  microlitre 
13C  carbon isotopic composition 
AAS  androgenic anabolic steroid 
AE  appearance energy 
APCI  atmospheric pressure chemical ionisation 
CI  chemical ionisation 
CRM  charge residue model 
Da  Dalton 
eV  electron volt 
EI  electron ionisation 
ELISA  enzyme-linked immuno sorbent assay 
ESI  electrospray ionisation 
FID  flame ionisation detector 
FIFA        Fédération Internationale de Football Association 
fg  femtogram 
GC  gas chromatography 
GCxGC two-dimensional gas chromatography 
GC-C-IRMS gas chromatography-combustion-isotope ratio mass spectrometry 
GC-FID gas chromatography-flame ionisation detector 
GLC  gas-liquid chromatography 
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HPLC  high performance liquid chromatography 
hr             hour 
i.d.  internal diameter 
IEM  ion evaporation model 
IRMS  isotope ratio mass spectrometer 
kV  kilovolts 
L  litre 
LC-MS liquid chromatography-mass spectrometry 
LLE  liquid-liquid extraction 
LOD  limit of detection 
LOQ  limit of quantitation 
m  metre 
min  minute(s) 
m/z  mass to charge ratio 
MALDI matrix assisted laser desorption ionisation 
mg  milligram 
mL  millilitre 
mm  millimetre 
ms  millisecond 
MS  mass spectrometer 
MS/MS tandem mass spectrometry or mass transition 
ng  nanogram 
NIST  National Institute of Standards and Technology 
PDB  Pee Dee Belemnite 
pg  picogram 
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PTV  programmable temperature vaporisation 
SELEX systematic evolution of ligands by exponential enrichment 
SIM  selective ion monitoring 
s/n  signal to noise  
SPE  solid phase extraction 
SRM  selected reaction monitoring 
TMS  trimethylsilyl 
UHP  ultra high purity 
UPLC  ultra performance liquid chromatography 
VPDB  Vienna Pee Dee Belemnite 
WADA World Anti-Doping Agency 
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1. Introduction 
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1.1. Background: A brief history of sports testing 
Sport, in all its forms, tends to bring out the competitive nature in men and women. For 
some athletes the desire to beat the competition, for the financial or social benefits resulting 
from success, can result in them using artificial means to enhance their performance.
1
 
The testing of human athletes for drug abuse began in the 1950s, when the widespread use 
of amphetamine first became evident. However, it was not until the death of two cyclists, 
one in the 1960 Rome Olympic Games and the other in the 1967 Tour de France, that 
things began to accelerate.
2 
Experimental testing procedures were first employed in the 
1968 Mexico City Olympic Games and official testing began at the 1972 Munich Olympic 
Games, where gas chromatography (GC) was first used with nitrogen–selective detection. 
Gas chromatography/mass spectrometry (GC/MS) was first employed at the 1976 Montreal 
Olympic Games and has been the main diagnostic method used since.
3 
Anabolic agents are the most common performance enhancing substances detected in 
athletes.
4
 The International Olympic Committee (IOC) banned the use of anabolic steroids 
in April 1974 and the World Anti-Doping Agency (WADA) was set up in 1999 with a view 
that two of its key activities should include the development of anti-doping capabilities and 
the monitoring of the World Anti-Doping Code - a document harmonizing anti-doping 
policies in all sports and all countries.
5 
By 2007, 223,898 samples were analysed by 33 
WADA accredited laboratories worldwide; there were 4,402 Total Findings (Adverse 
Analytical Findings and Atypical Findings), of which 2,269 were for the use of anabolic 
steroids.
6 
By 2011, this had increased slightly to 4,856 Total Findings from 243,193 
samples. Anabolic agents accounted for 59.4 % of the prohibited substances identified in 
reported findings.
7
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The number of drug tests conducted between 2005 and 2012 increased by 84,317; whilst, 
the percentage of adverse analytical finding has remained consistent between 1.1 to 2.0 %. 
The reported adverse analytical findings for anabolic steroids between 2005 and 2012 
ranged from 715 to 1038. These figures show that the increasing number of doping tests 
has not resulted in a significant increase in the number of adverse analytical findings, 
suggesting the current WADA methods have limitations. These include the detection of 
athletes using AAS on a low-dose and the differing metabolic profiles of the tested 
individuals making their detection difficult. Such limitations may result in undetected 
doping samples in both in-competition and out-of-competition doping control 
programmes.
8,9
 
The field of sports testing is always changing with new synthetic anabolic agents being 
developed and applied. Given the large range in anabolic agents available, their structural 
similarities and the fact that trace level analyses are being performed in complex matrices, 
it is not surprising that no single analytical solution or technology has been developed, or is 
likely to be developed, that is capable of screening all anabolic agents. It is proposed in this 
thesis that comprehensive chromatography coupled to time-of-flight mass spectrometry and 
an updated sampling technique will provide an additional tool to the analysts, which could 
be used to improve the analysis and screening of steroids contaminants.   
1.1.1.   Anabolic androgenic steroids (AAS)    
Anabolic androgenic steroids (AAS) are compounds that have the fused-ring structure of 
steroids and generate anabolic and androgen effects similar to those of testosterone. The 
anabolic effects of androgens include: accelerated growth of muscle, bone density, and red 
blood cells. The androgenic effects include changes in sexual characteristics, such as: 
4 
 
maturation of the penis and testes, voice changes, hair growth on the face, and increased 
aggressiveness. Since the anabolic effect can’t be completely separated from the androgenic 
effect they are known as anabolic androgenic steroids.
10
 
Testosterone is a natural androgenic steroid hormone produced by the testis and is 
ultimately derived from cholesterol.
11
 As with all hormones, testosterone is a messenger 
molecule that travels through the body until it is either metabolised or interacts with cells 
containing androgen receptors.
 
The mechanism for the biosynthetic formation of 
testosterone from cholesterol is shown in Figure 1.1.
11
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Figure 1.1. The mechanism for the formation of testosterone and estrogens from 
cholesterol, via progestogens and androgens, with 1-6 being a series of 
enzymes. 
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As can be seen in the figure, the conversion of cholesterol to testosterone proceeds via a 
number of progestogens (21 carbons) and androgens (19 carbons). Cholesterol itself is 
derived from lanosterol which, in turn, is formed from the cyclisation of squalene. Each of 
the steps in the formation of testosterone is catalysed by a series of enzymes, including: 
17hydroxylase [1]; 17,20 lyase [2], 3-hydroxysteroid dehydrogenase (3-HSD) [3], 
17-hydroxysteroid dehydrogenase (17-HSD) [4].
11
 Testosterone, in turn, is converted to: 
(a) dihydrotestosterone (DHT) by 5-reductase [5], contributing to male pattern baldness, 
prostate growth and sebaceous gland activity; or to (b) estradiol, through aromatase 
enzymes [6]. The primary pathway for the formation of estradiol is via estrone and 4-
androstenedione.  
Synthetic AAS are structurally modified to maintain the anabolic effect while reducing the 
androgenic effect. The use of anabolic steroids was first attributed to weightlifters in 1954 
and by 1965 synthetic AAS were being used by bodybuilders and weightlifters.
12
 
AAS stimulate protein synthesis in muscles cells allowing greater lean mass.
13
 The dose of 
the anabolic steroids taken is determined by the sports and the needs of the athletes. For 
example, endurance athletes use steroids primarily for the catabolism-blocking effect which 
prevents breakdown of muscles during intense exercise.
3,12
 Sprinters administer slightly 
higher dosages because of the strength and power required in the sport. This dosage can be 
almost double the natural replacement level.
3
 However, in sports requiring athletes to bulk 
up their muscle mass, such as bodybuilding, athletes will take dosages 10 to 100 times the 
normal physiological level.
3
 A theory underlining the high dosage effect of AAS suggests 
that glucocorticoids that bind to glucocorticoid receptors are displaced by a high dosage of 
AAS resulting in an anti-catabolic effect.
14
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Anabolic steroids are often taken in cycles of 6 of 12 weeks. Athletes will traditionally take 
more than one steroid, referred to as “stacking”. Stacking allows users to activate more 
receptor sites or to achieve a synergistic effect, i.e. the presence of one steroid enhancing 
the effect of the other.
3,12,15  
Steroid users will usually begin with a lower dose, progressing 
to a higher dose, and then reducing the dosage at the end of the cycle. Athletes will also 
indulge in a number of other drugs, to counteract the side effects of the initial drug, these 
include stimulants, diuretics, anti-estrogens and anti-inflammatories.
3,15 
1.1.1.1. The structure of anabolic androgenic steroids 
The structure of AASs are based around the steran nucleus. As shown in Figure 1.2, it 
consists of three condensed cyclohexane rings (A, B and C) and a cyclopentane ring (D).  
A B
C D
 
Figure 1.2. The steran nucleus. 
A number of modifications can be made to structures including the introduction of: 
3,9,13 
 carbonyl groups,  
 hydroxyl groups,  
 double bonds,  
 other substituents (such as alkyl groups), 
 ring structure changes 
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1.1.1.2. Steroid nomenclature  
There are a number of different methods for naming steroids, one such convention is:  
 prefix and suffix indicate presence of substituent,  
 “nor” is prefix to indicate the elimination of a methyl group,  
 if there is more than one prefix then they are written in alphabetic order,  
 the position of double bonds is indicated by numeration of  the lesser carbon atom, 
 substituents below the plane are denoted as and those above the plane are denoted 
as in this thesis they are denoted as a and b, respectively.   
The numbering of the carbon atoms in steran nucleus is shown in Figure 1.3.
16
 The simplest 
steroid is gonane, which only has hydrogen attached to the seventeen carbon fused-ring 
nucleus. 
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Figure 1.3. The numbering convention for carbon atoms in the steran nucleus.
 
1.1.1.3. The biological properties of anabolic androgenic steroids 
When testosterone was isolated in 1935, it was soon realised that it was inactive when taken 
orally, as it is transported to the liver and is metabolised to an inactive form. However, a 
structural modification in testosterone has been shown to change its biological activity, 
while its androgenic and anabolic actions are also influenced.
14,15,16
 For example, the 
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androgenic effect in testosterone is mainly due to the presence of the 17b-hydroxyl group 
and according to Gower et al., the androgenic activity is completely lost by the removal of 
this group.
15
 Oxidation of the 17b-hydroxyl group can also affect the androgenic activity 
and a reduction in androgenic activity is also observed following the introduction of an 
additional double bond into Ring A.
17
   
Analysis of the structure of natural steroids has led to the synthesis of many artificial   
hormones. Structural modification of testosterone, as shown in Figure 1.4, aims to increase 
the anabolic effect, reduce the metabolism of AAS and allow a lower dosage.
15,16
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Figure 1.4. The three major types of modification of testosterone.  
As stated previously, Gower et al., showed that a Type B modification of the hydroxyl 
group in the 17-position results in complete loss of androgenic activity, whereas Type A 
modification can also affect the androgenic activity.
17
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The reduction in the metabolism rate is achieved by slowing the release of AAS from the 
muscles into the blood. Type C modification of testosterone can result in the synthesis of 
nandrolone (19-nortestosterone) which contains no methyl group in the 19-position, as 
shown in Figure 1.5.  The loss of the methyl group results in it being released into the blood 
more slowly than testosterone.
18
 
OH
O
CH3
 
Figure 1.5. The structure of nandrolone.  
1.1.1.4. The metabolism of steroids - Phase I reactions   
Steroids are rapidly metabolised and can only be detected in their original state for a short 
period of time.  The study of steroid metabolites, which remain longer in the excreted urine, 
is therefore very important in doping analysis.
15,17,19
 The metabolism of steroids may be  
divided into two phases: Phase I and Phase II.  
In Phase I reactions, the AAS are converted to more polar compounds to facilitate their 
elimination from the body. Phase I catalyzed reactions involve oxidation, reduction and 
hydroxylation of rings A, B, C and D.
20
 
In the metabolism of Ring A, the reduction of the C4-C5 double bond is catalysed by the 
5a- and the 5b-reductase, located in the liver, resulting in 5a- and 5b-isomers, as shown in 
Figure 1.6.
20,21
 The structure of the steroids ultimately determines the metabolic pathway, 
as structural modification prevents certain metabolic pathways. AAS, such as metandienone 
11 
 
do not produce 5a-isomers.
21,22
 Depending on what substituents are present in Ring A, other 
metabolites may also be formed.
20,23
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Figure 1.6. Metabolism of Ring A, catalysed by 5a- and 5b-reductase. 
 
Ring B metabolism is more pronounced in AAS that have two double bonds present in 
Ring A. The main metabolic reaction is the beta-hydroxylation at C6, as shown in Figure 
1.7.
20, 24,25
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Figure 1.7. An example of Ring B metabolism.  
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Metabolism in Ring is C is not common; however, a hydroxylation at position 12 in Ring C 
takes place for the steroid metandienone, as shown in Figure 1.8.
20,25
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Figure 1.8. An example of Ring C metabolism. 
In Ring D hydroxylation, the most common reaction is at the 17b-position. This reaction is 
catalysed by the enzyme 17b-hydroxysteroid dehydrogenase (HSD) forming a 17-keto 
steroid, as shown in Figure 1.9.
26 
However, this reaction is reversible and depends on other 
metabolic steps. Steroids containing a 17-hydroxyl group are mainly excreted as a 17-keto 
metabolite. Hydroxylation can also take place at position 16 resulting in 16a- and 16b- 
isomers. This oxidation is also shown in horses administered with stanozolol.
23
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Figure 1.9. An example of Ring D metabolism.  
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1.1.1.5. The metabolism of steroids - Phase II Reactions 
Phase II reactions involve conjugation of AAS with glucuronic acid or sulphonic acid, as 
shown in Figure 1.10. Conjugation assists the elimination of the steroids from the body in 
urine, through an increase in the hydrophilic nature of the steroid.
19
 Conjugation in the A 
ring occurs at the 3-position with the 3a-hydroxyl group conjugating with glucuronic acid, 
while the 3b-hydroxyl group conjugates with sulphonic acid.
26 
Phase II reactions also occur 
prominently in the D ring. Glucuronidation occurs at the 17b-hydroxyl group; however, it is 
important to point out that in 17a-methyl steroids, glucuronidation does not occur because 
of steric hindrance. However, sulfate conjugates do form and the reaction was first 
described for metandienone administration in horses.
27
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Figure 1.10. Conjugation reactions of Ring A, with either a glucuronide or sulfate moiety. 
1.1.2.    World Anti-Doping Agency (WADA) Prohibited List  
The World Anti-Doping Agency (WADA) is the independent international body 
responsible for coordinating and monitoring the global fight against doping in sport.
5
  
Established in 1999, it has evolved into a global network of committed sports and 
government authorities and individuals working together to protect athlete health and the 
14 
 
integrity of sport. WADA publishes a Prohibited List, which, in 2007, defined prohibited 
substances grouped into the following categories:
28
 
S1. Anabolic androgenic steroids (AAS)  
- exogenous and endogenous  
S2. Hormones and related substances  
S3. Beta-2 agonists 
S4. Agents with anti-estrogenic activity 
S5. Diuretics and other masking agents 
S6. Stimulants 
S7. Narcotics 
S8. Cannabinoids 
S9. Glucocorticosteroids 
In the context of this thesis we will only consider the analysis of anabolic androgenic 
steroids (S1). 
1.1.2.1. Anabolic androgenic steroids (S1) 
WADA publish, and regularly update, a list of prohibited endogenous and exogenous AAS.  
The latest list includes forty six exogenous compounds named specifically, along with the 
statement that other substances with similar chemical structure or similar biological 
effect(s) should also be considered prohibited.  
Endogenous AAS (when administered exogenously) include the androgens shown in Figure 
1.1, namely: androstenediol, androstenedione, dihydrotestosterone, DHEA, and testosterone 
15 
 
and their metabolites and isomers. A list of twenty two such species is provided along with 
the statement that substances considered prohibited are not just limited to this list. 
Samples are considered to contain prohibited substances:  
 if the concentration of such prohibited substance in the athlete’s sample is above 
typical range of values normally found, 
 if the laboratory can show that the prohibited substance is of exogenous origin, 
 if the testosterone to epitestosterone (T/E) ratio is equal to or greater than 4.0.  
A simple threshold value in the urine sample cannot be used to prove exogenous 
administration of steroids that are produced endogenously, such as testosterone. This is 
because levels of such compounds can vary considerably in athletes. However, the steroid 
profile of testosterone glucuronide and its minor metabolite epitestosterone glucuronide 
(T/E ratio) should remain fairly constant in the urine excreted. Exogenous application of 
testosterone will result in an increase in the urinary concentration of testosterone 
glucuronide; however, the level of epitestosterone glucuronide will remain the same. In 
1983, the International Olympic Committee (IOC) adopted a T/E ratio of 6.0 as the 
threshold for constituting an offence. In doping analysis, if the T/E ratio was found to be 
greater than 6.0, longitudinal studies were undertaken to establish if the ratio was high due 
to physiological or pathological conditions. The athlete’s individual T/E reference value 
was established, the concentration of testosterone and epitestosterone and the concentration 
of major metabolites were also determined. In 2004, the guidance on this T/E ratio was 
changed.
29
 Any sample with a T/E ratio of > 4.0, or if concentrations are greater than the 
set limits for testosterone, epitestosterone, androsterone, etiocholanolone or DHEA then the 
urine sample should be submitted to gas chromatography/combustion/isotope ratio mass 
16 
 
spectroscopy (GC/C/IRMS). By using GC/C/IRMS, stable carbon isotope ratios (
13
C/
12
C) 
allow discrimination of endogenous and exogenous steroids, the exogenous sources 
containing less 
13
C than their endogenous homologues.   
The basis of GC/C/IRMS, is that stable carbon isotope ratios (
13
C/
12
C) found in organic 
molecules show very small variations due to the processes and feed stocks involved in their 
production; this measurable variability can be used to distinguish between endogenous and 
exogenous sources of steroids. The carbon isotopic composition of a sample is expressed as 
13C, is measured in units of per mil ( ‰ ) and is defined by the Urey equation (Equation 1):  
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Equation 1. Urey equation for determining the stable isotopic composition of carbon 
The symbol is standard notation and refers to the isotopic shift against a known reference 
standard. In the case of carbon the international reference standard was a Pee Dee 
Belemnite (PDB) carbonate, which has now been replaced by a new standard, Vienna Pee 
Dee Belemnite (VPDB).
30
 
Exogenous testosterone contains comparatively less 
13
C stable isotope than endogenous 
testosterone; this is because they are usually synthesised from soy, which is depleted in 
13
C 
when compared to traditional dietary sources of cholesterol. In the technical WADA 
documentation, adverse analytical findings are reported when the δ13C value is more than 
3 ‰  away from the value obtained from the chosen urinary reference steroids.29 
17 
 
It should be noted that a number of papers in the literature still debate the validity of the 
T/E>4.0 ratio and the required confirmatory test using gas chromatograph/combustion/ 
isotope ratio mass spectroscopy (GC/C/IRMS).
31,32,33
 
In one study, it was shown that shifts in δ13C can be caused by the length of time before 
urine samples are tested, as well as the length of time a subject stays in a different 
country.
31
 This two year longitudinal profile studied three caucasian male athletes that 
travelled between Africa and Europe, residing for one to two months in Africa, while the 
rest of the time was spent in Europe. Results showed enrichment of δ13C after a subject was 
tested within two weeks of arrival in Europe. However, when a subject was tested one or 
two months after arrival he did not show any δ13C enrichment. The length of stay in Africa 
also affected the enrichment of δ13C.  
Urine samples collected from African countries were found to have higher δ13C content 
because of diet. Ultimately, the δ13C in the African population is linked to the eating habits 
in the region. The higher consumption of maize and sugar cane in Africa will result in an 
enriched δ13C value for endogenous steroids, as they are produced from cholesterol, which 
is derived from plant tissue and will be dependent on the photosynthetic pathway of the 
plant consumed.
29
 It should be noted that the study did not find any false positive samples, 
as the range of δ13C was within the isotopic variation allowed by WADA. However, 
recommendations were made to evaluate further.  
In another case, when seven urine samples produced similar high testosterone to 
epitestosterone ratios of between 3.7 to 4.2, genetic profiling showed that three of the 
samples were from the same athlete. The results highlighted that the T/E ratio alone was not 
appropriate to identify individual urine samples.
34 
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Donike et al., the pioneers of the current anti-doping procedure, have suggested that a 
population-based reference range is not suitable because of individual variations, since the 
athlete can have an undetected increase in the T/E ratio.
35
 No formal procedure has yet been 
formulated for the interpretation of the time profile of the T/E ratio.
36
  
In one study, 520 urine samples were tested using the T/E ratio threshold of 4.0. The study 
returned 24 false positive and 34 true positives.
32
 The Bayesian interpretation of a statistical 
model used in this study detected a true positive result at T/E ratio of 2.1 and a false 
positive at T/E ratio of 14.2.
32
  
Furthermore, nine out of competition samples taken during and after the 2014 FIFA World 
Cup in Brazil, showed a T/E ratio higher than 4.0 and one in-competition sample had a T/E 
ratio of 4.1. However, when these samples were tested by GC-C-IRMS, to determine if the 
testosterone was exogenous, the result showed that all samples were false positives.
  
 
1.1.2.2. Urine analysis in sport testing   
The screening of athletes is usually enacted through the analysis of urine samples at 
specialised, accredited laboratories.
37
 The first stage of human urine testing is the collection 
of two samples, labelled A and B. This procedure is conducted by a sample collection 
officer and does not involve the testing house. The specific gravity of the urine is measured 
at this stage. The samples are uniquely bar-coded and sealed in tamper-proof packaging and 
an affidavit is signed by the athlete. Samples are then sent to the testing house. On arrival, 
the samples are logged into the laboratory information management system (LIMS). The 
specific gravity is re-measured and compared with the original results. If the two results are 
comparable then further analysis can take place. If, however, abnormal results are shown 
then the possibility of sample tampering or sample deterioration need to be addressed. The 
19 
 
B samples are stored; whereas, the A samples are divided into five aliquots, one for each of 
the following test methods: 
Sample 1A: Peptide hormones: enzyme-linked immunosorbent assay (ELISA) 
Sample 2A:  Basic drug compounds, stimulants, narcotics and beta blockers: 
         Gas chromatography/mass spectrometry (GC/MS) in full scan mode 
Sample 3A:  Conjugated steroids:  GC/MS and liquid chromatography/ tandem mass 
spectrometry (LC/MS/MS) 
       (GC/MS in selective ion monitoring (SIM) mode) 
Sample 4A:  Unconjugated steroids and diuretics:  GC/MS & LC/MS/MS 
Sample 5A:  Designer steroids: LC/MS/MS 
The first aliquot is tested for peptide hormones using enzyme-linked immunosorbent assay 
(ELISA).  ELISA is applied to species not compatible with chromatographic methods, such 
as peptide hormones. The main process in ELISA is the binding of the antigens to 
antibodies, if present in the sample. The plate is then washed to remove all interferences. A 
secondary antibody is then applied to the plate, followed by another wash. This secondary 
antibody is linked to an enzyme and when a substrate is added it will lead to catalysis and 
produce a coloured product or a detectable change in colour or fluorescence. 
The second aliquot, which tests for basic drug compounds, stimulants, narcotics and beta 
blockers is pH modified and an internal standard is added. Enzymatic hydrolysis of 
glucuronic acid conjugates is performed. Potential interferences are removed from the 
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sample via solid phase extraction, the eluent is then evaporated and reconstituted in a 
silylating mixture. The sample is screened by the GC/MS in full scan mode, using electron 
impact ionisation (EI) at 70 eV. An automated data processing system conducts a library 
search and detects peaks. A report is generated by the system which is then reviewed by an 
analyst.  
The third aliquot, testing for conjugated steroids, is enzymatically hydrolysed after pH 
modification and addition of an internal marker. It is then extracted using a combination of 
SPE cartridges to give a neutral and basic fraction. The neutral fraction is derivatised by 
forming trimethylsilyl derivatives and analysed by GC/MS in selective ion monitoring 
(SIM) mode, with 30 different acquisition time windows, each containing between 10 and 
15 ions. A report is automatically generated by the system. The ratio of testosterone to 
epitestosterone is also calculated by the automated procedure. The basic fraction is 
analysed by LC/MS/MS. 
The fourth aliquot tests for unconjugated steroids and diuretics. It is pH modified, an 
internal marker is added and then extracted by SPE, before splitting it into two portions. 
The first portion being tested by GC/MS after trimethylsilyl derivatisation and the second 
portion tested by LC/MS for diuretics.   
The final aliquot is used to test for difficult or problematic analytes, such as designer 
steroids which are specifically synthesized to avoid detection.  
If samples generate a suspicious finding then confirmatory analysis is undertaken. As this 
data may be used in the court of arbitration for sport, the whole procedure is now repeated 
by a single analyst. Blank urine samples and reference material are also used for 
confirmatory evidence for the presence of steroid in the urine sample.
37
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1.1.3.    The contamination of nutritional supplements  
Dietary supplements are often taken by athletes and the general public, and can include 
vitamins, minerals, herbs, and amino acids.
38
 Up until 2002, dietary supplements were 
regulated as a class of foods, not as drugs and therefore were not screened for safety or 
efficacy. Ambiguity in the law allowed companies to exploit health-promoting properties of 
dietary supplements without regulatory obligations to display any known risks.   
The following risks have been associated with dietary supplements:
39,40
 
 severe or acute side effects, e.g. kava with liver failure and aristolochic acid with 
kidney failure, 
 side effects may be associated with prescription medicine,  
 postponement or delay of conventional medical treatment, 
 harmful interaction with prescription and over-the-counter medications.  
The Financial Times reported that the global market for supplements, in 2001, was 
estimated at US$46 billion and the US supplement market, in 2000, was estimated at 
US$16·7 billion.
41
 In 2004, global sales were estimated to be between US$75-250 billion,  
this large range was due to the differing definitions of a supplement from country to 
country, resulting  in complex sales data.
42
 Nevertheless, the sales are expected to grow to 
US$384 billion in 2014.
43 
Factors influencing the growth of the supplement market include 
easy access through the internet, which makes it possible for users all over the world to 
access all products freely available in the USA and promotion of the use of supplements by 
top athletes. General population studies on the use of supplements show a 40 % rate of 
use.
44
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These products are most frequently used by sportsmen and sportswomen, ranging from 
amateur level to elite athletes, the category to which they are most aggressively marketed.
45
 
The high prevalence of use can be illustrated by a study following the Olympic Games held 
in Sydney in 2000.  In this study, the medication use of 2,758 athletes, selected for doping 
control, was evaluated.
46
 The major findings were that 51 % of athletes tested had used 
vitamins before competition and a large fraction of the tested athletes used other nutritional 
supplements. Some athletes even reported using up to twenty-six different supplements.
  
Commonly cited reasons for supplement use included: 
 to compensate for an inadequate diet, 
 to meet the abnormal demands of hard training, 
 to benefit performance, 
 to keep up with team-mates or opponents, 
 recommended by coach, parent or other influential individual. 
According to the 1994 Dietary Supplements Health and Education Act (DSHEA), 
nutritional supplements that did not claim to “diagnose, treat, prevent or cure disease” were 
not subject to regulation by the Food and Drug Administration (FDA).
47
 The advantage for 
supplements companies was that there was neither a requirement to prove claimed benefits 
nor any legislation to show safety with acute or chronic administration. No quality 
assurance and or strict labelling requirements led to supplement contamination.   
The FDA warned several manufacturers and distributors of unapproved drugs containing 
steroids and had stated that any further distribution or sale of these products without their 
approval would result in regulatory action, including seizure and injunction.
48
 The FDA is 
primarily concerned that the use of such products, that are marketed as dietary supplements 
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and promoted for building muscle and increasing strength, may cause serious long-term 
adverse health consequences in men, women, and children. These products claim to be 
anabolic and problems associated with anabolic steroids include: liver toxicity, testicular 
atrophy and male infertility, masculinisation of women, breast enlargement in males, short 
stature in children, adverse effects on blood lipid levels, and a potential to increase the risk 
of heart attack and stroke. 
The FDA have also recalled products containing excessive doses of vitamins A, D, B6 and 
selenium because of potentially toxic effects. Some products have been shown to contain 
impurities (lead, broken glass, animal faeces, etc.) because of poor manufacturing 
practice.
49
  
Although the primary goal of The Dietary Supplement Health and Education Act was to 
ensure consumers had easy access to diverse dietary supplements such as vitamins, it 
inadvertently resulted in several new steroids being introduced as nutritional 
supplements.
50,51
 Initially, these new steroids were precursors of testosterone and are 
therefore collectively referred to as prohormones.
52  
These hormone precursors have limited 
anabolic or androgenic properties themselves but are intended to be converted to fully 
active hormones, via the enzymatic process that occur during metabolism, typically 
resulting in the addition of whichever atoms happen to be missing from the chemical 
structure of the compound. 
In 1996, the first steroid introduced on the prohormone market was dehydroepiandrosterone 
(DHEA).
53
 When taken exogenously, this endogenous steroid was classified as a 
prohormone, as it was advertised to metabolises to testosterone after oral administration. 
Androstenediol, androstanediol and 19 Nor- analogues emerged at the same time. These 
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prohormones are thought to be converted in the body to testosterone and nandrolone, 
respectively. Boldine is also used as a prohormone for boldenone. Some prohormones have 
even been disguised as nutritional supplements, thus avoiding statutory control.
54
 
1.1.3.1. Nutritional supplement testing 
Geyer et al., have conducted three major studies on the contamination of nutritional 
supplements.
55-57
 Their initial analysis, published in January 2000, found contaminated 
nutritional supplements in three products. They conducted a second study, on a further 153 
nutritional supplements,
 
followed by an international study of 634 samples.  
 
In the first study, at the International Olympic Committee (IOC) accredited laboratory in 
Cologne, they reported the results of an analysis carried out on dietary supplements, none 
of which declared on the label that they contained steroids.
55
 The nutritional supplements 
tested had been produced in the USA. Nandrolone, testosterone and other steroids were 
identified in these supplements. When they were fed to healthy volunteers, they resulted in 
positive test results, i.e. enough steroids in the urine to result in a failure in a drug test.  
The total amount of steroids varied between 0.3 μg and 5,000 μg per capsule. After 
administration of one capsule of the above mentioned nutritional supplements, all 
volunteers showed positive results for the nandrolone metabolite, norandrosterone. Three to 
four hours after administration of the capsules, urinary concentrations of between 4 and 623 
ng/mL were measured for norandrosterone. A female volunteer additionally showed an 
increase in the ratio of testosterone/epitestosterone from 0.6 to 4.2.
55
 
The laboratory followed this up with the analysis of 153 supplements bought in the USA, 
UK, Sweden, Norway, Germany, Belgium, Israel and Austria.
56
 The study showed: 
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 18 different supplements (from 12 different companies) contained prohormones that 
had not been declared on the label,  
 15 of the 18 supplements contained 19-norsteroids, 
 19-nor-4-androstene-3,17-dione and 4-androstene-3,17-dione were the most 
commonly found prohormones in the contaminated nutritional supplements.   
Contaminated nutritional supplements included carnitine, vitamins, minerals, Tribulus 
Terrestris, ribose, branched chain amino acids, ornithine keto-glutarate, creatine, zinc, 
pyruvate, chrysin, guarana, conjugated linoleic acid, herbal extracts and glutamine. 
The extended analysis showed a number of disturbing findings. About 50 % of the analysed 
supplements showed a concentration of prohormones higher than 10 μg. The maximum 
detected was 5,140 μg. More than 10 % of the analysed supplements contained 
prohormones not declared on the label. The results showed that the amount of prohormones 
were much lower than the amount usually present in a prohormone product. Results also 
showed a sharp variation from capsules to capsules, which led the author to conclude that 
the prohormones had been introduced through cross contamination. Further evidence was 
provided by the fact that 4 out 12 (33 %) of the non-hormonal supplements that were found 
to be contaminated came from companies that also sold prohormones. Interestingly, 14 of 
the contaminated nutritional supplements did not come from companies that sold 
prohormones.  
Geyer et al., also quantified the amount of steroids needed to cause positive doping results. 
They concluded that 1000 μg/capsule of 19-norsteroids would cause a positive doping 
results for norandrosterone for more than 24 hours. However, they also showed that 19-
norandrosterone was still in the urine at a concentration of 2 ng/mL (WADA threshold) 
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four hours after the application of only 0.8 μg of norandrostenedione.56 More recently, 
separate studies by Watson and colleagues and van der Merwe et al., have shown similar 
results for dietary supplements.
58,59
 
Geyer et al., then conducted a comprehensive international study of 634 samples from 13 
countries and from 215 different suppliers.
57
 The study was conducted between October 
2000 and November 2001, with 289 supplements obtained from companies supplying 
prohormones and 345 supplements from companies not selling prohormones. 
Results showed that 94 samples were contaminated with prohormones:  
 23 samples contained prohormones of nandrolone and testosterone,  
 64 samples contained prohormones of nandrolone only,  
 7 samples contained prohormones of testosterone only. 
The distribution in the concentration of contaminated steroids varied from the study 
conducted earlier: 
 only 16 % of the samples had a concentration above 10 μg.  (compared to above 
50% in the earlier study), 
 most significantly, 75.5 % supplements had contamination levels below 5 μg,  
 56 % were below 2 μg - in fact 28.7 % were even below 0.2 μg.   
In this study, it was declared that capsules had the most significant contamination, followed 
by tablets and powders. Substantial numbers of positive tests were obtained from products 
bought in the Netherlands (26 %), the USA (19 %), the UK (19 %) and elsewhere. The 
names of the contaminated supplements have not been published, but they included 
vitamins and minerals, protein and amino acid supplements, creatine and many others.  
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In 2007, the IOC-accredited laboratory in Vienna published a study of 57 supplements. Parr 
et al., found that 12 (22 %) of these contained prohibited steroids.
60
 The identities of the 
companies and the products have been published. As in the Geyer et al. study the presence 
of anabolic androgenic steroids was assumed to be from contamination in the 
manufacturing, or perhaps the distribution process. The reason given was that the 
contaminants were only present at low levels and were variable between and within 
batches.  
In 2002, however, Geyer et al., found alarming concentrations of the androgenic anabolic 
steroid metandienone in three nutritional supplements.
61
 These three supplements were 
bought in England, via telephone order. Metandienone was present in very high amounts, 
an average of 17.30 mg/g in one supplement. The highest concentration of metandienone 
found in a single capsule was 28.9 mg/g. This is more than enough to produce serious side-
effects. Metandienone is a prescription only medicine. The therapeutic dose is 5-10 mg per 
day. If one was to consume the three capsules per day, as recommended by the 
manufacturer, this would result in metandienone dosages that were supra-therapeutic. Side 
effects of metandienone include abnormal liver function and physiological disorders. Long 
term application can lead to dependence and severe withdrawal symptoms. It has been 
alleged that this was a purposeful and deliberate contamination. 
Nutritional supplements have an important position in the consumer market. The need for 
regulator intervention was imperative, as the danger for consumers exposed to harmful 
substance is real. The most comprehensive worldwide study undertaken of 634 samples had 
shown 94 samples to be contaminated with anabolic androgenic steroids.
59
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In 2004, the US Congress amended the Anabolic Steroid Control Act, which resulted in the 
restricting of the sale of anabolic steroids and prohormones as nutritional supplements.
62 
The act stated: “The term 'anabolic steroid' means any drug or hormonal substance, 
chemically and pharmacologically related to testosterone (other than estrogens, progestins, 
corticosteroids and dehydroepiandrosterone).” It also listed seventeen compounds as 
prohormones, along with their salt, ester or ether. The list was not closed and therefore any 
compound that affects testosterone is now considered prohibited under US law. 
Although the history of nutritional supplement remaining entwined with DSHEA 
legislation, the regulation of nutritional supplements remains complex within the European 
Union. The difficulty is in distinguishing food supplements from medicinal products and in 
implementing this legislation across the union. 
The nutritional supplement market is driven by consumer demands and behaviour in 
individual state country; for example, garlic is sold in the UK for cold treatment, whereas in 
Germany it is sold for the treatment of arteriosclerosis.
63
 The consumption of a nutritional 
supplement is therefore often determined by an individual’s perception of the perceived 
benefit. A balance therefore needs to be found between protecting consumers from over 
consumption, or contamination, and at the same time providing freedom of choice.  
Under EU legislation it is illegal for a food product to make a statement regarding treatment 
and cure of a disease. Food Supplements are defined in Article 2 of 2002/46/EC Food 
Directive. The European Food Safety Authority (EFSA) defines a food supplement as a 
“sources of nutrient or other substance with a concentrated source”.63,64  
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In the UK the Government Chemist provides guidance on the classification of supplements 
as food or medicinal products.
65
 The guidance covers the latest UK and European 
legislation and also provides a decision tree to enable a classification to be made. One of 
the most important questions asked is “can it be administered to humans for restoring, 
correcting or modifying physiological function?” If the answer is yes, then the product is 
defined as a medicinal product and the Medicines Act (1990) applies; if the answer is no, 
then the product is a food and either the Food Safety Act 1990 or the Food Supplement 
(England) Regulations 2003(1) apply.
65
  
The Food Standard Agency and the Medicine Healthcare product Regulatory Agency 
(MHRA) monitor products within the UK.
65
 The Rapid Alert System in Food and Feed 
(RASFF) portal allows European Union member states to flag and register adverse 
contaminated nutritional products, thereby allowing a rapid response.
66
 
In view of the challenges facing any athlete, HFL Sport Science have developed the 
Informed-Choice Programme to help customers distinguish between established and rogue 
nutritional supplements practises.
67 
Their quality assurance program for sports nutrition 
products certifies that all nutritional supplements and/or ingredients with the Informed-
Choice logo have been tested for banned substances.
67 
 
Whilst legislation has been introduced to try to combat the problem with steroids and 
prohormones, based on the wealth of analytical evidence, several issues with the methods 
utilised were raised during the large-scale studies. In the extensive Geyer et al. study, 66 
samples could not produce reliable results. All testing laboratories are facing a similar 
problem with a number of their samples have produced inconclusive results and is mainly 
attributed to matrix effects.   
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It is clear from this brief review of the literature that sports testing, both in terms of 
deliberate and inadvertent administration, is a highly dynamic field that is constantly 
changing with trace level analyses being performed in complex matrices. Before we 
explore the hypothesis that comprehensive chromatography, coupled to time-of-flight mass 
spectrometry and new sample extraction techniques could provide a valuable additional 
tool to improve the screening of steroids contaminants, we will briefly review the 
techniques currently in use and to be applied in this thesis. 
1.2. A review of the analytical techniques applied in this thesis 
1.2.1.    Chromatographic separation  
Chromatography is derived from two Greek words, meaning colour and to write, and its 
verbatim translation is “colour writing”. The impact of chromatographic separation has 
been known about since antiquity – the idea that a mobile phase (e.g. liquid) could separate 
a mixture of compounds (e.g. different coloured dyes) when passed along a stationary 
medium (e.g. cloth or paper) has been utilised extensively over the ages. Prof. Leslie Ettre, 
stated that the word was first used in its current scientific context in a publication by 
Mikhail Tswett, in the German Botanical Society, in 1905; although, he had first described 
the separation of plant pigments, by liquid chromatography (LC) columns, in a lecture in 
1903.
68
 Separation was achieved in a glass column; however, initially there was little 
recognition of the botanist’s work.  
Further major developments were not made until 1941, when Martin and Synge reported on 
amino acid separation by liquid-liquid partition chromatography.
69
 Following on, in 1952, 
James and Martin then developed the first gas-liquid chromatographic (GLC) column, 
when they described the separation of volatile fatty acids by partition chromatography with 
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nitrogen gas as the mobile phase and a stationary phase of silicone oil.
70
 This paper is 
regarded by many as the first paper on GC and demonstrated that tiny amounts (< 1 g) of 
material could be separated by partitioning between the gas-liquid phases. 
Gas chromatography uses a permanent gas such as nitrogen, hydrogen or helium as the 
mobile phase.  Martin and colleagues discovered that by using a gas instead of a solvent for 
the mobile phase, the system was far more dynamic and more refined separations could be 
achieved. The use of thermal gradients can also improve the resolution in mixtures with 
volatile and semi-volatile components, by making use of their relative vapour pressures.  
Increasing the temperature influences the partition coefficient of the analytes between the 
stationary and mobile phase; when optimised, this can result in their focussing at the entry 
of the column and their elution into the detector in a narrow band, thus further enhancing 
compound resolution. Since the components of the mixture attain different migration rates, 
based on their interaction with the stationary phase, they will elute at different rates and 
under identical conditions will have highly reproducible retention times.  
It was the development of the flame ionisation detector (FID), by McWilliam and Dewar, in 
the late 1950s that allowed the potential of GC to be fully explored.
71
 Unlike previous 
detectors, the FID was capable of very low background noise and as a result it was capable 
of complex separations at very low sample volumes (< 1 L) and had very fast response 
times (~1 ms).
72 
Pauling was the first to illustrate its power for biological samples, by 
demonstrating the detection of over 250 volatile organic compounds (VOCs) in both breath 
and urine samples.
73
 
With an increasing number of detectors becoming available GC columns also developed, 
from packed open tubes containing silicone oil to packed columns containing, for example, 
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activated charcoal or silica gel. It was the development of capillary GC columns with their 
improved separation efficiencies resulting in greater peak capacity (number of compounds 
that can be resolved) and shorter run times that really established gas chromatography as 
the powerful analytical tool it is today. 
Capillary columns, as the name suggests, have narrow bores (typically 0.1 to 0.5 mm i.d.) 
and are usually manufactured from fused silica and are externally coated in a polyimide 
resin; although, de-activated metal columns now allow an increase in the upper operating 
temperature and are able to be used beyond the confines of the laboratory. They tend to be 
coated internally with a polysiloxane layer, the chemical composition of which can be 
modified to provide the most appropriate stationary phase material for the compounds to be 
separated. The columns can be wound tightly on to cages that enable tens of metres of 
column (15 or 30 m being used more often) to be housed in a standard GC oven. In 
addition, the analysis of highly volatile compounds are enhanced by the use of porous layer 
open tube (PLOT) columns instead of polysiloxane as the stationary phase. An additional 
consequence of the use of long, narrow tubes is that the peak capacity (separation 
efficiency) can be maintained with much lower volumetric flows (1-2 mL/min) of carrier 
gas than used in packed column systems (~20-40 mL/min), enabling the coupling of a GC 
to analytical detectors that require a vacuum for operation. It is the coupling of capillary 
columns with mass spectrometry that has fundamentally transformed the analysis and 
identification of components in complex matrices. 
1.2.2.    Mass spectrometry coupled to gas chromatography 
The coupling of a mass spectrometer to a gas chromatography column provides the analyst 
with one of the most useful tools. Having resolved the components of a complex sample on 
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the GC column, the mass spectrometer enables the differentiation of molecules of different 
relative molecular mass. The standard measurement unit is the Dalton (Da), based on the 
12
C isotope value of 12.0000. 
The invention of mass spectroscopy is often attributed to J. J. Thomson, who studied 
electrical discharges in gases.
74
 Thomson began working at the Cavendish Laboratory in 
Cambridge in 1880, and by using vacuum systems he was first able to show deflection of 
particles by magnetic and electric fields. Using this deflection he was then able to calculate 
the velocity of the particle. Using different gases, he obtained the same e/m value of the 
particles. He found that these were one thousandth of the mass of hydrogen. Thomson 
called the particles ‘corpuscles’ but were later to become known as electrons, a phrase 
coined by an Irishman, G. Johnstone Stoney.
75
 Thomson made the first announcement of 
the existence of the corpuscles at the Royal Institution on the 30
th
 of April 1897.
76,77
  
In 1907, Thompson began investigating positive rays hoping to identify particles that 
carried a positive charge. Ions of neon, generated in gas discharge tubes, were passed 
through parallel electric and magnetic fields in a parabolic trajectory; a photographic plate 
was placed in its path to measure the deflection. Thompson observed two patches of light 
on the photographic plate which he initially believed to be from another species but later 
recognised them as the two isotopes, neon-20 and neon-22. The mass of naturally occurring 
neon is 20.2, as the heavier isotope is present at ~10 % of the lighter isotope. The weak 
beam signal for the less abundant heavier isotope meant many were not convinced by 
Thompson’s findings.78   
Francis Aston joined Thompson at the Cavendish Laboratory in 1909 and in 1919 would 
go on to construct what has been recognised as the first mass spectrograph, the forerunner 
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of the mass spectrometer, for the separation of charged atoms based on their masses. The 
primary modification was that Aston allowed his particles to be deflected by the electric 
field before entering the magnetic field and the direction of the field was different.  
Ultimately it resulted in more accurate results and clearer photographs.
78
  
1.2.2.1. Electron ionization 
Electron Ionisation (EI), the primary mechanism used in most modern mass spectrometers, 
was introduced by Dempster in 1921.
79
 EI is a harsh ionization technique resulting in 
substantial molecular fragmentation. Despite this, the ionization process is highly 
reproducible, which can simplify compound identification and the fragmentation patterns 
generated can be used for compound ﬁngerprinting.   
The EI process itself requires the analyte to be in the gas phase. As shown in Figure 1.11, 
the electrons are emitted by the heated filament which are then focused into a region for 
interaction with the analyte molecules. Analyte molecules are introduced into the ionisation 
source and are ionised by the direct impact of a 70 eV electron, resulting in removal of an 
electron from the analyte molecules and the formation of positively charged radical cations. 
The ions formed are moved out of the ion source by an electric field. Depending on the 
lifetime of the excited state, fragmentation will either take place in the ion source, giving 
rise to stable fragment ions, or on the journey to the detector, forming metastable ions.
80 
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Figure 1.11.   Showing the electron ionization (EI) process in mass spectrometers, with the 
eluent of the GC column entering via the transfer line and the charged 
radical ions exiting in to the mass analyser, prior to separation and 
detection. 
The energy required to remove an electron from a molecule is termed the ionization energy 
(IE). This energy differs for each type of molecule. Most organic compounds are ionised in 
the IE range of 6 to 12 eV. At 70 eV, EI ensures an effective transmission of additional 
energy that induces a reproducible fragmentation of the molecule, which can enable 
structurally informative information to be derived from the mass spectra generated.
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The minimum energy required to form a fragment ion is called the appearance energy (AE) 
of this ion. The formation of fragment ions from the radical cations is caused by the excess 
internal energy present in the range of 0 to 20 eV. This high internal energy induces 
fragmentation of the molecular ion causing the molecular ion to fragment by breakage of 
chemical bonds. The bonds that are broken during the fragmentation process form a more 
stable ion.
81
 The distribution of energy among the ions formed, and the ensuing pattern 
of fragmentation produced from distinct chemical structures, depends on chemical bond 
strength and fragment ion stability. The EI ionisation process forms a basis for qualitative 
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and quantitative mass spectra analysis and interpretation. Furthermore, the extensive 
fragmentation can provide useful information into characteristic related to the structural 
features of a molecule under investigation.  
EI combined with a full mass spectrum scan can provide the user with openings into 
interpreting a contaminated mass spectrum. Similarly, it can provide relevant information 
on ions that may allow the user to separate two unresolved chromatographic peaks. The 
mass spectrum of unresolved compounds or shoulder peaks can then be analysed for 
artifacts or suspected peaks hidden beneath a main peak. This plays an important role in the 
pharmaceutical industry, with the identification and quantification thresholds for impurity 
peaks set by the regulatory body. Peaks above the threshold require the identity of the 
impurity for toxicological studies to ensure no harm to patient and thus allow the product to 
be marketed. 
Large spectral libraries of mass spectra (e.g. Wiley/NIST, 2008), consisting of full scan 
data obtained using electron ionization spectra are easily accessible. The collation of 
bespoke, in-house, compound specific libraries that are readily searchable for matching 
spectra can also be used for compound identification. However, it should be noted that a 
lack of a spectral match or a spectral mis-match can occur in trace analyses, usually caused 
by matrix interference or contaminated samples, and requires a skilled analyst to interpret 
the data.
81 
1.2.3.   Comprehensive gas chromatography/mass spectrometry (GCxGC/TOFMS) 
Comprehensive (two-dimensional) gas chromatography (GCxGC) was first described, in 
1991, by Phillips and Liu.
82
 In comprehensive chromatography, two capillary columns with 
different stationary phases are connected by a modulator, in order to achieve orthogonal 
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separation. By employing two different stationary phases, and the modulator, all of the 
sample introduced on the first column also undergoes a separate separation in the second 
column, resulting in an increase in chromatographic resolution (how well peaks are 
separated) and peak capacity (number of peaks that can be separated on a column).  
Effectively, in comprehensive chromatography the peak capacities of the two columns are 
multiplied, hence the use of the term GCxGC. Through the above processes, 
comprehensive chromatography generates peaks that are much sharper and narrower (0.1-
0.3 s) than in conventional one-dimensional gas chromatography (2-3 s). This not only 
increases their ability to be resolved from other analytes, matrix compounds and column 
bleed but also results in an increase in their signal/noise ratio, thereby allowing lower 
detection levels than in one-dimensional chromatography.   
The nature of the peaks eluting from the second column in comprehensive chromatography 
imposes constraints on the detectors that can be used. Quantification of a gas 
chromatography peak necessitates ~ 20 data points to be collected, so that its peak shape is 
well characterized. When peaks are 0.1 - 0.3 s wide, this necessitates spectra acquisition 
rates of 50-100 Hz. A schematic of the primary components used in the commercial 
comprehensive chromatography system utilized in this study, is provided in Figure 1.12.  
The detector used is a time-of-flight mass spectrometer with unit-mass resolution in the 
range of 5- 1000 Da and an upper spectra acquisition rate of 250 Hz.   
The Pegasus IV, from the Leco Corporation (St Joseph, Michigan), uses a standard Agilent 
6890 GC into which a twin-stage thermal modulator (Leco Quad-Jet) and a secondary oven 
(both described below) have been added. A liquid nitrogen cryostat is also added and 
connected to the thermal modulator, via a valve, to allow cryogenic trapping of the primary 
column effluent on demand. An air supply and two heated jets make up the remainder of 
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the thermal modulator. The GC is fitted with a standard split/splitless injector for sample 
introduction. 
 
Figure 1.12.   Showing the configuration of the Leco Pegasus IV, comprehensive gas 
chromatography system. 
 
Optimization of the injection bandwidth of the eluent on to the second column, from the 
first, is key for the success of comprehensive chromatography and is achieved by a two-
stage thermal modulator. The modulator consists of two cryotraps and two heaters that trap, 
focus and then deliver the analyte into the second column. The effluent from the first 
column is trapped and focused into a narrow band in the first stage, using a cold jet. The hot 
jet releases this narrow band into the cold 2
nd
 stage. The 2
nd
 stage then holds the sample as 
the 1
st
 stage cools and traps the next band. Once the 1st stage is cold, the 2
nd
 stage releases 
the sample into the secondary column. The 2
nd
 stage then cools and the 1
st
 stage releases the 
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next trapped sample. This cycle repeats continuously sampling slices from the first 
dimension. The first dimension peak is effectively split into several modulated peaks and 
then combined with the second dimension coordinates by the Leco ChromaToF software 
into a surface contour plot.   
Conventionally, in comprehensive chromatography the analytes are separated on a non-
polar column (primarily by volatility) in the first dimension, followed by separation on a 
more polar column in the second dimension. However, any combination of the vast array of 
commercial stationary phases are possible, as long as they are within the operating 
parameters of the system. The dimensions of the first column are as used in standard 
GC/MS applications (i.e. 25- 30 m in length, ~0.25 mm i.d.); whereas, the second column is 
much shorter (~1-2 m) and has a very small internal diameter (~0.1 mm). The size of the 
second column is driven by the requirement that the analytes have to elute from this column 
within the period of modulation (~4-10 s) applied to the first column. This modulation 
period is short and ensures that any separation achieved in the first dimension is preserved. 
Since this study started, Zoex (UK) Ltd now distribute an alternative thermal modulator and 
2D software, which has been developed by its parent US company. Their modulator utilizes 
a sampling loop and only one hot and cold jet.  It is reported to reduce peak tailing in the 
second dimension, further enhancing compound resolution and quantification. 
1.2.3.1. Time-of-flight mass spectrometer 
The time-of-flight mass analyser was originally described by Wiley and McLaren in 
1955.
83
 In contrast to other mass spectrometer systems in regular use in analytical 
laboratories, such a quadrupole or ion trap, a time-of-flight mass spectrometer (TOFMS) 
does not require electronic and radio frequency fields to be scanned to cover the mass range 
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of interest; making it ideal for applications such as comprehensive chromatography where 
very high sample acquisition rates are required.  
A time-of-flight mass analyser, as shown in Figure 1.13, measures the time it takes an ion 
to travel a fixed distance in a field-free region. The basic principle is that ions of different 
masses having the same kinetic energy will reach the detector at different times. Heavier 
ions will take longer to reach the detector than lighter ions. If the above underlying 
principle is to hold true then the initial kinetic energy of the ions entering the flight tube 
must be the same, otherwise the resolution (m/m) of the mass spectrometer will be 
compromised.  
Ions formed by the EI process are pulse accelerated, as a packet of ions, from the ion source 
into the field-free region (flight tube) for separation. The expectation is that the ions have 
almost the same kinetic energy and so their velocities will depend only on their mass to 
charge ratio (m/z). However, the actual position of their generation within the ionisation 
source will differ and so ions will be generated with a spread in kinetic energy.   
In order to reduce the influence of the spread in kinetic energy on the times-of-flight of the 
ions and to improve the instrument mass resolution, an electrostatic device called a 
reflectron is placed in the drift region. A reflectron is a series of electrostatic lenses that 
reduces the overall length of the mass spectrometer and is maintained at a particular 
distance from the ion source and the detector. Ions having higher kinetic energy penetrate 
deeper into the reflectron than lighter ions and thus travel further. Effectively the ions are 
packeted, thus reducing the flight time distribution and resulting in an increase in 
resolution.  
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Figure 1.13. Showing the basic elements of a time-of-flight mass spectrometer: the 
ionisation source with its push pulse plate; the ion focussing optics and 
reflectron in the flight tube, and the secondary electron multiplier (SEM). 
1.2.3.2.    Applications of comprehensive chromatography  
Comprehensive two-dimensional gas chromatography (GCxGC) has increasingly been 
recognized as a technique capable of providing improved resolution of compounds within 
complex matrices when compared to conventional, single dimension GC.
84,85
 Amongst 
others, the technique has been successfully applied to petrochemical, environmental and 
food analysis.
86
 Kueh et al., first described the application of comprehensive GCxGC for 
anti-doping control in equine and canine sports.
87
 Song et al., went to apply it to a drug 
standard mixture containing over 78 drug compounds.
88
 In our own laboratory, Bill 
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Guthery has explored the qualitative determination of various opiates and benzodiazepines 
in human serum and the qualitative detection of various drug types, including opiates, 
cocaine, methadone and diazepam, in hair samples using GCxGC/TOFMS.
89,90,91
 
During the period of this study, comprehensive gas chromatography has separately been 
applied in the field of anabolic steroids.
92,93,94,95,96 
The listed publications share our 
hypothesis that comprehensive gas chromatography can be relevant to steroid detection. Its 
application as a screening process, the detection of designer steroids and its coupling with 
molecular imprinted polymers has not, to the best of my knowledge, been published.  
1.2.4.    Mass spectrometry coupled to liquid chromatography 
The development of high performance liquid chromatography (HPLC) has reduced the 
need for complex clean-up procedures and derivatisation and when coupled to mass 
spectrometry has replaced gas chromatography/mass spectrometry as the preferred 
analytical technique for certain target species.
97
   
A triple quadruple mass spectrometer enhances the capabilities of a traditional scanning 
quadrupole mass spectrometer, by allowing the user to study mass transitions (MS/MS). A 
triple quadrupole MS actually consists of two quadrupoles and a collision cell which 
enables the molecular ion (parent ion) to be isolated by the first stage of the instrument and 
then fragment (daughter) ions to be generated through the application of a collision energy. 
These fragment ions are then separated in the secondary quadrupole region prior to 
detection. The process is known as selected reaction monitoring (SRM), and is an extension 
of selected ion monitoring (SIM) in traditional quadrupole and ion trap mass spectrometers. 
These highly diagnostic transition spectra give greater proof of the target ion and provide a 
higher sensitivity with modern triple quadrupoles detecting < 50 pg at the point of analysis. 
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When a triple quadrupole mass spectrometer is coupled with a liquid chromatography 
system a different ionisation process is required to the standard electron impact (EI) source 
used in gas chromatography/mass spectrometry. 
1.2.4.1. Electrospray ionisation 
The process of ion formation in electrospray ionisation (ESI) is complex and requires high 
voltage. Despite this ESI is often referred to as a “soft” ionization technique and this relates 
to the fact that the analyte’s structure remains intact, with very little fragmentation of the 
molecule occurring during the transfer of the ion from solution into the gas phase. This 
unique aspect of electrospray ionisation (ESI) has been revolutionary in the field of 
biological mass spectrometry, increasing the range of compounds analysed to include large, 
thermally labile and non-volatile compounds such as nucleic acids and proteins. Mass 
analyzers measure the mass to charge (m/z) ratio of molecules and have a specific range. 
Often biological molecules are high molecular weight compounds and are beyond the mass 
range possible for analysis. ESI allows multiple charge formation. The advantage is that the 
overall charge of the molecule increases whilst at the same time reducing the m/z values of 
the ions formed, thus enabling the analysis of molecules of high polarity and molecular 
weight.
98
  
Electrospray was ﬁrst introduced by Dole et al., in 1968, as a method to charge synthetic 
polymers.
99 
The pre-requisite of the technique is that the analyte be: a) ionized and b) in 
solution. The solution is pumped through a metal capillary, held at high voltage, by an 
HPLC pump. The transformation of analytes into gas-phase ions occurs at atmospheric 
pressure. The analyte is first dissolved in a volatile solvent and forms ions by the addition 
or removal of a hydrogen ion. The addition of hydrogen produces the positively charged 
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molecule ion, [M+H]+, whilst negatively charged ions are produced by the removal of a 
hydrogen ion, [M-H]-. The ions formed migrate to the tip of capillary needle held at high 
voltage, ~ 3 kV. This electric field induces a charge accumulation at the liquid surface. 
With increased repulsion at the tip, caused by ions accumulating, the liquid forms a Taylor 
cone. At a crucial interval, and due to increased Coulombic repulsive forces, the liquid 
breaks away from the tip of the Taylor cone to form highly charged droplets. The droplets’ 
release is aided by de-solvation by the nebulising gas (nitrogen) flowing outside of the 
capillary. Smaller droplets with an increasing charge-to-surface area ratio form, and gas 
phase ions are ultimately produced from the progressively smaller droplets.  
The formation of gas phase ions from these highly charged droplets is thought to proceed 
through two mechanisms, the ion evaporation model (IEM) and the charge residual 
model (CRM).
100
 Solvent evaporates from the droplets, leading to a decrease in droplet 
radius but no change in charge. At a particular radius, for a given charge, the 
charge repulsion (or Coulombic repulsion) within a droplet exceeds the surface 
tension, which results in Coulombic fission. The point at which this occurs is known as 
the Rayleigh Limit. The IEM proposes that these solvent evaporation and 
Coulombic fission cycles continue until droplets are of a certain radius, at which direct 
emission of ions into the gas phase occurs. The CRM model suggests that 
these evaporation/fission cycles continue until there is no more solvent remaining and only 
the charged analyte remains. There is a general consensus that ions with a small number of 
charges, at low m/z values, are preferentially formed by the IEM whilst multi-charged ions, 
at high m/z values, are formed by the CRM.
101
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1.2.5.   Molecular imprinted polymers (MIPs) 
1.2.5.1. Limitations of existing extraction methods 
As reported in the section on nutritional supplements, the detection of trace amounts of 
anabolic androgenic steroids, their metabolites and prohormones in nutritional supplements 
is highly challenging. Despite legislation, the range of compounds available to athletes is 
ever increasing, as are the ways of trying to conceal or mask the presence of a prohibited 
compound. Some of the issues in the screening of these substances are a result of the 
inherent limitations in the detection methods used; however the sample preparation method 
also contributes to the issue. 
As summarised in Section 1.1.2.2, an extensive clean-up procedure is required for the 
analysis of steroids in urine to enable their detection at the levels required by WADA. This 
is usually achieved through the use of solid phase extraction (SPE) cartridges. A wide range 
of sorbents can be used for conventional solid phase extraction, which include C8 and C18 
bonded phases on silica, polymeric resins, polar sorbents such as alumina, charcoal, silica 
and cyano & amino-bonded sorbents.   
Conventional SPE sorbents retain targeted analytes by non-selective means, such as 
hydrophobic interactions that can result in co-extraction of interfering matrix species.  
Urine samples are inevitably highly variable, the levels of matrix components such as 
amino acid, urea and water content can vary significantly. Similarly, compounds such as 
bilirubin may also affect the extraction process and reproducibility for the sample analysed.  
Variations in the sample matrix can also negatively affect the ability of the sorbent to 
extract the analytes of interest. The limitations of existing extraction methods has prompted 
the exploration, in this thesis, of a robust, more selective extraction process for the 
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screening of a range of steroid molecules, this alternative extraction process is known as 
molecular imprinted polymers (MIPs). 
1.2.5.2. A brief history of MIPs 
Whether it be enzymes, antibodies or receptors, molecular recognition and interaction is 
vital for biological function.
102
 Any disturbance in the human body’s mechanism to 
recognize and bind to the specific molecule can lead to malfunction and disease. This ‘lock 
and key’ model for interactions, initially proposed by Fischer to explain enzyme-substrate 
recognition, has been utilised by chemists for the development of synthetic receptors, called 
molecular imprinted polymers.
103,104,105
 
Molecular imprinting is based on the synthesis of a highly cross-linked polymer, built 
around a template (representative of the target), in the presence of a suitable functional 
monomer and cross-linker. As shown in Figure 1.14, a pre-polymerisable complex is 
formed between the template molecule and one, or more, functional monomers.  
Polymerisation is then initiated, either with heat or by photolysis, in the presence of an 
excess of cross-linking agent to produce the MIP. By removing the template molecule, 
numerous cavities remain with a well-defined size and shape and the desired functional 
groups which can act as selective recognition sites, i.e. artificial receptors, for molecules of 
interest.
105
 Target molecules can then be "recognised" by the polymer through size 
exclusion and the potential formation of hydrogen bonds, ionic interactions, hydrophobic 
binding, formation of reversible covalent bonds, etc.
104 
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Figure 1.14.   Showing how MIPs are generated (a) functional monomers and cross-linker 
molecules are mixed together forming a complex with the template molecule, 
(b) the functional monomers co-polymerizes with the cross-linker forming a 
highly cross-linked polymeric network, (c) removing the template releases 
complementary binding sites that can rebind the template. 
In the 1930s, a Ukrainian group led by Polyakov developed the first synthetic materials 
with biomimetic recognition properties.
106,107,108
 They showed that silica gel prepared in the 
presence of organic solvents had an affinity towards the template molecule. Their work was 
not widely recognised until 1947, when Linus Pauling’s student, Francis Dickey, developed 
silica gels for methyl orange and its derivatives. The "footprint" theory proposed by these 
authors was eagerly accepted and actively pursued by other researchers.
104
 
Since a revival of interest in the subject in the 1970s, chemists have synthesized a wide 
range of molecular imprinted polymers that combine the advantages of synthetic plastics, 
such as low cost, durability and robustness, with the recognition properties of natural 
receptors. In 1972, Wulff and co-workers published the first formal methodology for 
molecular imprinting in organic polymers.
109
 Many companies now sell tailor-made MIPs, 
for example MIP Technologies AB; POLYIntell and Semorex Inc.
105  
 
The preparation of an optimised molecular imprinted polymer depends on the selection of 
the most appropriate combination of the constituent parts for the particular application and 
target species of interest. Their selection can be achieved through theoretical modelling of 
the system, or more likely through empirical evaluation based on practical experience of 
48 
 
what MIP recipes have been used in the past. Further information on the primary 
components that are utilised to develop MIPs are summarised below.    
1.2.5.3. Functional monomer  
The choice of the functional monomer plays an important role in monomer-template 
complexes during the pre-polymerisation imprinting process. The functional monomer is 
chosen to assist the formation of strong interactions between itself and the template. The 
non-covalent imprinting approach is the most frequently used in imprinting and was 
developed by Mosbach and Arshady in the early 1980s.
110
 It has the advantage of being 
simpler to implement than covalent imprinting, is open to a wider range of templates and 
generates a greater number of high affinity sights.
104,105
 Acidic, basic and neutral monomers 
are regularly used for MIPs generation. Some frequently used non-covalent functional 
monomers (acidic and basic) are shown in Figure 1.15. The most common method for 
forming imprinted polymers is free radical vinyl polymerisation involving non-covalent 
interactions.
105
 The most frequently used functional monomers are methacrylic acid (acidic) 
and 4-vinylpyridine (basic). 
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Figure 1.15.  Representative functional monomers (acidic and basic) used in the 
preparation of molecular imprinted polymers (MIPs).
104,105 
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Whilst non-covalent imprinting has significant advantages over covalent bonding 
imprinting, the larger excess of monomers used can result in more non-specific binding 
sites, which can result in lower polymer specificity. The binding and release of template is 
efficient due to the weak electrostatic (e.g. ionic, dipole-dipole interactions), hydrogen 
bonding and Van der Waals interactions between the polymer and template and can be 
affected using mild changes in environment. As a result the polymerisation conditions need 
to be carefully chosen to maximise the polymer template interactions and preserve the 
formed complexes during the polymerisation stage.
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1.2.5.4. Initiator  
The polymerisation mechanism involves three distinct phases: initiation, propagation and 
termination. During initiation, radicals are formed by thermal or photochemical 
decomposition of the initiator, producing a metastable radical which reacts with the vinyl 
monomer to form a heterodimer, which contains a free radical. The polymerisation 
reactions then continues, and propagation occurs rapidly by the addition of a new monomer 
thus growing the radical chain. Termination then occurs either by the removal of the 
thermal source, dimerization of the radical chains or exhaustion of the monomers. 
Polymerisation should be performed in an inert atmosphere, usually nitrogen, to prevent 
chain termination through reaction of the radical with oxygen. A typical radical initiator, 
2,2-azobisisobutyronitrile (AIBN) is shown in Figure 1.16.   
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Figure 1.16.   2,2-azobisisobutyronitrile (AIBN), a  typical radical initiator used in the 
preparation of molecular imprinted polymers (MIPs).
102,103 
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1.2.5.5. Cross-linking agent 
The interaction of the monomer and the template and then subsequent removal of the 
template results in the formation of functional residues. Uniform distribution of these 
functional groups ensures an efficient imprinting and re-binding process for the target 
species. In order to achieve this uniform distribution within the polymer, a cross-linking 
agent is required. Common cross-linking agents are shown in Figure 1.17. 
Cross-linking plays an important role in preserving the binding specificity of an imprinted 
polymer. When functional groups are not sufficiently constrained by cross-linking, the 
binding specificity decreases. Conversely, an overly rigid structure formed by too much 
cross-linking may result in a decrease in loading capacity, caused by a restricted access of 
the analyte to the binding regions.  
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Figure 1.17.  Representative cross-linking agents used in the preparation of molecular 
imprinted polymers (MIPs).104,105 
As can be seen in Figure 1.17, trimethylolpropane trimethacrylate (TRIM) has one more 
vinyl group than ethylene glycol dimethylacrylate (EGDMA) and therefore has the 
potential to generate greater three-dimensional backbone rigidity, contributing to a higher 
binding specificity.  
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1.2.5.6. Solvent  
Several groups have reported that the physical state (toughness, ability to swell, 
morphology, pore size distribution and structure) of the MIPs and the imprinting process 
itself is dictated by the choice and the amount of the porogenic solvent used in the 
polymerisation recipe.
105
 The solvent selected will solubilise all the monomers in the pre-
polymerisation mixture, it will also stabilise the template-monomer complex and will help 
control the porosity of the resulting MIP. In non-covalent imprinting a non-polar solvent is 
preferred over a polar one, which would interfere with the electrostatic interactions needed 
for a successful imprint; for example, toluene and chloroform are widely used in 
imprinting. 
1.2.5.7. MIPs for the selective extraction of steroids 
The use of MIPs for the extraction and clean-up of steroids has not, to the best of the 
author’s knowledge, previously been reported; however, Shi et al., have reported 
selectively extracting cholesterol from different matrices including human serum, cow 
milk, yolk, shrimp, pork and beef samples using a MIP.
112 
Their results showed high 
afﬁnity and binding of their MIP for cholesterol. According to the authors, the matrix 
interferences were almost completely removed after molecular imprinted solid phase 
extraction (MISPE). The authors also emphasised that the yolk extracts, following MISPE, 
had better baselines, higher recovery and selectivity than that obtained after C18 solid 
phase extraction (SPE).
112
 
In this thesis, the aim was to develop non-covalently bonded molecular imprinted polymers 
that were capable of selectively extracting a range of steroids from urine. Testosterone was 
used as the template molecule with the view that once it was removed the cavities 
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generated would be complementary in shape, size, affinity and functionality and would 
therefore bind to a wide range of endogenous androgens, 19-nor-steroids, metabolites, 
prohormones and synthetic analogues of testosterone (designer steroids) that share the same 
four ring, fused nucleus as testosterone. Following elution of these steroids from the MIPs 
they will be analysed by comprehensive gas chromatography to provide a screening method 
for steroids present in complex matrices. 
Although the method will be used for the extraction of steroids from spiked synthetic urine 
it is anticipated that in the future it may also be applied to different biological and food 
samples such as human serum, contaminated meat and nutritional supplement with slight 
modification to accommodate solid sample analysis. 
1.2.5.8. The application of MIPs with steroids in the thesis 
As has previously been stated in Section 1.1.2.2, it is recognised that most steroids present 
in urine samples are actually present in the conjugated form, as a result of Phase II 
metabolism, to form either a sulphate or glucuronide moiety. It is also recognised that less 
than 3% of the total androgens excreted via urine are unconjugated, i.e. in the free form.  
Conjugation of steroid androgens is generally with glucuronide; however, steroid 
androgens such as testosterone, epitestoerone, androsterone and etiocholanolone may also 
be excreted as sulfates, with their ratio to glucuronide nearing 1:1, in some instance.   
As both sulfates and glucuronide conjugates are formed through metabolism, they are 
beyond the scope of this study, due to the significant practical and ethical approval 
constraints that this would have introduced in the project. In addition, none of the 
conjugates would be viable for comprehensive gas chromatography, as they are not volatile 
nor thermally stable.   
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The approach taken in this project, to evaluate the performance of the MIPs with synthetic 
urine spiked with steroids, is based on the fact that free steroids are available in urine and 
that many existing methods already utilise deconjugation or hydrolysis of the steroid 
conjugate prior to solid phase extraction, followed by derivatisation ahead of gas 
chromatographic separation. In addition, prohibited AASs in nutritional supplements, once 
extracted with a suitable solvent, will be in the free form and positive control samples for 
supplement testing are prepared by spiking with the steroid. The coupling of a free steroid 
MIPs method to the steroid deconjugation process and extraction methods used for 
nutritional supplement is beyond the scope of this thesis and should be addressed in the 
future, once the performance has been evaluated.   
1.2.6.    Aptamer-based detection  
In addition to molecular imprinted polymers, antibodies have been a popular choice for 
molecular recognition in diagnostic applications for more than four decades and have made 
an enormous contribution to a wide range of diagnostic assays routinely used in clinics.
113
 
Despite their widespread application, antibodies are not without their limitations: 
i) the production of monoclonal antibodies is a labour intensive and expensive 
process, 
ii) the generation of antibodies for toxins remains difficult, because the process begins 
in an animal,  
iii) the antibody may show variation from batch to batch, thus affecting the binding 
affinity,  
iv) an antibody can be irreversibly denatured by high temperatures. 
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Given these factors, aptamers have emerged, since the early 1990s, as an alternative to 
antibodies and molecular imprinted polymers in both diagnostic and therapeutic 
applications.
113,114
   
Aptamers (from the Greek words meaning “fitting” and “particle”) are three-dimensional 
structures with a well-defined single stranded sequence of oligonucleotide entities. They 
tend to be short (50-100 bases) and can be composed of RNA, DNA or modified bases. A 
large number of aptamers can be generated randomly in an oligonucleotide library and then 
those ligands that bind in vitro to a given target solute, with high affinity and selectivity, 
can be amplified for use in applications.
115
 The in vitro selection method is known as 
SELEX and has been widely developed, from that first reported by Gold's and Szostak’s 
groups in 1990.
114, 116, 117
 
In brief, SELEX uses a nucleic library (10
14
-10
15
 random oligonucleotide strands) which is 
incubated with the target molecule. The bound and unbound strands are separated and the 
target-bound strands are eluted from the target molecule and are amplified via a polymerase 
chain reaction. This selection process is repeated between 6 and 15 times, with increasingly 
stringent conditions, so that the nucleic acid obtained has the highest affinity to the target 
molecule.
114
 
The interest in current research remains based on their high affinity, specificity and 
reversible denaturation. The range of molecules that aptamers can bind to include nucleic 
acids, proteins and small organic molecules.
118
 Aptamers have been designed for targets 
that cover a wide range of diseases from HIV to tropical diseases and cancer.
118,119 
The 
versatility that aptamers display for target recognition have made them a good candidate for 
analytical diagnostic applications.  
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Aptamers overcome a number of the issues associated with the use of antibodies: 
i) their production does not require the use of animals and therefore they can be 
produced against a number of toxins, 
ii) as they are produced by chemical synthesis, with high accuracy and reproducibly, 
they show little or no batch-to-batch variation,
  
 
iii) aptamers can undergo modification to enhance their binding affinity to target 
molecules, which is a major advantage compared to antibodies, 
iv) aptamers elicit little or no immunogenicity in their therapeutic application. 
1.2.6.1. Attaching aptamers to magnetic beads  
In 1976, Prof. Ugelstad and co-workers were successful in producing polystyrene beads 
that were spherical and highly reproducible in size, a feat previously only achieved in zero-
gravity.
120 
The group then succeeded in making these beads magnetisable and they were 
commercialised by Invitrogen.   
Dynabeads M-280 (Streptavidin), from Invitrogen (Life Technologies), are used for the 
attachment of biotinylated molecules. Having a monolayer of recombinant streptavidin 
covalently coupled to the surface, these uniform and superparamagnetic beads are 2.8 m 
in diameter. Most published research literature utilises aptamers bound via streptavidin-
biotin. 
 
Magnetic beads not only ensure an optimal large surface area to immobilise the analytes on, 
but also provide an easy mechanism by which the target-bound beads can be removed from 
the supernatant. Traditional sample-enrichment processes, such as solid phase extraction, 
can require several complicated procedures and skilled analysts. 
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Aptamers immobilised on magnetic beads have already provided a solution to the high 
throughput screening demands of the sexually transmitted disease, chlamydia. At the time 
of analysis, an aptamer for testosterone was not commercially available. Therefore 
aptamers were considered that bound to estradiol, as the compound most closely relate to 
our steroids of interest.  
The goal of this work was to design and evaluate, through a short pilot study, the feasibility 
of an aptamer-based assay for the extraction of estradiol from complex matrices, prior to 
quantitation by mass spectrometry.   
Despite recent advances, the use of GC/MS coupled to an aptamer-based enrichment 
procedure remains elusive. To the best of my knowledge there is no method in literature 
using comprehensive gas chromatography/mass spectrometry with aptamer coated 
magnetic beads for such sample enrichment.  
1.3. Thesis overview  
The aim of the thesis is to develop and evaluate the potential of a non-targeted analytical 
screening technique that enables the extraction and detection of as wide a range of steroids 
as possible, from complex matrices, at levels that are appropriate for the challenges of 
sports and supplement testing and clinical applications. 
The analytical method to be investigated is comprehensive gas chromatography/time-of-
flight mass spectrometry coupled with molecular imprinted polymers. The hypothesis is: 
i) by harnessing the orthogonal separating power of two-dimensional gas 
chromatography it will enable very similar compounds to be resolved temporally, 
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enabling its application for the screening of a wide range of derivatised and 
underivatised steroids. 
ii) the coupling of the comprehensive chromatography eluent with the fast acquisition 
rate of a time-of-flight mass spectrometer further enhances the resolving power by 
enabling the capture of  the full mass spectrum at such a rate that peak 
deconvolution is also possible.   
iii) molecular imprinted polymers can be templated with testosterone with the aim of 
selective extracting a wide range of steroids from complex matrices, such as urine. 
This approach focuses on the shape-matching of the common steran nucleus of 
steroids and the associated binding with ketone and hydroxyl polar groups.  
iv) in contrast to existing targeted techniques, such as LC/MS/MS or GC/MS (SIM), 
this non-targeted screening process will also aim to capture a full mass spectrum 
profile of any steroid present in the sample; thereby reducing the potential for false 
negatives and will provide a highly visual chromatographic landscape so that the 
operators can concentrate their search for doping violations in specific regions (e.g. 
stimulants, prohormones or designer steroids) which are distinct from those of 
matrix compounds and instrumental artifacts, such as column bleed, 
The developed screening technique will be evaluated for its suitability for detecting a range 
of structurally similar, difficult to analyse, sports testing relevant prohormones and a 
smaller range of new designer steroids, such as THG, which share the same ring structure 
as testosterone. The quantities and concentrations of prohormones and designer steroids 
analysed in the thesis, both as standards and in spiked synthetic urine, have been dictated 
by the Minimum Required Performance Level (MRPL) specified by the sports testing 
regulatory agency, the World Anti-Doping Agency, in its Prohibited Lists.
5,121
 The 
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experimental work was conducted based on the MRPL concentration level of 10 ng/mL, for 
steroids in urine, as published in 2010. During this period of study, WADA have since 
reduced the MRPL levels, for most steroids to 5 ng/mL. Discussions of the results and the 
evaluation of the applicability of the method will take in to account both these values.  
Prior to evaluating the performance of MIPs coupled with comprehensive gas 
chromatography, a pilot study was conducted that set out to evaluate the potential of 
utilising aptamers bound to magnetic beads as a simple, extraction clean-up procedure for 
estradiol, prior to analysis by gas chromatography/mass spectrometry (GC/MS) and liquid 
chromatography/mass spectrometry (LC/MS/MS).  The results of this study are presented 
in Chapter 5. 
All analyses were performed at the Department of Physical Sciences, (formerly Planetary 
and Space Sciences Research Institute (PSSRI)) in the Science Faculty, at The Open 
University. Access, training and support was available for comprehensive gas 
chromatography and a Thermo Fisher triple quadrupole LC/MS/MS system. Access to both 
instruments for steroid analysis provided an exceptional opportunity; however, whilst there 
was experience of applying comprehensive chromatography to drug testing, there was no 
tradition in steroid analysis and the work presented in this thesis has been developed within 
the timeframe of this project. Similarly, there was no tradition of steroid analysis in the 
aptamers and molecular imprinted polymers groups. 
The foregoing chapters describe a journey from the initial challenges of steroid detection to 
a solution which combines the selectivity of a molecular imprinted polymer and the 
separation capabilities of comprehensive gas chromatography. This screening method will 
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then be applied to the detection of designer steroids modified specifically to avoid 
detection. 
Chapter 2: Outlines the experimental methods, the chemicals and reagents, the 
instrumentation and the preparative procedures undertaken for this thesis. The extraction 
methods and instrument operating conditions have been developed by a mixture of 
experience, critical review of published literature, personal communications and a degree of 
trial and error. 
Chapter 3:  The resolving power of comprehensive two-dimensional gas chromatography 
(GC x GC) coupled with time-of-flight mass spectrometry (TOFMS) is evaluated for a 
range of challenging prohormones. The twelve prohormones, shown in Figure 1.18, were 
provided by HFL Sports Science, and were selected as they are known to cause them 
issues: such as poor quantitation, high detection limits, poor peak shapes, unreproducible 
derivatisation and laborious and time-consuming extraction techniques. 
Both derivatised and underivatised prohormones will be explored. Their elution times, 
limit of detection and linearity will also be determined. The efficiency of two molecular 
imprinted polymers (templated with testosterone in this project) to recover these 
prohormones from spiked synthetic urine samples (10 ng/mL) will be characterised. 
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Figure 1.18. Prohormones to be investigated in this thesis. 
 
Chapter 4: The method developed was applied essentially unmodified to screen for the 
presence of an additional six designer steroids to evaluate the wider, non-specific 
capability of the screening process.  The designer steroids, shown in Figure 1.19, were 
provided by HFL Sports Science, as they are difficult to detect using the existing 
derivatisation methods employed in most sports testing laboratories.  Those with functional 
groups added at the C-17 position are particularly difficult to derivatise, due to steric 
hinderance. 
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Figure 1.19.  Designer steroids screened using the method developed in Chapter 4. 
Prior to spiking into synthetic urine, a rigorous validation of the suitability of the 
comprehensive gas chromatography/mass spectrometry (GCxGC/MS) for the quantitation 
of prohormone and designer steroids in standard mixes was conducted, at levels 
appropriate to sports testing at the time of study. The performance of the molecular 
imprinted polymers was re-evaluated using designer steroids spiked into synthetic urine at 
the 10 ng/mL level (WADA 2010) along with the original cohort of prohormones spiked at 
between 2-10 ng/mL, to explore if they had any influence. Methyltestosterone was also 
used as an internal standard. To our knowledge, no comprehensive GC x GC screening 
method that utilises molecular imprinted polymers and detects designer steroids has yet 
been developed.  
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Chapter 5:  In today’s modern analytical laboratories, automated systems are constantly 
being pursued. The acceptance criteria for new instruments or techniques include their 
longevity, the expertise required to operate them and the ability to reduce cost. A critical 
measure of a laboratory’s performance, investigating hundreds of urine or nutritional 
samples, is simply the number analysed in a day.  
Mass spectrometry–based systems, when coupled with chromatography, can provide the 
ultimate specificity for compound identification and are therefore widely implemented. 
However, there is a desire to evolve from existing, mainly manual, solid phase extraction 
methods, due to the labour intensiveness and associated solvent cost.  
In an attempt to bridge this gap, a pilot study was conducted to evaluate the hypothesis that 
small uniform magnetic particles coated in an aptamer (a complimentary molecular 
recognition technique to MIPs) could provide a simple sample clean–up method for the 
detection and quantification of estradiol by mass spectrometry. Accurate determination of 
the concentration of this endogenous hormone has a range of clinical applications. 
Chapter 6:  Conclusions and future work. 
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2.  Experimental 
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2.1.  Introduction 
This chapter is divided into two sections, based on the individual studies conducted within 
this thesis. The first section (Section 2.2) relates to the methodologies applied during the 
development and evaluation of molecular imprinted polymers for the selective extraction of 
prohormones from synthetic urine, followed by analysis by gas chromatography/mass 
spectrometry. The section is organised to provide a full description of materials and 
equipment used in each study and any preparative methods applied and instrumental 
settings used and is the basis of the studies reported and discussed in Chapter 3. It also 
describes the mixed steroid standards prepared for the more detailed validation study 
reported in Chapter 4 and the application of the method to a range of designer steroids. The 
method is then applied to evaluate the performance of MIPs with synthetic urine samples 
spiked with lower levels of prohormones (2 ng/mL) and designer steroids (10 ng/mL).  
The second section (Section 2.3) describes the materials, apparatus and methods used as 
part of a pilot study to evaluate the detection and quantitation of estradiol following 
extraction by an aptamer bound to magnetic beads. The results of this study are reported 
and discussed in Chapter 5. 
2.2. The development of a method for the analysis of prohormones and designer 
steroids by comprehensive gas chromatography/mass spectrometry (GCxGC/MS) 
following extraction by molecular imprinted polymers (MIPs) 
2.2.1. Materials 
The steroids used in this study were supplied by HFL Sport Science (Newmarket, Suffolk, 
UK), and form part of their screening process. Individual steroids were provided at 
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concentrations of 1 mg/mL and 10 g/mL in methanol. The following 12 steroids were 
initially provided: 5(10)-estrene-3b,17b-diol, 4-estrene-3b,17b-diol, 5(10)-estrene-3,17-
dione, 4-androstene-3b,17b-diol, DHEA, 5(6)-androstene-3b,17b-diol, 5a-androstane-
3b,17b-diol, 5a-androstane-3,17-dione, nandrolone, 5(6)-androstene-3,17-dione; 
testosterone and 1,4-androstadiene-3,17-dione. All steroids were handled in accordance 
with Class C, Schedule 4 (Part II) Regulations. REA1090 - Buffer solution (pH 9.00) was 
purchased from LGC Ltd. (Teddington, Middlesex, UK). Surine (synthetic urine) was 
purchased from Cerilliant (Sigma-Aldrich Company Ltd., Poole, Dorset, UK).  
All solvents used (acetonitrile, hexane, methanol, undecane) were of HPLC grade and were 
purchased from Fisher Scientific (Loughborough, Leicestershire, UK). Derivatising agents 
(ammonium iodide (NH4I), Di-methyl formamide (DMF), N-methyl-(tert-
butyldimethylsilyl)-N-trifluoroacetamide (MTBSTFA) and ethanethiol) were obtained from 
Sigma-Aldrich Company Ltd. (Poole, Dorset, UK). 
Methacrylic acid (MAA), 4-Vinylpyridine (4-VP), trimethylolpropane trimethacrylate 
(TRIM) and azo-N,N,′-diisobutyronitrile (AIBN) were all obtained from Sigma-Aldrich 
Company Ltd. (Poole, Dorset, UK) for the preparation of the molecular imprinted 
polymers. All solvents used at this stage (acetic acid, acetone, acetonitrile, chloroform, 
methanol) were of HPLC grade and were purchased from Fisher Scientific (Loughborough, 
Leicestershire, UK). Testosterone was obtained through the Science Faculty Chemical 
Health and Safety Advisor (The Open University, Milton Keynes, UK) and used in 
accordance with Class C, Schedule 4 (Part II).  
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2.2.2. Apparatus and equipment 
Vortexing was performed using the MS3 Basic (IKA, Staufen, Germany). Centrifugal 
evaporation was performed using a SF50 and CVP100 pump (Genevac Ltd., Ipswich, 
Suffolk, UK). Heating was performed in Techne DB-3A dry block heater (Bibby Scientific, 
Staffordshire, UK). Glass vials were obtained from Chromacol Ltd. (Welwyn Garden City, 
Herts, UK). Solid-phase extraction (SPE) and molecular imprinted polymer extraction 
(MIP) were performed using a 12-port vacuum manifold (Sigma-Aldrich Company Ltd., 
Poole, Dorset, UK). Strata C18 SPE cartridges (3 mL) were purchased from Phenomenex 
(Macclesfield, Cheshire, UK). De-ionised water was obtained from a Synergy 185 Water 
Purification System (Merck Millipore Ltd., Watford, Hertfordshire UK). 
2.2.3. Preparation of the derivatised mixed prohormone standard  
A mixed standard was prepared by adding 20 µL of each of the 12 prohormones, at an 
initial concentration of 1 mg/mL in methanol, and then diluting with an equal volume of 
methanol to give a concentration of each prohormone of 0.04 mg/mL. 100 μL of this 
solvent was evaporated to dryness under a gentle stream of nitrogen.  
The tert-butyldimethylsilyl (TBDMS) derivatising reagent was prepared by the standard 
HFL method: 18 g of ammonium iodide, 1.5 mL DMF, 3 mL MTBSTFA and 30 mL of 
ethanethiol were all mixed thoroughly, capped and left for 10 mins.
1
 100 μL of this solution 
was then added to the dried prohormones and incubated at 100 ºC for 1 hour. Methanol (0.5 
mL) and reagent grade water (0.5 mL) were added and whirl mixed. Hexane (2 mL) was 
then added to the mix. The sample was inverted gently and the top hexane layer was 
transferred to a small glass tube. The hexane extraction was repeated another two times. 
The sample was then evaporated under nitrogen gas and reconstituted in 30 μL of 
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undecane.
1 
As described below, the sample was then analysed by GC/MS in both 1D and 
2D-GC modes. 
2.2.4. Instrumental parameters used for analysing the derivatised prohormones by 
gas chromatography/ mass spectrometery (GC/MS)     
The GC/MS analyses were performed using a Leco Pegasus® IV time-of-flight (TOF) mass 
spectrometer (Leco Corporation, St Joseph, Michigan, USA) fitted with an Agilent 6890 
gas chromatograph (GC) (Agilent Technologies, Santa Clara, California, USA) modified to 
house a secondary oven and a twin stage cryo-modulator (Leco Quad-Jet). The GC was 
equipped with an Agilent split/splitless injector and a CombiPAL autosampler (CTC 
Analytics AG, Zwingen, Switzerland). The ionisation source was held at 280 C and the 
ionisation energy was set at 70 eV. The MS was calibrated against m/z ions 69, 131, 219 
and 502 using perfluorotributylamine (PFTBA). Data processing and mass spectral 
deconvolution was performed with the Leco ChromaToF® software. The GC analyses were 
performed in two different modes: one dimension (1D) and two dimensions (2D); as 
described in the following paragraphs.   
2.2.4.1. 1D-GC mode 
The gas chromatography separation was performed using a Restek RXi5MS (30 m x 0.25 
mm i.d. x 250 μm) (Thames Restex, Sauderton, Buckinghamshire, UK) capillary column in 
the first dimension and a SGE BPX50 (1.79 m x 0.11 mm x 0.1 m) (SGE, Milton Keynes, 
Buckinghamshire, UK) capillary column in the second dimension. This is the traditional 
non-polar first dimensional column and shorter polar second dimensional column used for 
comprehensive gas chromatography and is a combination that has successfully been used in 
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the laboratory by others. The carrier gas used was helium (1.0 mL/min, constant flow).   
The injector temperature was held at 280 °C, with a 1 μL splitless injection (valve time of 
90 s). The main oven temperature programme was 100 °C (1.5 min), 10 °C /min to 340 °C 
(10.0 min). The secondary oven was operated at 15° C above the primary oven. The 
modulation time was set for 0 s (effectively the cryogenic modulator was disabled) and all 
the compounds will therefore elute directly into the mass spectrometer. The TOF mass 
spectrometer was operated at 6 spectra/s acquisition rate in the mass range:  45 to 550 Da.    
2.2.4.2. 2D-GC mode 
The operating conditions in the 2D-GC mode were identical to those used in the 1D-GC 
mode, except for the modulation time set at 4 s, and the TOF mass spectrometer being 
operated at an acquisition rate of 200 spectra/s, in the mass range: 45 to 550 Da. As is the 
convention, the acquisition rate was optimised to provide at least 20 data points across a 
peak. Since the width of the analyte peaks obtained in 2D mode are significantly narrower 
than in 1D mode, following cryogenic modulation, the acquisition rate needs to be 
significantly higher than that used in the 1D mode. 
2.2.5. Preparation of the underivatised prohormone standard mix 
100 L of each prohormone solution (10 g/mL, in methanol), provided by HFL Sport 
Science, was added to a 2 mL autosampler vial which gives a final concentration of each 
prohormone of 833 ng/mL and a total volume of 1200 L. 500 L of the mixed standard 
was dried and reconstituted in the same volume of acetonitrile.  
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2.2.6. Instrumental parameters used for analysing underivatised steroids by 
comprehensive gas chromatography / mass spectrometry (GCxGC/MS) 
Underivatised prohormones were resolved using comprehensive gas chromatography. As 
previously reported, this was achieved through the use of an Agilent 6890 GC, modified to 
house a secondary oven and twin-stage cryo-modulator. Cryo-cooling was enabled by 
nitrogen gas passing through a liquid nitrogen dewar. The GC was equipped with an 
Agilent split/splitless injection port and a CombiPAL autosampler. The separation was 
performed using a J&W DB-5ms (30 m × 0.25 mm × 0.25 m; Agilent Technologies) 
capillary column in the first phase and an SGE  BPX50 (2 m × 0.1 mm × 0.1 m; SGE, 
Milton Keynes, UK) in the second phase. The carrier gas used was helium (Air Products, 
BIP Grade) in constant ﬂow mode (1.0 mL/min). The modulation time was set at 6 s with 
the period of the hot pulses set at 0.6 s.  
The samples were injected onto a splitless liner (3 mm internal diameter). The injector 
temperature was held isothermally at 220 ºC for a 1μL splitless injection (valve time of 90 
s).  The main oven temperature programme was 65 ºC (90 s), 15 ºC/min to 290 ºC (15 min).  
Over the entire run, the secondary oven was maintained 15 ºC higher than the main oven 
and the modulator temperature was kept 30 ºC higher than the main oven. 
The analysis was performed using a Leco® Pegasus® IV time- of-ﬂight (TOF) mass 
spectrometer. The TOF mass spectrometer provided unit-resolution in the mass range 5-
1000 Da. The ion source temperature was 230 ºC and the ionisation energy was 70 eV (EI). 
The TOF mass spectrometer was operated with an acquisition rate of 200 Hz. A solvent 
delay of 500 s was used. The data processing and mass spectral deconvolution were 
performed with the Leco® ChromaToF® software. 
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2.2.7. Validation studies for the analysis of underivatised steroids by comprehensive 
gas chromatography / mass spectrometry (GCxGC/MS) 
The linearity of the GC/MS response for each of the steroids in acetonitrile was determined.  
A mixed standard, in acetonitrile, was used to prepare a 5-point calibration curve at 
concentrations of 500, 200, 150, 125 and 50 ng/mL for each steroid. Based on a 1 L 
splitless injection of each solution, this is equivalent to a range of 500 - 50 pg being 
injected on column. 
The limits of detection (LOD) and limits of quantitation (LOQ) were calculated by repeat 
injections (x10) of 1 L of the lowest concentration standard (50 ng/mL), equal to 50 pg on 
column. The limit of detection was taken as a value that was 3 x the standard deviation 
determined at this lowest concentration; whereas the limit of quantitation was taken as a 
value of 10 x the standard deviation.   
2.2.8. Preparation and characterisation of the molecular imprinted polymers 
Molecular imprinted polymers can be developed to achieve selective binding for a family 
of similar compounds. A variety of potential polymer “recipes” were therefore investigated, 
using the literature as a guide. Gadzala-Kopciuch used progesterone, testosterone and 17b–
estradiol as templates to develop SPE cartridges for clean-up and detection of steroids in 
urine using LC. They reported good results and clear sample clean-up.
2
 Doue et al., used 
17b-estradiol as a template for analysis of 12 steroids in cattle urine.
3
 SPE was used as a 
clean-up before GC-MS analysis. Satisfactory recoveries (65%+) were recorded for all 
compounds. This is similar to the work described here in that one template is used for 
several compounds. We sought to improve on the detection protocol by the use of GCxGC-
MS. A number of different monomer systems (2-vinylpyridine, 4-vinylpyridine, 
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hydroxyethylmethacrylate, methacrylic acid) were considered, as were the crosslinkers: 
ethylene glycol dimethacrylate and divinylbenzene. Finally, based on the available 
literature and strongly guided by the experience of Dr Nicholas Turner in this field, MAA 
and 4-VP (monomers) and TRIM (crosslinker) were selected for study. The relative uptake 
of each of these was studied for both the MIP (testosterone imprinted polymer) and NIP (a 
reference non-imprinted polymer). 
Testosterone was used as a template for three reasons. Firstly, it is one of the simplest 
steroidal structures and its chemistry is well understood. Secondly, many of the “designer” 
steroids that are used in doping aim to mimic the functionality of testosterone, so this 
molecule should potentially act as a good surrogate template. Finally, as testosterone is an 
endogenous steroid it is not analysed in the same way as the prohormone compounds of 
interest (such as nandrolone). By using testosterone as the surrogate template we can reduce 
the risk of false positives that may be caused by leaching of the template. 
The prohormone compounds selected for study share a high level of similarity to 
testosterone, in terms of structure, charge and the functional groups present. These 
similarities increase the probability that a MIP developed for a close analogue will bind to 
all targets, but also offer the opportunity to demonstrate the viability of the developed 
technique to separate and quantify structurally similar compounds.  
For the polymerizing procedure, the template (testosterone), the monomers (MAA or 4-
VP), cross-linker (TRIM) and free-radical initiator (AIBN) were dissolved in the porogen 
solvent, chloroform, in the molar ratio 1:4:20. A quantity of 20.0 mg of testosterone was 
dissolved into 1.510 mL of chloroform in a glass vial (4.5 mL).  To this solution, 23.5 μL 
of methacrylic acid (monomer) and 1.745 mL of TRIM were added and mixed by 
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vortexing. AIBN (10 mg) was then added to this solution and again mixed via vortexing. 
Once all the components were dissolved, the solution was sparged with oxygen-free 
nitrogen for 1 minute and the vial sealed. Polymerization was achieved by heating the 
solution in the sealed glass vial, in a dry oven, at 60 °C for 24 hours.
4
 
After polymerization, the vials were smashed and the monolithic polymers obtained were 
ground in a mortar and pestle and wet-sieved through a mesh metal sieve. Fine particles 
were removed by repeated sedimentation using acetonitrile and up to 2 litres of acetonitrile 
was required for this procedure. A fraction with particle sizes of 38–63 μm was then 
collected. At least four repeated grinding and sieving cycles were necessary over 7 to 10 
days, to reduce the size of the particles and to obtain an adequate amount of particles for 
packing into the cartridges.   
Removal of the imprinted testosterone from the MIPs particles was undertaken by a Soxhlet 
extraction with methanol–acetic acid (9:1, v/v) for 48 hours, this period had previously 
optimised within the group. Non-imprinted polymers (NIPs) were synthesized and prepared 
simultaneously, under the same conditions but without adding the testosterone template. 
Six empty SPE cartridges (3 mL) were packed with 20 mg of MIPs or NIPs (3 of each).  
This was undertaken by placing a frit carefully into the empty cartridge, weighing the 
amount of MIP, and then adding an additional frit. The MIPs extraction was performed on a 
12-port SPE vacuum manifold. The polymers were conditioned prior to use with methanol 
(1 mL) and with water (1 mL). 
The two molecular imprinted polymers generated were named M5 (MAA) and M6 (4-VP), 
respectively. Similarly, the non-imprinted polymers were named B5 (MAA) and B6 (4-
VP), respectively. 
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Scanning electron microscope images were recorded using secondary and backscatter 
electron detectors on an FEI Quanta 200 3D, with a tungsten filament source operating at 
an accelerating voltage of 15 kV, beam current 0.5 nA and a 15 mm working distance. 
2.2.9. An evaluation method to determine the percentage recovery of underivatised 
prohormones from synthetic urine using MIPs   
The recovery of the analytes was determined by comparison of peak areas from synthetic 
urine samples spiked with known amounts of steroids (10 ng/mL), processed according to 
the described method versus non-extracted pure standards which represent 100% recovery. 
As for the sections above, the response factors (determined as peak areas) of each of the 
steroids were determined from 1 L splitless injections of a mixed standard in acetonitrile. 
The polymers were conditioned with methanol (1 mL) and then with water (1 mL). 1 mL of 
synthetic urine was spiked at the 10 ng/mL level for each prohormone. 1 mL of buffer, at 
pH 9, was then added and the 2 mL solution was whirl-mixed three times before being 
added to each of the MIPs cartridges. The spiked, buffered urine samples were loaded onto 
the MIPs cartridges in three steps (100 L, 900L and 1000L). The washing step was 
then performed with 1 mL of water and 1 mL of 40 % methanol in water (v/v).   
Elution of the extracted analyte was achieved by adding 1 mL of pure methanol. The load, 
wash and elution solvents were collected in 70 mm glass tubes. The elution solvents were 
then transferred to a 2 mL autosampler vial and each was evaporated using a SF50 
(Genevac). Once dry they were then reconstituted in 20 μL of acetonitrile and the solution 
of underivatised hormones were injected in the comprehensive gas chromatography system. 
Urine samples were prepared in triplicate at each concentration. Speciﬁcity was 
demonstrated by analysis of blank urine samples. 
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2.2.10.   Further validation of the GCxGC-MS method when applied to prohormones 
and designer steroids  
The screening method developed and optimised for the detection of the 12 prohormones, 
was evaluated for its ability to detect and identify a wider range of steroids present in urine 
samples, including several designer steroids. A request for epitestosterone, methyl 
testosterone and a range of “designer steroids” was made to HFL Sport Science. As a result, 
seven additional steroids were provided for the study. These included: methyl testosterone, 
epitestosterone, Xtren, trenazone, gestrinone, tetrahydrogestrinone, and epistane. Methyl 
testosterone was used as an internal standard. The solvents, reagents and materials prepared 
for the initial prohormone study were once again utilised in this study. 
Stock solutions of the six designer steroids were prepared in methanol, at a concentration of 
100 g/mL. 100 L aliquots of the six designer steroids were then combined and added to 
400 L of MeOH, to make a mixed designer steroid stock solution, each at a concentration 
of 10 g/mL. This was further diluted with methanol to generate a second mixed designer 
steroid stock solution at 1 g/mL. The stock solution was then diluted in methanol to 
produce DS#1, with each steroid present at a concentration of 0.5 g/mL.  
Combining together 500 L of DS#1 with an equal volume of a mixed prohomone stock 
standard (at 500 ng/mL) resulted in a mixed designer and prohormone standard (DSP#1) 
with each steroid present at a concentration of 250 ng/mL.   
An internal standard solution was prepared in methanol, with methyltestosterone at a 
concentration of 500 ng/mL. The dilution of the above mixed standards with varying 
amounts of methanol, followed by the dilution of these intermediary solutions with a 
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consistent 1:3 mix of the internal standard solution resulted in a range of mixed 
designer/prohormone solutions, with the internal standard present at a concentration of 167 
ng/mL in each. DSPI#1 contains the prohormones and designer steroids, each at a 
concentration of 100 ng/mL; whereas DSPI#2 and DSPI#3 contain each of the designer 
steroids and prohormones at concentrations of 50 and 25 ng/mL, respectively. 
2.2.11.   A method to evaluate the performance of the MIPs screening technique, when 
applied to urine samples containing designer steroids (10 ng/mL)  in the presence 
of prohormones                   
1 mL samples of synthetic urine were spiked with designer steroids and an internal standard 
(methyl testosterone) at 10 and 500 ng/mL of each, respectively. The urine samples were 
also spiked with the 12 prohormones, over a range of concentrations (2 to 10 ng/mL), to 
ascertain whether their presence influenced the measurement of the designer steroids. The 
solution therefore contained a total of 19 steroids, to which 1 mL of buffer, at pH 9, was 
added and whirl-mixed three times.  
As before, the polymers were conditioned with methanol (1 mL) and then with water (1 
mL). The spiked urine samples were loaded on the MIPs cartridges in three steps (100 L, 
900L and 1000L). The washing step was then performed with 1 mL of water and 1 mL 
of 40 % methanol in water (v/v).   
Elution of the extracted analyte was achieved by adding 1 mL of pure methanol. The load, 
wash and elution solvents were collected in 70 mm glass tubes. The elution solvents were 
then transferred to a 2 mL autosampler vial and each was evaporated using a SF50 
(Genevac). Once dry they were then reconstituted in 20 μL of acetonitrile.  
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It should be noted that since conducting these experiments the WADA specifications for 
anabolic androgenic steroids have changed. In 2013 it reduced to 5 ng/mL, from a level of 
10 ng/mL in 2010.
5,6
  
The level of recovery for the designer steroids was determined by the use of standard 
solutions that mimicked the process that the urine samples experienced, without the 
addition to urine and MIPs extraction. These standards bracketed the MIPs samples 
analysed on the GCxGC/MS. The average peak area obtained for each designer steroid in 
these standards was divided by the peak area of the internal standard. The percentage 
recovery in each of the MIPs cartridges was then calculated from the ratio of peak areas for 
each designer steroid relative to the peak area for the internal standard divided by the 
values in the bracketed controls.    
2.3. A pilot study to evaluate the feasibility of the analysis of estradiol by GC/MS 
and LC/MS/MS following extraction by aptamers  
2.3.1. Materials 
The DNA aptamer (5-Biotin GCTTCCAGCTTATTGAATTACACGCAGAGGGTAGCG-
GCTCTGCGCATTCAATTGCTGCGCGCTGAAGCGCGGAAGC-3) was purchased from 
Integrated DNA Technology Inc. (Leuven, Belgium). De-ionised water was obtained from 
a Synergy 185 Warer Purification System (Merck Millipore Ltd., Watford, Hertfordshire, 
UK).  Estradiol was purchased from Sigma-Aldrich Company Ltd. (Poole, Dorset, UK).  
Tris-HCl, NaCl, EDTA, MgCl2, and urea were purchased from Sigma-Aldrich Company 
Ltd. (Poole, Dorset, UK).  N-tert-butyldimethylsilyl - N-methyltrifluoroacetamide 
(MTBSTFA) with 1% tert-butyldimethyl chlorosilane (TBMCS) was purchased from 
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Sigma-Aldrich Company Ltd. (Poole, Dorset, UK).  Solvents (HPLC Grade) were 
purchased from Fisher Scientific Ltd. (Loughborough, Leicestershire, UK). 
2.3.2. Apparatus and equipment  
Vortexing was performed using the MS3 Basic (IKA, Staufen, Germany). The magnetic 
beads (Dynabeads M-280) and the magnetic block were purchased from Invitrogen (Oslo, 
Norway). Centrifugal evaporation was performed using a SF50 and CVP100 pump 
(Genevac Ltd., Ipswich, Suffolk, UK). The autoclaving of water was performed using an 
Autoclave 2100 Series (Prestige Medical Ltd., Blackburn, UK). Heating was performed in 
Techne DB-3A dry block heater (Bibby Scientific, Staffordshire, UK). Eppendorf tubes 
were obtained from the central stores. Glass vials were obtained from Chromacol Ltd. 
(Welwyn Garden City, Herts, UK). 
2.3.3. Preparation of the GC/MS calibration standards 
Estradiol standards were prepared by weighing the solid material and dissolving in 
methanol. Concentrations of 14,286 g/mL, 1428.6 g/mL, 142.86 g/mL, 1.4286 g/mL, 
0.14286 g/mL were used to prepare a calibration curve. A volume of 100 L of the 
sample was transferred to a 2 mL glass vial and dried using a Genevac SF50 centrifugal 
evaporator with CVP100 pump. 100 L of the derivatising reagent (MTBSTFA with 
1% TBDMCS) was then added and incubated at 100º C, for 1 hour, in a Techne DB-3A dry 
block heater. Of this, 1L aliquots were then injected into the GC system 
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2.3.4. Optimised parameters used for the GC/MS 
The analytical instrument used in this study is a Leco Pegasus® IV time-of-flight (TOF) 
mass spectrometer (Leco Corporation, St Joseph, Michigan, USA)  fitted with an Agilent 
6890 gas chromatograph (GC), (Agilent Technologies, Santa Clara, California, USA)  
modified to house a secondary oven and a twin stage cryo-modulator (Leco Quad-Jet).   
The analyses were performed in 1 D-GC mode and a secondary oven was fitted but the 
cryo-modulator was not operated. The GC was equipped with an Agilent split/splitless 
injector and a CTC CombiPAL autosampler (CTC Analytics AG, Zwingen, Switzerland).  
The chromatographic separation was performed using a SGE BPX50 (30 m x 0.25 mm i.d. 
x 250 μm film thickness) (SGE, Milton Keynes, Buckinghamshire, UK) capillary column 
and a SGE BPX5 (2m x 0.1mm x 0.1µm; SGE UK) second capillary column. The carrier 
gas used was helium (Air Products, BIP Grade, 1.0 mL/min, constant flow). The injector 
temperature was held at 280 °C, with a 1 μL splitless injection (valve time of 90 s). The 
main oven temperature programme was 200 °C (1.50 min), 6 °C /min to 320 °C (4.80 min).  
The TOF mass spectrometer was operated at 10 spectra/s acquisition rate in the mass range:  
50 to 650 Da. The ionisation source was held at 280C and the ionisation energy was set at 
70 eV. The MS was calibrated against m/z ions 69, 131, 219 and 502 using 
perfluorotributylamine (PFTBA). Data processing and mass spectral deconvolution were 
performed with the Leco ChromaToF® software. 
2.3.5. Preparation of the LC/MS/MS calibration standards 
The initial mobile phase (5% MeOH / 95% deionised water) was spiked with estradiol over 
a range of concentrations (100 ng/mL, 10 ng/mL, 1ng/mL, 100 pg/mL). A calibration curve 
for estradiol was obtained by assigning the concentration of estradiol to x and the peak area 
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of estradiol to y, respectively. Subsequently, linear regression was performed over the 
estradiol concentration range of 100 ng/mL to 100 pg/mL.   
2.3.6. Optimised parameters used for the LC/MS/MS 
A TSQ Quantum LC/MS/MS (Thermo Electron Corporation), equipped with an electron 
spray ionisation (ESI) source and a Surveyor HPLC system was employed for the 
evaluation of the efficacy of the estradiol extraction from the aptamer. The two columns 
evaluated were: 
1.  Hypersil GOLD, C18 Column (150 x 4.6 mm, 5 µm) connected to a C18 guard-
cartridge, in a guard-cartridge holder, from Thermo-Fisher; 
2. XBridge, C18 Column  (50 x 2.1 mm, 2.5 µm) from Waters. 
Data acquisition was performed in negative ion mode, using the transitions:   
m/z 271 → 145,  m/z  271 → 183,  m/z 271 → 158  and  m/z 271 → 158. 
The ions were selected by the automated Xcaliber software, determined as the ions present 
with the highest abundance. The mobile phase conditions were optimised, the lowest 
baseline noise was achieved by using a gradient consisting of water (Line A) and methanol 
(Line B) separated on a XBridge C18 Column, at a flow rate of 200 L/min. The gradient of 
the mobile phase started with 5 % methanol for 2 mins, it was then ramped up to 90 % 
methanol over 12 mins and maintained at 90 % methanol for 3 mins, before being returned 
to the initial conditions. The initial condition used is highly aqueous, greater interaction of 
the non-polar 17b-estradiol with the C18 Column is therefore expected. Ramping the mobile 
phase to a more organic condition, using methanol, will result in the elution of the 17b-
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estradiol. The ESI-MS/MS conditions were: spray voltage (4000 V); sheath gas (nitrogen, 
10 arbitrary units of gas pressure); auxiliary gas (nitrogen, 10 arbitrary units of gas 
pressure); ion transfer capillary temperature (330 °C); collision gas (argon, 1.5 mTorr gas 
pressure). The negative ion polarity injection volume was configurable from 10-50 μL. 
2.3.7. Method for binding the aptamer onto the magnetic beads 
Following the manufacturer’s protocol, the magnetic beads (Dynabeads M-280, coated with 
streptavidin) were first washed with a Binding and Washing buffer (10 mM Tris-HCl (pH 
7.5), 1 mM EDTA, 2 M NaCl) before use.
7
 After the trapping of the washed beads on to the 
magnet, the supernatant was removed and the beads were re-suspended in the same volume 
as originally added. A volume of 100 μL of the beads suspension was then introduced into 
an Eppendorf tube containing 50 μL of Binding and Washing buffer and 50 μL of aptamer 
solution (2 M). After 15 minutes of vortexing, the tube was placed on a magnetic block to 
allow the collection and separation of the beads; the supernatant was then removed and the 
beads were washed twice with the Binding and Washing buffer.  
The binding process was confirmed by measuring a change in the UV spectrum (scanned 
between 200 and 300 nm) transmitted through the solution before and after exposure to the 
beads. Before adding the beads, the aptamer solution showed an absorbance at λ max = 260 
nm. After the above procedure, there was no absorbance at λ max = 260 nm, indicating that 
the aptamer had bound to the magnetic beads. 
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2.3.8.  An overview of the method for evaluating the performance of the aptamer 
coated on to magnetic beads 
As previously discussed, effective sample clean-up strategies and efﬁcient chromatographic 
separations are required for the elimination of matrix interference to enable target species to 
be detected and quantified in complex biological samples. However, clean-up methods that 
require a large number of steps can lead to analyte loss. The bead-based method shown in 
Figure 2.1 only requires the following steps: 
i) the estradiol is spiked into the Hormone Binding Buffer; 
ii) 100 L  of this spiked buffer is added to the vial and vortexed with the aptamer 
coated magnetic beads for 1 hour; 
iii) the beads are magnetized and the supernatant is decanted and prepared for GC/MS 
and/or LC/MS/MS analysis; 
iv) the magnet is removed and an Elution Buffer (100 L) is added and vortexed for 20 
minutes;   
v) the beads are magnetized and the Elution Buffer supernatant is removed and 
prepared for GC/MS and/or LC/MS/MS analysis. 
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Figure 2.1  A schematic representation of the experimental procedure, showing the 
generation of the various solutions that were then prepared for analysis to 
evaluate the performance of the procedure.  
 
The various buffers used during the study were prepared following a review of the literature 
and their compositions are listed below: 
8
  
 Hormone Binding :  0.454 mM estradiol, 100 mM Tris-HCl, 200 mM NaCl, 25 mM 
KCl, 10 mM MgCl2, 5% ethanol, pH 8.0 
 Elution (#1): 40 mM Tris-HCl (pH 8), 10 mM EDTA, 3.5 M urea; 
 Elution (#2): 10 % sodium dodecyl sulphate (SDS). 
 
2.3.9.  A GC/MS method for the evaluation of the binding efficiency of the aptamer 
for estradiol and the efficiency of the Elution Buffer 
A 100 μL suspension containing the aptamer coated beads, was magnetised and the 
supernatant removed. 100 μL of the Hormone Binding solution, containing estradiol at 
Aptamer coated 
beads are vortexed with 
estradiol (1 hr) in the 
Hormone Binding Buffer 
 
The beads are 
magnetised and the 
supernatant decanted 
for analysis  
After decanting 
Elution Buffer 
is added and 
vortexed (20 m) 
 The beads are magnetised 
and the supernatant 
decanted ready for sample 
analysis 
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0.459 mM, was then added and vortexed for 1 hour, at room temperature. The beads were 
then magnetically separated and the supernatant was removed by pipette and diluted up to 1 
mL in distilled water, to be prepared for GC/MS analysis. Liquid-liquid extraction, using 1 
mL of hexane, was undertaken by inverting the 10 mL screw top glass vial ten times. The 
extracted hexane layer was transferred into a 2 mL autosampler vial with a glass pipette and 
then dried using a Genevac SF50 centrifugal evaporator with CVP100 pump. 100 L of the 
derivatising reagent (MTBSTFA with 1%  TBDMCS) was then added and incubated at 
100º C, for 1 hour, in a Techne DB-3A dry block heater. 1L aliquots were injected into the 
GC system for analysis. 
100 L of the Elution Buffer was added to the magnetic beads and vortexed. After 20 
minutes, the tube was placed on a magnetic block to allow collection of the beads; the 
supernatant was then removed and prepared for GC/MS analysis, as above.  
2.3.10.   A GC/MS method for determination of the percentage recovery of estradiol 
from the aptamer 
For the recovery standard, 100 μL of the Hormone Binding Buffer (0.454 mM Estradiol, 
100 mM Tris-HCl, 200 mM NaCl, 25 mM KCl, 10 mM MgCl2) was diluted to 1 mL with 
de-ionised water in a 10 mL screw top glass vial and then this solution was extracted with 
hexane (1 mL). The liquid-liquid extraction was undertaken by inverting the glass vial ten 
times. The extracted hexane was then transferred into a 2 mL autosampler vial with a glass 
pipette and then dried using a Genevac SF50 centrifugal evaporator with CVP100 pump. 
100 L of the derivatising reagent (MTBSTFA with 1% TBDMCS) was then added and 
incubated at 100º C, for 1 hour, in a Techne DB-3A dry block heater (Techne). 1L 
aliquots were injected into the GC system. 
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2.3.11.    Extraction of the buffer for LC/MS/MS analysis 
A 100 μL suspension of the Binding Buffer (spiked with 1 ng/mL of estradiol) was diluted 
to 1 mL with de-ionised water and then extracted with 1 mL of hexane. The extracted 
hexane was then dried and reconstituted in 100 µL of the mobile phase (90% 
methanol/10% water). The analysis was repeated three times. 
A 100 μL suspension of Binding Buffer spiked with 1 ng/mL of estradiol was diluted to 1 
mL with de-ionised water and then extracted with 1 mL of TBE. The extracted TBE was 
then dried and reconstituted in 100 L of the mobile phase (90% methanol/10% water).  
The analysis was repeated three times. 
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3.  The development of a method for the analysis of 
prohormones by comprehensive gas chromatography/ 
mass spectrometry following extraction by molecular 
imprinted polymers 
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3.1. Introduction 
The Olympic drug testing body and WADA have huge a responsibility to ensure the 
accuracy of its testing processes so that those athletes that are doping are not missed (false-
negative) and innocent athletes are not accused incorrectly (false-positive). The use of two 
test samples helps reduce the number of false-positives; whereas, the use of no-notice 
testing of athletes, while out of competition, narrows the window of opportunity to achieve 
benefit from banned substances.
1
 Anabolic agents are the most common performance 
enhancing substances detected in athletes. 
As shown in Chapter 1, the steroid structure can be best described as a fused tetracyclic 
nucleus, modified by the addition or removal of polar or non-polar functional groups and 
by different levels of saturation of the nucleus. The detection of the anabolic agent can be 
confounded by the large number of endogenous steroids and metabolites naturally present 
in low amounts within the complex matrix of the urine.   
Another challenge is the sheer number and variety of steroids that have been produced in 
the laboratories of pharmaceutical companies but discarded during the development stage.
2
 
With unpublished side effects, these steroids often find a route in to doping violation and 
can cause serious harm to the athlete. The development of new designer steroids, that are 
modified to specifically avoid detection, is also a serious concern.  
Furthermore, the requirements for low limits of detection has made unavoidable the use of 
the selective ion monitoring (SIM) mode on the quadrupole mass spectrometer; which, 
although highly sensitive, does have limitations when used in a comprehensive screening 
programme and may be exploited to produce false-negative results. These limitations stem 
from the fact that the SIM mode utilises a selection of pre-determined ions, from the 
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expected fragmentation profile of a given steroid or a group of steroids, at given retention 
times within the chromatogram. If a rogue chemist is aware of these detection windows, 
following derivatisation, then they can undertake a number of strategies to manipulate the 
steroid structure. For example, the steroid structure can be modified to introduce steric 
hindrances, thus preventing the derivatisation process. 
Currently, sample preparation includes a number of analytical steps with the overall 
extraction efficiency and selectivity of the method dependent on the technique used. Early 
methods of steroid analysis usually involved solvent extraction as the first step.
3 
The main 
drawback of liquid–liquid extraction is emulsion formation and the extraction can require 
the use of a large volume of toxic and flammable solvents. Non-polar solvents are often 
used to minimize the extraction of interfering compounds in the analyses of non-polar 
steroids.
3
 Modern methods for the extraction of steroids from urine usually involve liquid-
liquid or solid phase extraction.
4,5,6,7
 
Steroids are present in urine in the conjugated form, because the hydrophilic nature of the 
conjugated steroid aids urinary excretion. During Phase II metabolism, lipophilic steroids 
are conjugated with either a glucuronide or sulphate moiety. Steroids in the unconjugated 
form contribute to less than 3% of the total steroids excreted in urine.
8,9,10
 Steroid 
androgens are generally conjugated with a glucuronide moiety. Conjugated steroids can 
disintegrate under the high temperatures used in GC analysis, the first step thus requires de-
conjugation of the steroid into its free form. The choice of hydrolysis method is dependent 
on the steroid and conjugate moiety and hydrolysis conditions are often inefficient.  
Hydrolysis is often carried out by enzymatic or chemical means. Hydrolysis of a sulphate 
moiety is analytically more challenging, as many sulfate conjugates are resistant to enzyme 
hydrolysis or generate unwanted by-products and chemical hydrolysis is not without issue.
8
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Each preparation step in steroid analysis has its own challenges, from the efficient cleavage 
of the glucuronide or sulphate to the optimized conditions required for derivatisation.
8
 
These issues have resulted in the recent focus on direct conjugation analysis of steroids 
with a glucuronide moiety by LC/MS and LC/MS/(MS), thus removing the need for 
hydrolysis or derivatisation.  
LC/MS/(MS) is often deemed as the solution for all issues related to steroid detection. 
However, since the optimised mobile phase conditions, the column selected and the pre-
requisite for steroids to be in ionic form are all dependent on the steroid structure, 
manipulation of the steroid structure can still be used by the rogue chemist to avoid 
detection. The relatively poor chromatographic performance of LC, compared to GC, is 
another issue facing the movement towards LC/MS/(MS) as a solution for the screening for 
unknown steroids.  
The application of LC-MS/(MS) for the detection of steroids remains limited, owing to the  
the difficulty in ionizing anabolic steroids under ESI conditions, due to the lack of acidic or 
basic moiety in their chemical structure. The characteristic structure of anabolic steroids 
can also have a limiting effect in their ionization efficiency. In a recent study, it was shown 
that steroids which contain a conjugated keto-functional group at C3 showed good proton 
affinity and stability; generating the [M+H] ion as the most abundant precursor ion. 
Conversely, steroids containing conjugated/unconjugated hydroxyl functional groups at C3, 
generated multiple ions, and showed poor stability with relatively high LODs.
11
 
It is proposed that a combination of comprehensive gas chromatography/mass spectrometry 
and existing LC/MS/(MS) methods could narrow the window of opportunity so much so 
that it becomes a deterrent to rogue chemists, as the challenges involved in designing 
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steroids that can avoid detection by both techniques will be too great. Comprehensive gas 
chromatography can provide additional surveillance modes for the screening of new 
compounds for less effort than LC/MS/MS, since electrospray ionisation and mobile phase 
condition optimisation are not critical.  
Whilst it is widely accepted that GC/MS analyses are traditionally constrained to 
derivatisable steroids, this chapter will describe the development and evaluation of a new 
method that will couple bespoke molecular imprinted polymers (MIPs) with comprehensive 
gas chromatography/time of flight mass spectrometry (GCxGC/MS) for the extraction, 
separation, identification and quantification of underivatised steroids (equivalent to free or 
hydrolysed steroids) spiked into synthetic urine. Due to practical and ethical considerations 
the study of conjugated steroids in urine is beyond the scope of this work. It is recognised 
that if this technique is to be applied for Sports Testing then it will either need to have the 
sensitivity to detect unconjugated steroids directly in urine or a hydrolysis technique will 
need to be developed prior to the application of the MIPs and GCxGC/MS. The study is 
based on the assumption that the latter will be applicable and this work is thus providing 
the proof of principle evaluation of the latter stages of the process.  
A cohort of twelve steroids were provided by HFL Sport Science for the evaluation of the 
method. The cohort were selected to capture the diverse range present in endogenous and 
exogenous anabolic androgenic steroids, their metabolites and prohormones. The structures 
of the steroids can be found in Figure 1.14 of Chapter 1. As the majority of these steroids 
are classed as prohormones, the cohort will be referred to collectively as the 
“prohormones”. For example, 5(10)-estrene-3b,17b-diol, 4-estrene-3b,17b-diol and 5(10)-
estrene-3,17-dione are all precursors for nandrolone. Nandrolone is one of the most 
frequently detected anabolic androgenic agents detected. Its occurrence has consistently 
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remained high, with 155 adverse analytical findings reported by WADA accredited 
laboratories in 2009, contributing to 4.7 % of the total anabolic steroids detected.
12
 In 2010, 
this increased to 250 occurrence, an overall contribution to 7.4 %, making it the second 
highest detected AAS after stanozolol.
13 
In 2011, data published by WADA showed a 
similar result with 240 occurrences, an overall contribution of 7.2 %.
14
 The popularity of 
nandrolone as an anabolic agent amongst athletes is mostly related to the structural 
modification providing favourable anabolic properties while at the same time reducing the 
androgenic properties. 
Initially, this chapter will report and discuss the issues encountered when analysing a 
mixture of the twelve prohormones, following derivatisation, using both a single GC 
column and comprehensive chromatography. 
It will then characterise and evaluate the performance (chromatographic resolution, 
linearity, limit of detection and limit of quantitation) of the comprehensive chromatography 
(GCxGC/MS) method with underivatised steroid standards, containing the twelve 
prohormones. The quantity of each of the steroids analysed will be representative of the 
detection levels required by the WADA in urine samples. In 2010 WADA’s Prohibitive 
List specified that hormones should be detectable at the 10 ng/mL level. During the project, 
the MRPL was subsequently reduced to 5 ng/mL. One of the hormones methyltestosterone, 
used as an internal standard in Chapter 4, has a lower detection level of 2 ng/mL.   
The performance of two non-covalently bonded molecular imprinted polymers (MIPs) and 
two non-imprinted molecular polymers (NIPs), that were developed to selectively extract a 
range of steroids from urine, will then be evaluated. Testosterone has been used as the 
template molecule, with the view that once it is removed the cavities generated will be 
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complementary in shape, size, affinity and functionality and will therefore bind to a wide 
range of endogenous androgens, 19-nor-steroids, metabolites, prohormones and synthetic 
analogues of testosterone (designer steroids). Scanning electron microscope images of the 
wet-sieved molecular imprinted polymers, templated with testosterone during this project, 
will be provided and discussed.   
Although the method will be used for the extraction of steroids from spiked synthetic urine 
it is anticipated that in the future it may also be applied to different biological and food 
samples such as human serum, contaminated meat and nutritional supplements with slight 
modification to accommodate solid sample analysis. 
3.2.  Results and Discussion 
3.2.1.   Chromatographic resolution of derivatised prohormone standards 
A standard solution, containing a mixture of the twelve prohormones (40 gmL of each in 
methanol), was prepared and the analytes were derivatised, as described in Section 2.2.3 to 
provide a solution with 260 ng/L of each derivatised hormone in undecane (assuming 
completed conversion). The derivatised prohormones were analysed on the Leco Pegasus 
IV GCxGC-TOFMS in both 1D- and 2D-GC modes, using the gas chromatography and 
mass spectrometry parameters summarised in Section 2.2.4. Table 3.1 summarises the 
prohormones present in the initial mixture and the derivatised species identified, along with 
their diagnostic ions and their retention times on a single GC column.  
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Table 3.1. Summary of the key parameters determined for each of the derivatised 
prohormones analysed in the 1D- GC mode.  
Steroid 
Number 
Prohormone Derivatised Species 
Identified 
Quantitation 
Ion, m/z 
(Th) 
First Dimension 
Retention Time 
(s) 
1 5(10)-estrene-3b,17b-diol bis-(O-tert.-butyldimethylsilyl)- 447 1145.77 
2 4-estrene-3b,17b-diol Not detectable  - - 
3 5(10)-estrene-3,17-dione bis-(O-tert.-butyldimethylsilyl)- 500 1212.58 
4 4-androstene-3b,17b-diol bis-(O-tert.-butyldimethylsilyl)- 462 1192.09 
5 DHEA Not detectable - - 
6 5(6)-androstene-3b,17b-
diol 
bis-(O-tert.-butyldimethylsilyl)- 462 1224.24 
7 5a-androstane-3,17-diol bis-(O-tert.-butyldimethylsilyl)- 461 1208.25 
8 5a-androstane-3,17-dione Underivatised 217 1024.99 
9 Nandrolone bis-(O-tert.-butyldimethylsilyl)- 502 1211.9 
10 5(6)-androstene-3,17-
dione 
Underivatised 286 1045.48 
11 Testosterone bis-(O-tert.-butyldimethylsilyl)- 459 1231.07 
12 1,4-androstadiene-3,17-
dione 
Not detectable - - 
Potential mechanisms for the generation of the fragment ions in the mass spectra of each of 
the derivatised prohormones are provided in Appendix A1.1. Derivatisation introduces the 
tert-butyldimethylsilyl as a functional group replacing either, or both, the hydroxyl or 
ketone group at both ends of the prohormones structure, depending on the individual 
prohormone.  Its presence inevitably changes the fragmentation pathways, when compared 
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to those of the native prohormones (Appendix A1.2). The most common fragmentation of 
the derivatised prohormones is the loss of tert-butyl group (57 Da), as exemplified by 4-
androstene-3b,17b-diol,bis-(0-tert.-butyldimethylsilyl). A one step cleavage of the (0-tert.-
butyldimethylsilyl) group (132 Da) results in a fragment forming at m/z 387. The 
fragmentation is most commonly initiated at the D ring, perhaps due to the ring constraint. 
The subsequent loss of H2 group results in an ion forming at m/z 384. Fragmentation at the 
A ring of the derivatised prohormone is accompanied with a rearrangement, resulting in the 
loss of m/z 56 and reattachment of H group to the silyl group.  
Figure 3.1 illustrates the chromatogram obtained for the derivatised prohormones. The 
numbering of the peaks is consistent with the numbering of the steroids in Table 3.1. It is 
clear from the abundance responses that it would have been preferable to have diluted the 
sample prior to analysis, and this may have contributed to some of the loss of 
chromatographic resolution discussed.  
 
Figure 3.1. Chromatogram illustrating the retention times of the derivatised 
prohormone species determined in the total ion chromatogram (TIC) in 1D-
GC mode.  The retention times for the derivatised versions of [1] 5(10)-
estrene-3b,17b-diol, [3] 5(10)-estrene-3,17-dione, [4] 4-androstene-3b,17b-
diol, [6] 5(6)-androstene-3b,17b-diol, [7] 5a-androstane-3,17-diol, [9] 
nandrolone and [11] testosterone are labelled on the chromatogram. 
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Figure 3.2 illustrates the chromatogram obtained and identifies the elution regions for both 
derivatised and underivatised prohormones. 
 
Figure 3.2.    A 2D surface plot (TIC) illustrating the retention regions for the derivatised 
and underivatised prohormone species and their relative location with 
respect to matrix species.    
 
Table 3.2 summarises the derivatised prohormone species identified, their diagnostic ion 
and their retention times, following analysis by comprehensive gas chromatography.   
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Table 3.2. Summary of the first- and second- dimension retention times and diagnostic 
ion of the derivatised prohormones species identified in the 2D-GC mode. 
Steroid 
Number 
Prohormone Derivatised 
Species 
Quantitation 
Ion,  m/z 
(Th) 
First 
Dimension 
Retention 
Time (s) 
Second 
Dimension 
Retention 
Time (s) 
1 5(10)-estrene-
3b,17b-diol 
bis-(O-tert.-
butyldimethylsilyl)- 
447 1588 2.260 
2 4-estrene-3b,17b-
diol 
bis-(O-tert.-
butyldimethylsilyl)- 447 1548 2.100 
3 5(10)-estrene-3,17-
dione 
bis-(O-tert.-
butyldimethylsilyl)- 
& underibvatised 
500 
1628 2.605 
4 4-androstene-
3b,17b-diol 
bis-(O-tert.-
butyldimethylsilyl)- 
462 1640 2.475 
5 DHEA Not detectable - - - 
6 5(6)-androstene-
3b,17b-diol 
bis-(O-tert.-
butyldimethylsilyl)- 462 1644 2.555 
7 5a-androstane-3,17-
diol 
bis-(O-tert.-
butyldimethylsilyl)- 
& underibvatised 
461 
1648 2.595 
8 5a-androstane-3,17-
dione 
Underivatised 217 1368 2.795 
9 Nandrolone bis-(O-tert.-
butyldimethylsilyl)- 502 1624 2.475 
10 5(6)-androstene-
3,17-dione 
Underivatised 286 1408 2.865 
11 Testosterone bis-(O-tert.-
butyldimethylsilyl)- 459 1648 2.655 
12 1,4-androstadiene-
3,17-dione 
Underivatised 122 1420 2.935 
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It is clear from the total ion chromatogram shown in Figure 3.2 that the derivatised and 
underivatised prohormones elute in different regions of the 2D surface plot. The 
underivatised species, mainly diones, elute together in one location and the derivaritised 
species in another. The main difference is that the derivatised species are retained in the 
first dimension column for longer, indicating that they have a lower partition coefficient 
into the mobile phase, which suggests that they either have greater interaction with the 
stationary phase or lower volatility than the underivatised diones (5(10)-estrene-3,17-dione, 
5a-androstane-3,17-dione, 5(6)-androstene-3,17-dione, 1,4-androstadiene-3,17-dione) and 
the saturated, 5a-androstane-3,17-diol.  
It is also clear from the total ion chromatogram that it is difficult to resolve the derivatised 
species from each other and the significant levels of matrix species present. Figure 3.3 
illustrates how the derivatised prohormones region can be resolved from other species 
through the use of their diagnostic fragmentation ions (m/z= 447, 461, 463). Whereas, 
Figure 3.4 provides an expanded view of the same 2D surface plot, which allows the 
individual prohormones to be uniquely identified. 
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Figure 3.3.     A 2D surface plot for the extracted ions (m/z= 447, 461 and 463) illustrating 
the retention times of the derivatised prohormone in both dimensions.  
 
Figure 3.4.   Expanded view of the previous 2D surface plot for the extracted ions (m/z= 
447, 461 and 463) illustrating the limited separation of the derivatised 
prohormones.  
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The results obtained in both chromatographic modes confirm the previous findings of HFL 
Sport Science, using standard one-dimensional chromatography; namely, that for the wide 
range of prohormones that need to be screened, derivatisation does not provide a complete 
solution. DHEA (5(6)-androstene-3b-ol-17-one) was not detectable in either 
chromatographic mode of operation, whereas nandrolone (17b-hydroxyestra-4-en-3-one) 
and testosterone (4-androstene-17-ol-3-one) were both detected as the derivatised species.  
In contrast to the other prohormones, which are all either diols or diones, these three 
compounds have both a hydroxyl and carbonyl group. Nandrolone and testosterone have 
the hydroxyl group at the 17-position whereas DHEA has it at the 3-position. DHEA is also 
unsaturated at the 5-position in Ring B, in contrast to nandrolone and testosterone which 
are unsaturated at the 4-position in Ring A. 4-estrene-3b,17b-diol (derivatised) and 1,4-
androstadiene-3,17-dione (underivatised) were not detected in 1 D mode, but were found in 
2D mode. As can be seen in Figure 3.2, the application of the second dimension column 
pulls the prohormones away from most of the matrix species, present as a result of the 
derivatisation process, placing them in a cleaner chromatographic region. However, as 
shown in Figures 3.3 and 3.4, it is the coupling of this temporal, chromatographic 
resolution with the high acquisition rate of the TOFMS that enables the prohormones to be 
fully resolved using their diagnostic fragmentation ions. 
Certain hormones are found derivatised (5(10)-estrene-3b,17b-diol, 4-estrene-3b,17b-diol, 
4-androstene-3b,17b-diol, 5(6)-androstene-3b,17b-diol, nandrolone, testosterone), others 
are found both in the derivatised and underivatised forms  (5(10)-estrene-3,17-dione, 5a-
androstane-3,17-diol) whilst some others are not derivatised at all (5a-androstane-3,17-
dione, 5(6)-androstene-3,17-dione, 1,4-androstadiene-3,17-dione). Taking account of the 
conditions used, some basic relationships can be deduced from these findings: 
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i. underivatised species elute significantly earlier than derivatised species;  
ii. diols and species with a hydroxyl group at the 17- position (e.g. nandrolone and 
testosterone) will, in the main, derivatise;  
iii.  diones, will, in the main, not derivatise;  
iv.  there are exceptions to the above rules and therefore each compound must be 
evaluated individually. 
It was known that derivatisation adds time and complexity to the analysis process. In 
addition, as shown above and previously by others, it also makes the interpretation of the 
data more difficult and makes some steroids species very difficult to quantitate or even 
detect. The derivatisation of steroids also reduces the resolving power of comprehensive 
chromatography, as the functional groups are removed in the process. Effectively, it 
removes functional groups that potentially allow different hormones, which have very 
similar structures, to be resolved. The case for evaluating the elution characteristics of 
underivatised steroids by comprehensive chromatography is clear. 
3.2.2.  Chromatographic resolution of underivatised prohormones standards   
A standard solution, containing a mixture of the twelve prohormones (833 ng/mL of each in 
acetonitrile), was prepared as described in Section 2.2.5. 1 L of the underivatised 
prohormone mixture (i.e. 833 pg of each injected on column) was analysed on the Leco 
Pegasus IV GCxGC-TOFMS in comprehensive, two-dimensional gas chromatography (2D-
GC) mode, using the gas chromatography and mass spectrometry parameters summarised 
in Section 2.2.6. This quantity of steroids, approximately equivalent to 16.7 ng/mL in urine, 
was selected as the response factors of the steroids was at the time unknown. The column 
configuration incorporated a relatively non-polar J&W DB5-MS (30 m x 0.25 mm x 0.25 
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m) column in the first dimension and a moderately polar BPX50 (2 m x 0.1 mm x 0.1 m) 
in the second dimension, a configuration commonly used.   
Before trying to understand the elution characteristic on both columns, it is appropriate to 
briefly review their chemical composition, as this will determine the partition coefficients 
of the analytes between the mobile and stationary phases and, in turn, why they were 
selected for this application. As shown in Figure 3.5, both DB5MS (BPX5 equivalent) and 
BPX50 have phenyl groups introduced in to the backbone (x) and as side chains (y) on to 
the dimethyl polysiloxane backbone of the stationary phase. 
 
Figure 3.5.  Substitution of the dimethyl polysiloxane backbone.  
As the names suggest the proportion of the substitution is significantly greater in BPX50 
(50%) than DB5MS (5%). This substitution helps make the stationary phase less likely to 
thermally degrade, thereby reducing column bleed, which is important when coupling to a 
mass spectrometer. The addition of these aromatic substituents slightly increases the 
polarity of the column and introduces aromaticity, which can interact with unsaturated 
bonds in the analytes. Given the chemical commonality in the substituents used, but 
different stoichiometry, one might anticipate that the elution characteristics should be 
similar in both columns. The significantly greater level of substitution in the BPX50 will 
amplify any interactions with unsaturated and polar groups in the analytes, in comparison to 
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DB5MS (BPX5), as will the smaller column diameter in the secondary column; however, it 
should also be remembered that the second column is significantly shorter and is held at a 
slightly higher temperature than the first column. The short retention time on the second 
column significantly limits which stationary phases can be utilised. 
The first- and second- dimension retention times and the quantitation ion for each 
prohormone are summarised in Table 3.3. Before running the prohormone mixture the 
elution times of each of the prohormones were confirmed individually and their mass 
fragmentation patterns stored in a library. 
Table 3.3. First- and second- dimension retention times obtained by GCxGC/TOFMS 
analysis of mixed standard of twelve prohormones, from a 1 L injection of 
a mixed standard containing 833 ng/mL of each steroid in acetonitrile. 
 
Number 
 
Prohormone 
Quantitation 
Ion, m/z 
(Th) 
First Dimension 
Retention Time 
(s) 
Second 
Dimension 
Retention Time 
(s) 
1 5(10)-estrene-3b,17b-diol 225 1214 2.430 
2 4-estrene-3b,17b-diol 218 1226 2.435 
3 5(10)-estrene-3,17-dione 131 1238 2.565 
4 4-androstene-3b,17b-diol 220 1256 2.595 
5 DHEA 255 1256 2.610 
6 5(6)-androstene-3b,17b-diol 205 1268 2.655 
7 5a-androstane-3,17-diol 292 1280 2.695 
8 5a-androstane-3,17-dione 229 1286 2.810 
9 Nandrolone 110 1304 2.905 
10 5(6)-androstene-3,17-dione 124 1328 3.040 
11 Testosterone 124 1346 3.110 
12 1,4-androstadiene-3,17-
dione 
122 1352 3.185 
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The 2D surface plots, for the total ion chromatogram (TIC) obtained for the mixture of the 
twelve underivatised prohormones, are shown in Figure 3.6 and 3.7.   
 
Figure 3.6.    A 2D surface plot of the total ion chromatogram (TIC) illustrating the 
retention region of the underivatised prohormone species.  
 
 
Figure 3.7.   A 2D surface plot (TIC) illustrating the retention times of each of the 
underivatised prohormone species. A standard solution containing 833 pg of 
each of the twelve prohormones in acetonitrile was injected.  5(10)-estrene-
3b,17b-diol [1] and 4-estrene-3b,17b-diol [2] co-elute, as do 4-androstene-
3b,17b-diol [4] and DHEA [5].  
114 
 
Figure 3.6, clearly identifies the prohormone region; whereas, Figure 3.7 labels the location 
of each of the twelve prohormones. As well as resolving the prohormones in two 
dimensions it should be noted that this family of compounds are also well resolved from the 
column bleed and matrix compounds. In addition, as anticipated, the partitioning 
characteristics of the two columns are similar, with the result that the elution times of the 
analytes on the second column correlate with those of the first column, producing the 
distinctive shape of the prohormone region. On reviewing Figure 3.7, it became apparent 
that not all the prohormones were resolved in the total ion chromatogram. 5(10)-estrene-
3b,17b-diol and 4-estrene-3b,17b-diol (Peaks #1 & #2) co-eluted; as did 4-androstene-
3b,17b-diol and DHEA (Peaks #4 & #5). Through studying the individual fragmentation 
mechanisms of the prohormones, collated in Appendix A1.2, diagnostic ions for each of 
these compounds could be identified that enabled each of the twelve prohormones in the 
mixture to be uniquely identified and quantified.   
As can be seen from these proposed mechanisms, the underivatised prohormones all follow 
similar, but subtly different, fragmentation processes. The range of fragmentation 
mechanisms are best illustrated by selecting one of the prohormones as a case study, in this 
case 4-androstene-3b,17b-diol. Here, electron ionization results in the formation of a 
molecular ion, at m/z 290, that readily eliminates water (18 Da) to form a fragment at m/z 
272. This elimination means that the m/z 290 peak is significantly lower abundance than 
the m/z 272 fragment. The loss of ring A yields the base peak ion at m/z 220. In accordance 
with the fragmentation processes of most prohormones, the core backbone of the four rings 
remains intact, with the formation of the fragment ion at m/z 257, resulting from the 
elimination of a methyl radical (15 Da) from the m/z 272 fragment described earlier. The 
presence of a hydroxyl group in the C-17 position or C-3 position can result in elimination 
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of the water from both position as demonstrated in 5(10)-estrene-3b,17b-diol. The 
fragmentation profile provides important diagnostic value for the detection of prohormones 
in their native form. For example, the presence of the m/z 110 is highly indicative of the 
presence of nandrolone.  
Figures 3.8 to 3.11 contain the 2D surface plots for these diagnostic ions and illustrate the 
power of coupling comprehensive chromatography with the high acquisition rate of the 
time of flight mass spectrometer.   
 
Figure 3.8.   A 2D surface plot showing the location of 5(10)-estrene-3b,17b-diol using its 
diagnostic ion (m/z = 225). 
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Figure 3.9.   A 2D surface plot showing the location of 4-estrene-3b,17b-diol using its 
diagnostic ion (m/z = 218). 
 
  
Figure 3.10.   A 2D surface plot showing the location of 4-androstene-3b,17b-diol using its 
diagnostic ion (m/z = 220).  
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Figure 3.11.    A 2D surface plot showing the locations of DHEA (#5), 5a-androstane-3,17-
dione [8] and testosterone [11], using the diagnostic ion (m/z = 288).  
Obtained from a 1 L injection of a standard solution containing the twelve 
prohormones at a concentration of 833 ng/ml of each, in acetonitrile. 
By reviewing the chromatograms and the elution times in Table 3.3, some basic 
relationships can be derived from the interaction of the stationary phases with the 
prohormones. The diols elute between 1214 and 1280 s in the first dimension and between 
2.430 and 2.695 s in the second. Similarly, the diones elute between 1238 and 1352 s in the 
first dimension and between 2.565 and 3.185 s in the second. DHEA (5(6)-androstene-3b-
ol-17-one), which has a carbonyl group at the 17-position and a hydroxyl group at the 3b- 
position elutes at 1256 s / 2.610 s, respectively; whereas nandrolone (17b-hydroxyestra-4-
en-3-one) and testosterone (4-androstene-17-ol-3-one), which both have the carbonyl group 
at the 3-position, a C=C bond in the 4-position, as well as a hydroxyl group at the 17- 
position, elute at 1304s / 2.905 s and 1346 s / 3.110 s, respectively. The nor-19 steroids 
elute before the androsta(e)nes. Whilst there is overlap, generically we can state that diols 
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elute before steroids with both a carbonyl and hydroxyl group which, in turn, elute before 
diones.  
As stated previously, the chemical composition of the two stationary phases are the same, 
except for the relative proportions of their substitution, therefore the mechanisms for 
partition of the steroids between the carrier gas and the stationary phase of the first column 
will be similar to that with the secondary column. The partition coefficients between the 
mobile and stationary phase will be driven by a combination of the interactions e.g, 
dispersion (non-polar components), dipole-dipole (carbonyl and hydroxyl groups), 
unsaturated groups) with i) the dimethyl polysiloxane segment of the stationary phase 
and ii) the phenyl substituents. The different shapes/configurations of the prohormones will 
also influence how the various function groups interact with the stationary phase. In the 
first column, with only 5 % substitution, interactions with the dimethyl portion is likely to 
dominate, even though dispersion forces are much weaker than the others; whereas, in the 
secondary column, with 50 % substitution, the interactions with the phenyl substituents will 
be much more significant. The much smaller diameter of the secondary column will also 
significantly facilitate interactions with the stationary phase, allowing much shorter 
columns to achieve compound separation within the modulation time. 
The partition coefficient will be driven by subtle differences in: the overall shape of the 
sample molecules; the nature, number and location of functional groups present; the 
number and location of the double bonds in the rings. The three-dimensional conformation 
of the parent 17-carbon tetracyclic will be strongly influenced by the location of an 
unsaturated carbon-carbon bond and the presence of a carbonyl group (C=0) in place of a 
hydroxyl group. The presence of the double bond will result in the carbon atoms adopting a 
planar (120 bond angle, sp2 hybridisation) arrangement instead of the tetrahedral 
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arrangement (109.5 angle, sp3 hybridisation) when only single bonds are present. Double 
bonds are also shorter than single bonds, which will result in a slight twisting of the 
cyclohexane ring. It appears that the presence of C=C and C=O bonds both enhance 
interactions with the stationary phase and result in their partitioning on to the mobile phase, 
presumably as a result of interactions with the aromatic phenyl groups. 
It is likely that the separation in the first column is mainly driven by the relative volatility 
of the species present. Indeed, apart from nandrolone, the three 19-norsteroids, lacking a 
methyl group attached to the 10-position, elute first in both the first and second dimension 
To summarise the findings: 
i. 19-norsteroids elute before their androsta(e)ne equivalents (as evidenced by 4-
estrene-3b,17b-diol eluting before 4-androstene-3b,17b-diol and nandrolone eluting 
before testosterone); 
ii. Diols elute before diones (evidenced by the fact that 5 of the first seven species are 
diols and 3 of the last five species are diones); 
iii. The presence of a carbonyl group at the 3- position as well as double bond at the 4- 
position of Ring A (nandrolone and testerone) increases retention on the columns, 
even with a hydroxyl group at the 17-position, this is likely to be due to 
delocalisation of the charge over between the double bonds and its interaction with 
the aromatic substituents in the stationary phase; 
iv. Nor-19 steroids, separated only by the location of a double bond (as evidenced by 
5(10)-estrene-3b,17b-diol and 4-estrene-3b,17b-diol) will effectively co-elute, but 
may be distinguished by their diagnostic fragmentation ions; 
120 
 
v. Androstenes, separated only by the location of a double bond can be resolved (as 
evidenced by the separation of 5(6)-androstene-3b,17b-diol and 4-androstene-
3b,17b-diol); 
vi. In terms of diones, the elution order is estrene, androstane, androstene and 
androstadiene.  
3.2.3. Validation studies for the use of GCxGC/MS with underivatised prohormone 
standards  
As described in Section 2.2.7, the mixed standard, in acetonitrile, was used to prepare a 5-
point calibration curve at concentrations of 500, 200, 150, 125 and 50 ng/mL for each 
steroid. Based on a 1 L splitless injection, this is equivalent to between 500 - 50 pg of 
each steroid being injected on column. If one also takes in to consideration the MIP method 
developed and described in Section 2.2.9, and assuming complete recovery, the quantity of 
prohormone injected would be equivalent to that extracted from urine samples containing 
between 1 and 10 ng/mL (WADA MRPL 2010) of each steroid, respectively. The equations 
and squared correlation coefficients for the linear least square fit for the peak area for each 
of the steroids is summarised in Table 3.4 and the plots for each of the steroids are provided 
in Figure A2 in Appendix A2. The ions used for quantitation were listed in Table 3.3. All 
prohormones were found to give a linear signal over the concentration range measured.  
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Table 3.4. The equations and the squared correlation coefficients for the linear least 
square fit for each of the steroids over the range of 50-500 pg injected 
  
Number 
 
Prohormone 
 
Regression Equation 
 
R
2
 
1 5(10)-estrene-3b,17b-diol y = 32.12 x - 871.77  0.9949 
2 4-estrene-3b,17b-diol y = 37.29 x  - 1379.30  0.9980 
3 5(10)-estrene-3,17-dione y = 44.28 x – 154.39 0.9954 
4 4-androstene-3b,17b-diol y = 158.98 x – 5041.39 0.9959 
5 DHEA y = 57.76 x – 1295.39 0.9980 
6 5(6)-androstene-3b,17b-diol y = 20.05 x – 654.69 0.9952 
7 5a-androstane-3,17-diol y = 49.60 x – 2727.22 0.9957 
8 5a-androstane-3,17-dione y = 89.59 x + 1301.20 0.9939 
9 Nandrolone y = 233.03 x – 5011.66  0.9975 
10 5(6)-androstene-3,17-dione y = 152.22 x – 234.54  0.9956 
11 Testosterone y = 628.05 x – 46215.40 0.9842 
12 1,4-androstadiene-3,17-dione y = 1273.07 x – 5398.49 0.9989 
As reported in Section 2.2.7, the theoretical limits of detection (LOD) and quantitation 
(LOQ) for each prohormone were estimated by repeat injections (x10) of 1 L of the lowest 
concentration standard (50 ng/mL), equivalent to 50 pg on column. The limit of detection 
for each was defined as 3 times the standard deviation from the average obtained; whereas 
the limit of quantification was taken as being 10 times the standard deviation. The standard 
deviation is calculated by multiplying the relative standard deviation of the peak areas 
measured for the quantitation ion by the mass injected (50 pg), as summarised in Table 3.5. 
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Table 3.5.     Theoretical limit of detection and quantitation calculated for each prohormone 
Number Prohormone Peak Area 
(RSD) 
LOD 
(pg) 
LOQ 
(pg) 
1 5(10)-estrene-3b,17b-diol 0.131 19.7 65.5 
2 4-estrene-3b,17b-diol 0.092 13.8 46.0 
3 5(10)-estrene-3,17-dione 0.137 20.6 68.5 
4 4-androstene-3b,17b-diol 0.180 27.0 90.0 
5 DHEA 0.122 18.3 61.0 
6 5(6)-androstene-3b,17b-diol 0.175 26.3 87.5 
7 5a-androstane-3,17-diol 0.078 11.7 39.0 
8 5a-androstane-3,17-dione 0.121 18.2 60.5 
9 Nandrolone 0.150 22.5 75.0 
10 5(6)-androstene-3,17-dione 0.086 12.9 43.0 
11 Testosterone 0.168 25.2 84.0 
12 1,4-androstadiene-3,17-dione 0.102 15.3 51.0 
Based on the results obtained from this standard method for the estimation of the limits of 
detection and quantitation, it would appear that the twelve prohormones should all be 
detectable below ~30 pg on column; and quantitation should be possible below ~100 pg on 
column.    
In terms of sensitivity, this method would indicate that 4-androstene-3b,17b-diol will be the 
hardest to detect and quantify, followed by 5(6)-androstene-3b,17b-diol and testosterone.  
Conversely, 5a-androstane-3,17-diol, 4-estrene-3b,17b-diol and 5(6)-androstene-3,17-dione 
should be detectable at lower levels. As these figures are estimates, based on the 
reproducibility of the peak area measurements, it remains to be determined if these levels 
are achievable, in particular when extracted from urine. 
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The LOD and LOQ values reported are based on a 1 L injection from prohormone 
standards in acetonitrile at a concentration of 50 ng/mL, i.e. 50 pg injected on column. 
Based on a proposed concentration factor of at least 50, for the extraction of urine samples 
(1 mL of urine onto MIPs followed by elution into 1 mL of methanol, drying and 
reconstituting into 20 L of acetontrile) and the injection of 1 L of this reconstituted 
solution, one might expect that the method developed during this study should be capable 
of detecting the prohormones at, or below, 1 ng/mL level in urine samples. Levels that are 
well below both of the latest WADA minimum required performance level (MRPL) values 
for most androgenic anabolic steroids in urine (10 and 5 ng/mL, respectively).   
There is, of course, the caviat that most steroids are present in urine in the conjugated form 
and would probably require hydrolysis prior to MIPs extraction. As previously reported 
unconjugated steroids make up approximately ~3% of the total steroids present in urine. At 
the 2010 WADA levels, this would have necessitated a limit of detection of ~15 pg on 
column. Interestingly, most of the prohormones in Table 3.5 are estimated to be detectable 
at around that level. 
Therefore, with the caviat that a hydrolysis method will probably be required to 
deconjugate the steroids, prior to MIPs analysis, the method was determined to be fit for its 
intended purpose of detecting androgenic anabolic steroids in urine samples at the WADA 
limits of 10 ng/mL and should be explored further. With MRPL value now lowered to 5 
ng/mL, for most species in 2012, and assuming that the unconjugated steroids are present at 
3% of all steroids in a urine sample, then the current method would not be directly 
applicable to untreated urine samples. This would require a limit of detection of ~ 8 pg on 
column (5/33 = 0.15 ng/mL in urine). It should, however, be noted that the level of 
detection in this study could be further improved by either: increasing the quantity of urine 
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passed over a larger MIPs cartridge or by utilising a greater proportion of the sample 
extracted. For example, by increasing the volume (from 1 L up to 20 L) of acetonitrile 
injected in to the mass spectrometer, through the use of a programmable temperature 
vapourisation (PTV) injector such as the Optic 4 from ATAS GL, or similar devices from 
Agilent Technologies or Gerstel.  This will require further investigation, as the ability to 
directly extract a family of unconjugated steroids from urine without prior treatment will be 
a significant step forward.  
Whether such approaches work will depend on the ability of the MIPs to resolve the target 
compounds from the matrix peaks that will be present if larger volumes of urine or solvent 
are used and ultimately the background noise for the quantitation ion in the 
chromatographic region of interest. 
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3.2.4. Evaluating the performance of molecularly imprinted polymers for the 
extraction of underivatised prohormones from spiked synthetic urine. 
The molecular imprinted polymers (M5 & M6), templated with testosterone, and the non-
imprinted polymers (B5 & B6) were prepared as described in Section 2.2.8. Prior to use, 
following crushing in a mortar and pestle, wet-sieving through a mesh and collection of the 
38 to 63 m fraction, the polymers produced were imaged on a scanning electron 
microscope (SEM).    
As can be seen in Figures 3.12 and 3.13, the MIPs particles are irregular in shape and 
highly angular, which would suggest that further crushing in the mortar and pestle would be 
required to make them more spherical, which would be more suitable for the ideal packing 
of a solid phase extraction (SPE) tube. From the images collected the sizes of the particles 
appear to be similar with the dimensions of the individual particles being consistent with 
the mesh size of the sieves used. Whether further crushing is necessary is debatable since 
the generation of more spherical particles would inevitably result in smaller particles, 
which could restrict the flow of the solvent through the SPE cartridge. Conversely, highly 
irregular and angular particles could result in open channels or pathways through the SPE 
cartridges which could prevent the target species sufficiently interacting with the MIPS, 
resulting in them being carried straight through. The highly labour intensive and time-
consuming nature of the crushing and wet-sieving process, as used in this study, also puts 
constraints on what is viable. Automation of the process is feasible and would be necessary 
for this technique to be implemented on a wider scale. 
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Figure 3.12.   A close up image (1671x magnification) of the M5 molecular imprinted 
polymers obtained using a scanning electron microscope.  
 
 
Figure 3.13.   An image (331 x magnification) of the M6 molecular imprinted polymers 
obtained using a scanning electron microscope.   
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The percentage recoveries of each of the target analytes on triplicate cartridges containing 
either imprinted (M5/M6) or non-imprinted (B5/B6) polymers were determined using the 
method specified in Section 2.2.9. In brief: 1 mL of synthetic urine was spiked at the 10 
ng/mL level for each prohormone; it was then added to each of the MIPs cartridges, washed 
and then eluted. The eluents were then dried and reconstituted in acetonitrile and the 
hormones were injected underivatised in the comprehensive gas chromatography system.  
Before we study the performance of the polymers, it is worth reviewing the qualitative 
evidence provided by these chromatograms, of the additional benefits of utilising 
molecularly imprinted polymers, and also the quality of the chromatograms obtained.  
One of the proposed benefits is that they can be highly specific and significantly reduce the 
level of non-specific binding between the stationary phase and matrix compounds.  This 
should result in a significant reduction in the quantity of matrix compounds that are 
introduced into the GC-MS or GCxGC-MS. In traditional single dimension GC-MS 
analyses, these matrix species would co-elute with target analytes, interfering with their 
quantitative determination. In comprehensive chromatography, as shown in Figure 3.15, 
this is less of an issue; however, in terms of long term robustness of the method, a reduction 
in the level of non-target species being introduced is going to be advantageous, as it reduces 
the need to clean the injector, the column and the mass spectrometer ion source.   
Figure 3.14 illustrates the level of matrix compounds that are present when a spiked 1 mL 
synthetic urine sample is extracted with a) C18 (Strata) SPE cartridge, b) M5 MIPs 
imprinted with testosterone and using methacrylic acid (MAA) as the monomer, and c) M6 
MIPs imprinted with testosterone and using 4-vinyl pyridine (4-VP) as the monomer.   
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Figure 3.14.    2D surface plots (TIC), showing the extent of the matrix present in the 
eluents from 1 mL of synthetic urine spiked at the 10 ng/mL level per 
prohormone:  a) C18 (Strata) SPE cartridge, b) M5 (MIPS cartridge) with 
MAA as the monomer.  
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Figure 3.14   2D surface plots (TIC), showing the extent of the matrix present in the eluents 
from 1 mL of synthetic urine spiked at the 10 ng/mL level per prohormone: 
    c) M6 (MIPS cartridge) with 4-VP as the monomer 
 
The 2D surface plots would seem to indicate that the eluent from the M6 cartridge has 
significantly lower levels of matrix species than M5 which, in turn, has much less than the 
SPE cartridge. This would suggest that the use of 4-vinyl pyridine as the monomer in M6 is 
resulting in a reduction of the non-specific binding relative to the other two. As it appears 
to also extract the prohormones, this may imply the development of specific cavities 
templated by testosterone. The corresponding 2D surface plots for the non-imprinted 
polymers are shown in Figure 3.15. Interestingly, the level of matrix present for B5 does 
not appear to be as great as for M5. This suggests that following templating, the MAA 
monomer is resulting in both specific and non-specific binding of matrix compounds, as 
well as the target species. 
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Figure 3.15.   2D surface plots (TIC), showing the extent of the matrix present in the eluents 
from 1 mL of synthetic urine spiked at the 10 ng/mL level per prohormone: 
a) B5 (non-imprinted cartridge) with MAA as the monomer 
b) B6 (non-imprinted cartridge) with 4-VP as the monomer 
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Having explored the influence of the polymers based on the specificity of the matrix 
species extracted, it is appropriate to review the chromatograms obtained for the 
prohormones. Figure 3.16 shows a close up of the prohormone region for the eluent from 
the M5 imprinted cartridge. As stated previously, this 2D surface plot of the total ion 
current (TIC) has resulted from the spiking of a 1 mL of synthetic urine sample at 10 
ng/mL and the processing of the sample using the method described in Section 2.2.9.  
 
Figure 3.16.    A 2D surface plot (TIC) showing the prohormone region for the eluent of the 
M5 imprinted cartridge, following extraction from 1mL of spiked synthetic 
urine. 
All of the 12 prohormones are detected and elute in the same order as in the standard 
samples shown previously. Figure 3.17 labels each of the prohormones in the TIC, whereas 
Figure 3.18 illustrates how 5(10)-estrene-3-17-dione can be better identified and quantified 
by selecting one of its diagnostic fragmentation ions (m/z = 131). 
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Figure 3.17.    A 2D surface plot (TIC) showing the positions of each of the prohormones 
for the eluent of the M5 imprinted cartridge, following extraction from 
spiked synthetic urine. 
 
Figure 3.18.    A 2D surface plot showing how 5(10)-estrene-3-17-dione, can be better 
characterised by extracting its diagnostic ion (m/z = 131).  The sample 
results from extraction by M5 of 1mL of synthetic urine spiked at 10 ng/mL. 
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Figure 3.19 identifies each of the prohormones seen in a 2D surface plot of the total ion 
current in the eluent of M6 imprinted polymer extraction of the spiked synthetic urine.  
Whilst, Figures 3.20 and 3.21 illustrate how 5(10)-estrene-3b,17b-diol and 4-estrene-
3b,17b-diol can be resolved using their diagnostic ions, m/z= 225 and 210, respectively.   
 
 
Figure 3.19.    A 2D surface plot (TIC) showing positions of each of the prohormones for 
M6 MIPs extraction of 1 mL of synthetic urine spiked at 10 ng/mL for each. 
5(6)-androstene-3b,17b-diol [6] and 5a-androstane-3,17-diol [7] are 
resolved but hard to label. 
 
Figure 3.20.    A 2D surface plot showing the location of 5(10)-estrene-3b,17b-diol using 
its diagnostic ion (m/z = 225). 
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Figure 3.21.   A 2D surface plot showing the location of 4-estrene-3b,17b-diol to the 
bottom left, using its diagnostic ion (m/z = 218).  
Figure 3.22 provides an alternative perspective for the same deconvolution of 5(10)-
estrene-3b,17b-diol [1] and 4-estrene-3b,17b-diol [2], using their diagnostic ions. 
 
Figure 3.22.  2D raw data showing the elution characteristics of m/z= 225 and m/z=218 
ions in both chromatographic dimensions, along with the spectrum numbers 
and peak markers.  
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Applying the same rationale, Figures 3.23 to 3.25 illustrate how 4-androstene-3b,17b-diol 
[4] and DHEA [5] can be resolved using the retention times of their diagnostic 
fragmentation ions. 
 
Figure 3.23.   A 2D surface plot showing the location of 4-androstene-3b,17b-diol using its 
diagnostic ion (m/z = 220).   
 
Figure 3.24.     A 2D surface plot showing the location of DHEA, using its diagnostic ion 
(m/z = 288).   
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Figure 3.25.  2D raw data showing the elution characteristics of m/z= 288 and m/z=220 
ions in both chromatographic dimensions, along with the spectrum numbers 
and peak markers. 
 
3.2.5. Evaluating the percentage recovery of the prohormones from synthetic urine 
using cartridges containing imprinted (M5) and non-imprinted (B5) polymers that 
use MAA as the monomer 
Based on the method described in Section 2.2.9, the performance of imprinted and non-
imprinted polymers, utilising MAA as the monomer, were evaluated.  The results obtained 
for each prohormone are recorded in Tables 3.6 (M5, imprinted) and 3.7 (B5, non-
imprinted), respectively. Table 3.8 then evaluates whether imprinting with testosterone as 
the template had a significant influence on the extraction of the prohormones from urine.   
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Table 3.6. Percentage recoveries of each of the prohormones, based on their extraction 
from 1 mL of synthetic urine (spiked at 10 ng/mL) added to three cartridges 
of the imprinted MIPs (M5).  
Number Prohormone Recovery 
M5.1 
(%) 
Recovery 
M5.2 
(%) 
Recovery 
M5.3 
(%) 
Average 
Recovery 
M5 
(%) 
Standard 
Deviation 
n-1 
(%)  
1 5(10)-estrene-
3b,17b-diol 
86.2 84.0 79.4 83.2 3.5 
2 4-estrene-
3b,17b-diol 
84.8 77.3 79.2 80.4 3.9 
3 5(10)-estrene-
3,17-dione 
99.3 100.7 113.3 104.4 7.7 
4 4-androstene-
3b,17b-diol 
105.4 110.9 98.7 105.0 6.1 
5 DHEA 73.3 76.0 74.2 74.5 1.4 
6 5(6)-
androstene-
3b,17b-diol 
86.7 77.1 66.9 76.9 9.9 
7 5a-androstane-
3,17-diol 
59.9 60.0 75.6 65.2 9.1 
8 5a-androstane-
3,17-dione 
86.9 88.8 76.8 84.1 6.4 
9 Nandrolone 76.8 82.7 69.9 76.5 6.4 
10 5(6)-
androstene-
3,17-dione 
80.2 79.6 69.8 76.5 5.8 
11 Testosterone 79.9 86.1 76.4 80.8 4.9 
12 1,4-
androstadiene-
3,17-dione 
89.7 94.2 85.4 89.8 4.9 
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Table 3.7. Percentage recoveries of each of the prohormones, based on their extraction 
from 1 mL of synthetic urine (spiked at 10 ng/mL) added to three cartridges 
of the non-imprinted polymer (B5).  
Number Prohormone Recovery 
B5.1 
(%) 
Recovery 
B5.2 
(%) 
Recovery 
B5.3 
(%) 
Average 
Recovery 
B5 
(%) 
Standard 
Deviation 
n-1 
(%) 
1 5(10)-estrene-
3b,17b-diol 
44.9 56.1 60.5 53.8 8.1 
2 4-estrene-
3b,17b-diol 
53.8 81.1 73.4 69.4 14.1 
3 5(10)-estrene-
3,17-dione 
57.7 77.5 88.2 74.5 15.5 
4 4-androstene-
3b,17b-diol 
78.5 115.4 113.5 102.5 20.8 
5 DHEA 70.6 74.4 72.1 72.4 1.9 
6 5(6)-
androstene-
3b,17b-diol 
61.5 83.1 77.3 74.0 11.2 
7 5a-androstane-
3,17-diol 
60.2 71.4 77.3 69.7 8.7 
8 5a-androstane-
3,17-dione 
66.0 87.1 83.2 78.8 11.3 
9 Nandrolone 63.5 79.3 78.5 73.8 8.9 
10 5(6)-
androstene-
3,17-dione 
75.1 79.8 80.5 78.5 3.0 
11 Testosterone 63.4 82.6 79.4 75.1 10.3 
12 1,4-
androstadiene-
3,17-dione 
83.4 102.5 100.5 95.5 10.5 
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Table 3.8. An evaluation of whether the imprinting with testosterone had a significant 
influence on the extraction of the prohormones from urine.   
 
Number Prohormone Average 
Recovery 
M5 (%) 
Average 
Recovery 
B5 (%) 
Significant 
Influence at the  
2 level? 
1 5(10)-estrene-
3b,17b-diol 
83.2 +/- 6.9 53.8 +/- 16.1 Yes 
2 4-estrene-
3b,17b-diol 
80.4 +/- 7.8 69.4 +/- 28.2  No 
3 5(10)-estrene-
3,17-dione 
104.4+/-15.4 74.5+/- 31.0 No 
4 4-androstene-
3b,17b-diol 
105.0 +/- 12.2 102.5 +/- 41.6 No  
5 DHEA 74.5 +/- 2.8  72.4 +/- 3.8 No 
6 5(6)-
androstene-
3b,17b-diol 
76.9 +/- 19.8 74.0 +/- 22.3 No 
7 5a-androstane-
3,17-diol 
65.2 +/- 18.1 69.7+/ - 17.4 No 
8 5a-androstane-
3,17-dione 
84.1 +/- 12.8 78.8 +/- 22.5 No 
9 Nandrolone 76.5 +/- 12.8 73.8 +/- 17.8 No 
10 5(6)-
androstene-
3,17-dione 
76.5 +/- 11.6 78.5 +/- 5.9 No 
11 Testosterone 80.8 +/- 9.8 75.1 +/- 20.6 No 
12 1,4-
androstadiene-
3,17-dione 
89.8 +/- 8.8 95.5 +/- 21.0 No 
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As can be seen in Table 3.6, the percentage recovery of the 12 prohormones, using the M5 
imprinted polymer, ranged between 65 and 105 % for the diols; whereas the recovery of 
DHEA, nandrolone and testosterone, respectively, ranged from 75 to 81 %. The diones had 
a percentage recovery of between 77 and 105 %. 
The percentage recovery of the 12 prohormones, using the B5 non-imprinted polymer, 
ranged between 54 and 102 % for the diols; whereas the recovery of DHEA, nandrolone 
and testosterone, respectively, ranged from 72 to 75 %. The diones had a percentage 
recovery of between 75 and 96 %. In most cases the repeatability of the percentage 
recovery was better with M5 than B5.  
Table 3.9 reports the results from the repeat analysis of the M5 cartridges following 
washing, with triplicate GC/MS analyses of each eluent, for the prohormones numbered [1] 
to [6].  Table 3.10 provides the results for the prohormones numbered [7] to [12].  
Time pressures and the desire to explore the applicability of the technique with designer 
steroids meant that repeat analyses, with triplicate GC/MS analyses of each eluent, were not 
performed for M6, B5 nor B6. The results obtained from the study utilising M5 was 
deemed as sufficient confirmation of the reproducibility of the assay.  
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Table 3.9. Repeat analysis of M5 MIPs cartridges, following washing, with triplicate 
GC/MS analyses of each eluent, for the prohormones numbered [1] to [6]. 
Number Prohormone Injection 
No. 
Recovery 
M5.1 
(%) 
Recovery 
M5.2 
(%) 
Recovery 
M5.3 
(%) 
Average M5 
Recovery 
(%) 
1 5(10)-
estrene-
3b,17b-diol 
1 
2 
3 
Average 
94.9 
92.9 
92.5 
93.5 
122.7 
91.4 
84.0 
99.3 
120.8 
124.4 
103.6 
116.2 
 
103.0+/- 15.6 
2 4-estrene-
3b,17b-diol 
1 
2 
3 
Average 
100.0 
95.6 
84.9 
93.5 
119.5 
95.1 
97.9 
104.2 
114.0 
122.7 
97.9 
111.5 
 
103.1+/-12.7 
3 5(10)-
estrene-3,17-
dione 
1 
2 
3 
Average 
38.9 
55.5 
47.4 
47.3 
103.6 
71.2 
83.7 
86.2 
113.4 
103.7 
100.1 
105.7 
 
79.7+/-27.6 
4 4-
androstene-
3b,17b-diol 
1 
2 
3 
Average 
108.6 
101.9 
105.0 
105.1 
118.1 
94.5 
95.6 
102.8 
100.7 
112.1 
102.4 
105.1 
 
104.3+/-7.6 
5 DHEA 1 
2 
3 
Average 
99.9 
102.2 
93.6 
98.6 
108.2 
91.9 
89.6 
96.6 
132.6 
124.5 
108.0 
121.7 
 
105.6+/-14.7 
6 5(6)-
androstene-
3b,17b-diol 
1 
2 
3 
Average 
72.4 
79.8 
59.6 
70.6 
111.7 
96.6 
75.8 
94.7 
115.2 
97.4 
78.0 
96.9 
 
87.4+/-18.8 
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Table 3.10. Repeat analysis of M5 MIPs cartridges, following washing, with triplicate 
GC/MS analyses of each eluent, for the prohormones numbered [7] to [12]. 
Number Prohormone Injection 
No. 
Recovery 
M5.1 
(%) 
Recovery 
M5.2 
(%) 
Recovery 
M5.3 
(%) 
Average M5 
Recovery 
(%) 
7 5a-
androstane-
3,17-diol 
1 
2 
3 
Average 
81.6 
73.3 
81.3 
78.7 
74.9 
69.6 
72.9 
72.4 
82.7 
88.6 
73.1 
81.5 
 
77.5+/-6.2 
8 5a-
androstane-
3,17-dione 
1 
2 
3 
Average 
103.3 
98.5 
93.7 
98.5 
112.8 
92.6 
89.4 
98.3 
133.5 
124.6 
110.4 
122.8 
 
106.5+/-15.1 
9 Nandrolone 1 
2 
3 
Average 
94.7 
90.6 
90.1 
91.8 
86.6 
74.7 
75.9 
79.1 
116.3 
101.6 
86.6 
101.5 
 
90.8+/-12.7 
10 5(6)-
androstene-
3,17-dione 
1 
2 
3 
Average 
89.3 
89.0 
87.0 
88.4 
99.1 
77.2 
75.2 
83.8 
115.6 
102.2 
92.7 
103.5 
 
91.9+/-12.5 
11 Testosterone 1 
2 
3 
Average 
131.1 
117.6 
93.3 
114.0 
134.9 
100.3 
100.9 
112.0 
130.9 
135.0 
125.0 
130.3 
 
 
118.7+/-16.5 
12 1,4-
androstadiene-
3,17-dione 
1 
2 
3 
Average 
90.0 
90.6 
90.0 
90.2 
102.6 
79.6 
80.4 
87.5 
115.2 
105.2 
94.3 
105.0 
 
94.2+/-11.6 
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It is clear that templating had no significant influence, at the 2  level, on the performance 
of the polymer developed using methacrylic acid (MAA). Apart from 5(10)-estrene-3b,17b-
diol, the percentage recovery for templated (M5) was not significantly different to that 
obtained for the non-templated (B5) polymer. This would suggest that using the 
methacrylic acid (MAA) as the monomer results in non-specific binding for steroids, 
presumably through non-covalent electrostatic interactions between the carboxylic acid 
groups on the polymer and the hydroxyl and ketone groups in the prohormones and matrix 
species. 
Repeating the extractions on all three M5 cartridges, following washing, resulted in an 
increase in the average percentage recovery of between 10 and 20%, for all prohormone 
species. GC-MS analyses on each extract were conducted in triplicate. The percentage 
recovery ranged between 78 and 104 % for the diols; whereas the recovery of DHEA, 
nandrolone and testosterone, respectively, ranged from 91 to 119 %. The androgenic diones 
had a percentage recovery of between 92 and 107 %, whilst 5(10)-estrene-3,17-dione was 
recovered at 25 %. These results would seem to indicate that the washing process was 
incomplete and would need further investigation if the MIPs were to be re-used; however, 
as the imprinting conferred no significant improvement over the non-imprinted polymer 
this was not explored further in this study.  
3.2.6.   Evaluating the percentage recovery of the prohormones from synthetic urine 
using cartridges containing imprinted (M6) and non-imprinted (B6) polymers that 
use 4-VP as the monomer 
Having established that imprinting with testosterone had no significant influence on the 
recovery performance of the polymers, when utilising MAA as the monomer, the 
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imprinting process was evaluated using 4-vinyl pyridine (4-VP) as the monomer. The 
percentage recovery of each of the target analytes from synthetic urine was determined 
using the method specified in Section 2.2.9. Triplicate cartridges, containing either 
imprinted (M6) or non-imprinted (B6) polymers, were utilised and the results for each 
prohormone are recorded in Tables 3.11 and 3.12, respectively. Table 3.13 evaluates 
whether the imprinting had any significant influence on the extraction of the prohormones 
from urine. 
As can be seen in Table 3.11, using the imprinted polymer (M6), the percentage recovery 
ranged between 70 and 96 % for the diols; whereas the recovery of DHEA, nandrolone and 
testosterone, respectively, ranged from 68 to 84 %.  The diones had a percentage recovery 
of between 84 and 100%. 
Table 3.12 illustrates that the use of the non-imprinted polymer (B6) results in lower 
percentage recovery of all the prohormones. The percentage recovery ranged between 28 
and 37 % for the diols; whereas the recovery of DHEA, nandrolone and testosterone, 
respectively, ranged from 25 to 37 %.  The diones had a percentage recovery of between 37 
and 55 %. In most cases, the repeatability of the percentage recovery was comparable for 
both M6 and B6.  
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Table 3.11.    Percentage recoveries of each of the prohormones based on their extraction 
from 1 mL of synthetic urine (spiked at 10 ng/mL) on three cartridges of M6. 
Number Prohormone Recovery 
M6.1 
(%) 
Recovery 
M6.2 
(%) 
Recovery 
M6.3 
(%) 
Average 
Recovery 
M6 
(%) 
Standard 
Deviation 
n-1 
(%) 
1 5(10)-estrene-
3b,17b-diol 
80.0 71.0 90.2 80.4 9.7 
2 4-estrene-
3b,17b-diol 
77.6 67.7 63.7 69.7 7.1 
3 5(10)-estrene-
3,17-dione 
125.3 107.1 118.9 117.1 7.9 
4 4-androstene-
3b,17b-diol 
106.7 89.3 90.8 95.6 9.6 
5 DHEA 61.2 70.5 73.6 68.4 6.5 
6 5(6)-
androstene-
3b,17b-diol 
81.3 78.5 82.2 80.7 1.9 
7 5a-androstane-
3,17-diol 
87.1 70.0. 76.1 77.7 8.7 
8 5a-androstane-
3,17-dione 
86.5 92.1 101.7 93.4 7.7 
9 Nandrolone 86.7 78.2 83.7 82.9 4.3 
10 5(6)-
androstene-
3,17-dione 
94.4 86.4 99.5 93.4 6.6 
11 Testosterone 87.3 84.4 79.5 83.7 3.9 
12 1,4-
androstadiene-
3,17-dione 
92.6 82.1 79.2 84.6 7.1 
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Table 3.12. Percentage recoveries of each of the prohormones based on their extraction 
from 1 mL of synthetic urine (spiked at 10 ng/mL) on three cartridges of the 
non-templated polymer (B6).   
Number Prohormone Recovery 
B6.1 
(%) 
Recovery 
B6.2 
(%) 
Recovery 
B6.3 
(%) 
Average 
Recovery 
B6 
(%) 
Standard 
Deviation 
n-1 
(%) 
1 5(10)-estrene-
3b,17b-diol 
31.6 37.2 28.3 32.4 4.5 
2 4-estrene-
3b,17b-diol 
33.0 29.1 25.6 29.2 3.7 
3 5(10)-estrene-
3,17-dione 
65.3 46.1 54.5 55.4 9.6 
4 4-androstene-
3b,17b-diol 
30.0 45.6 37.3 37.7 7.8 
5 DHEA 24.2 28.6 21.3 24.7 3.6 
6 5(6)-
androstene-
3b,17b-diol 
30.7 29.2 23.3 27.7 3.9 
7 5a-androstane-
3,17-diol 
34.4 25.3 23.0 27.5 6.0 
8 5a-androstane-
3,17-dione 
37.6 43.6 30.2 37.1 6.8 
9 Nandrolone 38.4 40.2 32.9 37.2 3.8 
10 5(6)-
androstene-
3,17-dione 
43.7 41.6 30.0 38.4 7.4 
11 Testosterone 34.7 39.7 30.3 34.9 4.7 
12 1,4-
androstadiene-
3,17-dione 
38.3 44.9 34.3 39.2 5.3 
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Table 3.13. Evaluating whether the templating of the 4-vinyl pyridine polymer with 
testosterone had a significant influence on the extraction of the prohormones.  
Number Prohormone Average 
Recovery 
M6  
(%) 
Average 
Recovery 
B6 
(%) 
Significant 
Influence at the  
2 level? 
1 5(10)-estrene-
3b,17b-diol 
80.4 +/- 19.4 32.4 +/- 9.0 Yes 
2 4-estrene-3b,17b-
diol 
69.7 +/- 14.2 29.2 +/- 7.4  Yes 
3 5(10)-estrene-3,17-
dione 
117.1+/-15.8 55.3+/-19.2 Yes 
4 4-androstene-
3b,17b-diol 
95.6 +/- 19.2 37.7 +/-15.6 Yes 
5 DHEA 68.4 +/- 13.0 24.7 +/- 7.2 Yes 
6 5(6)-androstene-
3b,17b-diol 
80.7 +/- 3.8 27.7 +/- 7.8 Yes 
7 5a-androstane-3,17-
diol 
77.7 +/- 17.4 27.5 +/- 12.0 Yes 
8 5a-androstane-3,17-
dione 
93.4 +/- 15.4 37.1 +/- 13.6 Yes 
9 Nandrolone 82.9 +/- 8.6 37.2 +/-7.6 Yes 
10 5(6)-androstene-
3,17-dione 
93.4 +/- 13.2 38.4 +/- 14.8 Yes 
11 Testosterone 83.7 +/- 7.8 34.9 +/- 9.4 Yes 
12 1,4-androstadiene-
3,17-dione 
84.6 +/- 14.2 39.2 +/- 10.7 Yes 
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It is clear from the tables that templating the 4-vinyl pyridine monomers with testosterone 
did have a significant influence on the recovery performance of the polymer. The 
percentage recovery of all the prohormones using the templated polymer (M6) were 
significantly higher than those obtained for the non-templated polymer (B6) and 
comparative to those achieved with MAA. This would suggest that in contrast to the non-
specific binding when using methacrylic acid as the monomer, that using 4-vinyl pyridine 
as the monomer and testosterone as the template results in the formation of specific binding 
cavities with conformations that are capable of reversibly trapping and releasing the 
steroids. Presumably, these non-covalent interactions ( and dipole-dipole) are between 
unsaturated bonds on the polymer and those in the ring structure and the substituents of the 
prohormones.  
3.3. Conclusions 
In an attempt to overcome the issues associated with traditional analytical techniques, this 
chapter has explored a novel approach to the extraction, separation, detection and 
quantification of a cohort of prohormones, spiked into synthetic urine at concentrations that 
are appropriate for sports testing, as specified by the MRPL values published by WADA.  
The method developed extracted unconjugated steroids from the urine using molecular 
imprinted polymers (MIPs) templated with testosterone. Two variants of the MIPs were 
developed, using different monomers, and their performances evaluated against non-
imprinted versions of the polymers. Uniquely, this work has combined the selectivity of 
molecular recognition polymers with the high resolving power of two-dimensional gas 
chromatography/time-of-flight mass spectrometry to enable the identification and 
quantitation of all the prohormones without the need for derivatisation. 
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The regulations in place at the time of the study, as prepared by the World Anti-Doping 
Agency (WADA) (2010 Prohibited List) stated that 46+ compounds (exogenous and 
endogenous) require close monitoring and were not allowed to be present in concentrations 
above 10 ng/mL.  
The steroid compounds chosen for this study were selected for two reasons. Firstly, they are 
close structural analogues of testosterone and nandrolone; and are banned substances with 
respect to WADA's anti-doping watch-list. Some of these compounds act as prohormones 
and are converted to testosterone and nandrolone in the body. Therefore they are of 
commercial and legal interest, and as such are a good demonstration of the potential of the 
developed technique. Secondly the compounds studied share a high level of similarity to 
testosterone and each other, in terms of charge and functional groups. These similarities 
allowed a MIP to be developed for a close analogue of structurally similar compounds that 
is relevant for WADA testing for both exogenous and endogenous steroids. 
Based on the findings in this chapter, it is possible to draw the following conclusions: 
1. In agreement with previous studies, the identification and quantification of the 
cohort of twelve prohormones, following derivatisation, is difficult.  In addition, 
the results confirm the following:  
a. the level of derivatisation is highly variable and many of the derivatised 
species will co-elute; 
b. diols and species with a hydroxyl group at the 17- position (e.g. nandrolone 
and testosterone) will, in the main, derivatise;  
c. diones, will, in the main, not derivatise;  
150 
 
d. there are exceptions to the above rules and therefore each compound must be 
evaluated individually; 
e. underivatised species elute significantly earlier than derivatised species;  
f. the derivatisation process itself generates species which can interfere with 
detection of the target species, especially when the sample is analysed using 
standard single dimension gas chromatography/mass spectrometry.  
2. The majority of the underivatised prohormones in a mixed standard solution, were 
resolved chromatographically using two-dimensional comprehensive 
chromatography. They also all eluted in a distinct region of the 2D surface plot of 
the total ion chromatogram (TIC) that was well resolved from the majority of the 
matrix compounds and column bleed. 
3. Whilst 5(10)-estrene-3b,17b-diol and 4-estrene-3b,17b-diol (Peaks #1 & #2) co-
eluted in the total ion chromatogram, as did 4-androstene-3b,17b-diol and DHEA 
(Peaks #4 & #5); all of these species could be resolved and quantified using their 
diagnostic fragmentation ions.  
4. In terms of the elution characteristics of the individual prohormones and the groups 
of steroids, we could conclude the following: 
a. 19-norsteroids elute before their androsta(e)ne equivalents (as evidenced by 
4-estrene-3b,17b-diol eluting before 4-androstene-3b,17b-diol and 
nandrolone eluting before testosterone); 
b. Diols elute before diones (evidenced by the fact that 5 of the first seven 
species are diols and 3 of the last five species are diones); 
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c. The presence of a carbonyl group at the 3- position as well as double bond at 
the 4-position of Ring A (nandrolone and testerone) increases retention on 
the columns, even with a hydroxyl group at the 17-position, this is likely to 
be due to polarisation or delocalisation of the charge in the C=O and C=C 
double bonds and their interaction with the delocalised aromatic substituents 
in the stationary phase; 
d. Nor-19 steroids, separated only by the location of a double bond (as 
evidenced by 5(10)-estrene-3b,17b-diol and 4-estrene-3b,17b-diol) will 
effectively co-elute, but may be distinguished by their diagnostic 
fragmentation ions; 
e. Androstenes, separated only by the location of a double bond (as evidenced 
by 5(6)-androstene-3b,17b-diol and 4-androstene-3b,17b-diol) can be 
resolved chromatographically; 
f. In terms of the diones, the elution order is: estrene, androstane, androstene 
and androstadiene.  
5. The integrated area responses measured for a specific quantitation ion for each of 
the underivatised prohormones in a mixed standard, were linear over the range of 
50 to 500 pg injected. This is equivalent to the quantity of material that could be 
recovered from urine samples spiked at 1 to 10 ng/mL on using the extraction 
method developed in this thesis.  The correlation coefficients were in the range 
from 0.98 to 0.998, over the concentration range studied. 
6. The limits of detection (LOD) and quantitation (LOQ) for each prohormone were 
estimated by repeat injections of the mixed standard containing 50 pg of each 
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prohormone injected on column.  Based on the results obtained from this standard 
method (LOD=3SD; LOQ=10xSD), it would appear that the twelve prohormones 
should all be detectable below ~30 pg on column (0.6 ng/mL equivalent in spiked 
urine); and quantitation should be possible below ~100 pg on column (2.0 ng/mL 
equivalent in spiked urine). All the prohormones should therefore be detectable 
below the minimum required performance limit of 10 ng/mL defined by WADA in 
2010. There is of course the caviat that most steroids are present in urine in the 
conjugated form and would probably require hydrolysis prior to MIPs extraction.  
As previously reported unconjugated steroids make up approximately ~3% of the 
total steroids present in urine. At the 2010 WADA levels, this would have 
necessitated a limit of detection of ~15 pg on column.  Most of the prohormones 
are in Table 3.5 are estimated to be detectable at around that level. 
7. Therefore, with the caviat that a hydrolysis method will probably be required to 
deconjugate the steroids, prior to MIPs analysis, the method was determined to be 
fit for its intended purpose.   
8. Since this part of the study was completed, WADA lowered its value to 5 ng/mL, 
for most species, in 2012.  Therefore, as it now stands, assuming that the 
unconjugated steroids are present at 3% of all steroids in a urine sample, then the 
current method would not be directly applicable to untreated urine samples. This 
would require a limit of detection of ~ 8 pg on column (5/33 = 0.15 ng/mL in 
urine).   
9. It should, however, be noted that the level of detection in this study could be further 
improved by either: increasing the quantity of urine passed over a larger MIPs 
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cartridge or by utilising a greater proportion of the sample extracted; for example, 
by increasing the volume (from 1 L up to 20 L) of acetonitrile injected in to the 
mass spectrometer, through the use of a programmable temperature vapourisation 
(PTV) injector such as the Optic 4 from ATAS GL, or similar devices from Agilent 
Technologies or Gerstel.  This will require further investigation, as the ability to 
directly extract a family of unconjugated steroids from urine without treatment, will 
be a significant step forward.  Whether such approaches work will depend on the 
ability of the MIPs to resolve the target compounds from the matrix peaks that will 
be present if larger volumes of urine or solvent are used and ultimately the 
background noise for the quantitation ion in the chromatographic region of interest. 
10. The imprinting of a polymer with testosterone, using methacrylic acid (MAA) as the 
momoner, did not result in a significant increase in the percentage recovery of the 
prohormones over the non-imprinted polymer; when used to extract the cohort of 
prohormones from 1 mL of synthetic urine spiked at 10 ng/mL.  
11. The imprinting of a polymer with testosterone, using 4-vinyl pyridine (4-VP) as the 
monomer, resulted in a significant increase in the percentage recovery for all the 
prohormones when compared with the non-imprinted polymer: 
a.  using the imprinted polymer (M6), the percentage recovery ranged between 
70 and 96 % for the diols; whereas, the recovery of DHEA, nandrolone and 
testosterone, respectively, ranged from 68 to 84 %.  The diones had a 
percentage recovery of between 84 and 100 %. 
b.  using the non-imprinted polymer (B6) the percentage recovery ranged 
between 28 and 37 % for the diols; whereas the recovery of DHEA, 
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nandrolone and testosterone, respectively, ranged from 25 to 37 %.  The 
diones had a percentage recovery of between 37 and 55 %, In most cases 
the repeatability of the percentage recovery was comparable for both M6 
and B6.  
12. In addition to illustrating that the method is capable of detecting a cohort of 
unconjugated, underivatised steroids (prohormones) at concentrations that are 
appropriate for sports testing, it also appears to open up the opportunity for the 
screening of any banned, forbidden or unknown compounds that is based around 
the steroid nucleus. The high acquisition rate of the time-of-flight mass 
spectrometer, coupled with the high signal-to-noise characteristics of the sharp 
peaks generated in cryogenic comprehensive chromatography,  means that it 
uniquely suitable for the screening of known and unknowns as all the ions between 
50-500+ amu can be collected simultaneously. This, in stark contrast to the 
quadrupole mass spectrometer systems which, due to their scanning nature, must 
rely on pre-defined windows of selected ions to achieve the desired performance, 
thus leaving open the opportunity for abuse.  
The GC/MS method and the MIPs developed in this study will now be re-applied 
unchanged, to evaluate whether it can be applied to the detection of designer steroids, 
developed to deliberately get around the sport testing protocols, in the presence of 
prohormones.  
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4.  Further validation of the MIPS method coupled to 
comprehensive gas chromatography / mass spectrometery 
and its application to designer steroids  
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4.1. Introduction  
Designer steroids can be defined as a substance or a compound that undergoes a major or 
minor modification, for the sole purpose of avoiding detection. It is often a synthetic steroid 
derived by chemical modification from another, usually an anabolic steroid. In contrast to a 
prohormone, it does not need to be converted to an active form via enzymatic activity 
within the liver or stomach. Being active from the moment they are orally ingested, they 
almost immediately contribute to the cocktail of active hormones in the plasma. They also 
tend to be more potent and have greater anabolic properties than prohormones, and 
therefore any additional benefits must be considered alongside the more pronounced side 
effects. They are typically blended with prohormones and other agents, to counteract side 
effects, in a process known as “stacking”.1  
A minority of athletes are prepared to put their health at risk by using such designer 
steroids, no matter how small the advantageous anabolic properties may be. This is despite 
the fact that designer steroids are not usually supported by any published trial data and they 
have no guarantee as to the quality or long term consequences of taking the product 
provided by distributors of designer steroids.   
In stark contrast, the pharmaceutical industry is regulated by the Medicines and Healthcare 
products Regulatory Agency (MHRA) in the UK and by the Food and Drug Administration 
(FDA) in the USA. Therefore, active pharmaceutical ingredients undergo rigorous checks 
and include specific limitations on impurities and/or degradation products formed during 
manufacture. For example, the quality guidelines produced by the International Conference 
for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for 
Human Use (ICH) require that impurities above 0.05% must be reported, above 0.1% they 
must be identified, whereas impurities above 0.15% must undergo further toxicology 
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studies.
2 These above levels apply for drug substances administered at ≤ 2 g/day, whilst 
lower percentage values apply for drugs exceeding 2 g/day.
2
 Pharmaceutical product are 
also assigned a shelf life based upon on extensive stability data. No such supporting 
information is available for designer steroids. 
Similarly, the difficulty in gaining ethical approval for in vivo metabolism studies of 
designer steroids has led to a lack of toxicological profiles and efficacy of designer steroids 
available in peer reviewed journals. What literature that is available, regarding designer 
steroids, is often out dated, part of a marketed product or available on internet forums 
where discussions take place between steroid users. Compared to scientific publications, a 
larger amount of information is freely available on websites, online discussion groups, and 
forums. The plethora of information includes structure of compounds and discussion on 
efficacy and safety for potential users. After an exhaustive literature search, some non-peer 
reviewed articles, that are specific for the designer steroids tested in this chapter, are 
reported and have been acknowledged in the Reference section accordingly.
1,4,5,6,8,910,11,12,15
 
Designer steroids have left unique and defined mark in both the history of Olympic sport 
and drug testing. Most notably, tetrahydrogestrinone (THG), a previously unknown doping 
substance, only came to light when a syringe containing the designer steroid was sent to 
doping officials in 2003.
3 
 
THG was developed by Patrick Arnold for the Bay Area Laboratory Co-Operative 
(BALCO), an American nutritional supplement company, through the hydrogenation of 
gestrinone over a catalyst.
3,4
 Ultimately, this resulted in the disqualification of several 
athletes after they were subsequently found to have used the steroid. The two most famous 
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names embroiled with the BALCO scandal were Barry Bonds and Marion Jones. UK 
sprinter, Dwain Chambers, was also associated with the scandal.
5
    
THG is a highly potent agonist for the androgen and progesterone receptors. It is an order 
of magnitude more potent than either nandrolone or trenbolone, but has 
no estrogenic activity.
6
 It has been found to bind to the androgen receptor with similar 
affinity to dihydrotestosterone.
3
 
In 2004, Catlin et al., were the first to develop and evaluate sensitive and specific methods 
for the rapid screening of urine samples for underivatized THG, by liquid 
chromatography/tandem mass spectrometry (LC/MS/MS) and the analysis of the 
combination trimethylsilyl ether-oxime derivative of THG,  by gas chromatography/high-
resolution mass spectrometry (GC/HRMS).
3
   
They also confirmed that THG was not detectable in urine by the standard doping control 
anabolic steroid screening, which uses pertrimethylsilyl derivatives and GC/MS analysis; 
they went on to state that other screening methods, which rely on alternative derivatisation 
and GC/MS, are possible but are very cumbersome for THG. In their method, they avoided 
artefact formation by first incubating the THG, at 65 C, in a solution of methylhydroxyl-
amine (25 mg/mL) in pyridine. This step was used to prevent the protonation of the oxygen 
causing enolisation. The trimethylsilyl ether was then prepared by incubating for 1 hour, at 
60 C, in a mixture of N-methyl-N-trimethylsilyltrifluoroacetamide, ammonium iodide and 
dithioerythritol. A proposed mechanism for the derivatisation process is provided in Figure 
4.1. 
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Figure 4.1.   A proposed mechanism for the derivatisation of THG. 
Whilst they demonstrated that underivatised THG was readily detectable by LC/MS/MS, 
they recognised that the cost of such a system was a burden on the doping control 
laboratories and that a simple screening method, by either GC/MS or immunoassay would 
be more desirable. They also went on to conclude that although GC/MS analysis of THG 
MOX-TMS by their method is more time consuming, it is a more sensitive and more 
definitive approach than LC/MS/MS.   
The BALCO scandal has shown that the doping screening methods are vulnerable to false 
negative results, especially when targeted by rogue analysts and athletes. As illustrated in 
Chapter 3, the range of potential prohormones that could be taken by an athlete is enormous 
and no single derivatisation method, when coupled with traditional one dimensional gas 
chromatography/mass spectrometry (GC/MS) analysis, is capable of providing the 
performance levels required by WADA. This issue is further complicated when one also 
considers the range of designer steroids that can be manufactured to deliberately avoid 
derivatisation.  
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Derivatisation of steroids can be carried out by using silylation or acylation reactions, with 
the choice of derivatisation mixture dependent on the steroids of interest, as co-elution of 
the derivatised steroids may occur. As stated above, silylation is the preferred steroid 
derivatisation approach for GC/MS; with the most popular being N,O-bis(trimethylsilyl)-
trifluoroacetamide (BSTFA) and the more volatile N-methyl-N-trifluoroacetamide 
(MSTFA). The use of catalysts is very common in the silylation process and necessary for 
tertiary hydroxyl groups and enolisation of the carbonyl function. A derivatisation 
procedure using MSTFA with ethanethiol and ammonium iodide (as an alternative to 
TMIS) suitable for GC/MS analysis, has been routinely used by the WADA-accredited 
laboratories for athletic drug testing.
7
 However, this method may lead to the formation of 
ethyl thio adducts which can cause interpretation problems in the sample analysis. In 
addition, the failure of some steroids to provide a single reaction product, together with the 
chemical rearrangement of others, has been reported as a hindrance to official testing 
laboratories. 
As was also shown in Chapter 3, most underivatised prohormones can be extracted from 
spiked urine samples using molecular imprinted polymers (MIPs) templated with 
testosterone and then resolved chromatographically by comprehensive gas chromatography 
/ time of flight mass spectrometry (GCxGC/ToFMS). Those prohormones that could not be 
resolved chromatographically were capable of being resolved using the time of flight mass 
spectrometer. In contrast to traditional scanning instruments (quadrupole or ion trap), the 
ability of the TofMS to collect ions over the full mass range at very high acquisition rates, 
enables co-eluting peaks to be separated using the deconvolution software and through the 
extraction of diagnostic fragmentation ions.   
163 
 
Focusing the selectivity of the MIPS on the conformation and electrostatic characteristics of 
the fused-ring nucleus of testosterone has resulted in a non-targeted extraction process for a 
family of steroids that share similar characteristics. When coupled with the GCxGC/ 
ToFMS, this enables a full mass spectrum profile to be collected of any steroid present in 
the urine sample.  
This chapter will explore whether the method developed in the previous chapter can be 
applied, without significant modification, to the detection of designer steroids shown in 
Figure 4.2. The steroids under investigation are: epitestosterone, Xtren, trenazone, epistane, 
gestrinone and tetrahydrogestrinone (THG).  Methyltestosterone will be used as the internal 
standard. 
Epitestosterone, has been included as it has an identical chemical composition to 
testosterone, the only difference being the relative orientation of the hydroxyl group at the 
17-position. It is anticipated that it will elute from the gas chromatography columns very 
close to testosterone and therefore should be characterised as part of the method 
development. Being an inactive epimer of testosterone it only tends to be administered in a 
cream form, to keep an athlete administering low levels of testosterone below the required 
T/E ratio used for drug doping violations.   
As can be seen from the Figure 4.2, dienedione (Xtren) and dienolone (Trenazone) are both 
estradienes, differing only by the functional group at the 17-position, with Xtren having a 
ketone, whereas trenazone has a beta-hydroxyl group. Therefore, Xtren is also a 
prohormone and a designer steroid, as it must be converted enzymatically to trenazone to 
become active. Xtren is administered orally whereas trenazone is administered topically, as 
it has poor oral bioavailability.
8
 The prohormone is reported to be more effective. The 
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orientation of the double bonds in the fused rings, in contrast to 1,4-androstadiene-3,17-
dione and especially testosterone, mean that both Xtren and trenazone will not aromatise 
and therefore show non-estrogenic properties. In practice, this is thought to result in leaner 
muscle mass, less water retention and less bloating. Trenazone is reported as having an 
anabolic/androgenic ratio of 100/10 compared to methyltestosterone. It does, however, 
show progestenic activity.
9
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Figure 4.2.   The molecular structures of the “designer steroids” selected for evaluating 
the GCxGC/TOFMS and the molecular imprinted polymer extraction 
method, developed in Chapters 2 and 3.   
Epistane (methylepitiostanol) is the only designer steroid in the cohort that does not have a 
ketone group at the 3-position; instead, it has a bridging sulphur epimer between the 2- and 
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3- position, its fused-ring structure is saturated and it has methyl groups attached at the 10-, 
13- and 17- positions. The latter introduces steric hindrance in the derivatisation of the 
beta- hydroxyl group. Whilst epistane does not share the same configuration at the 3-
position as the other steroids, it is one of the most popular designer steroids as the addition 
of the methyl groups make it orally active, preventing digestion, and it is believed to share 
the non-aromatisation (non-estrogenic) characteristics of epitiostanol.
10
 In addition, 
epistane has an anabolic/androgenic ratio of 660-1000/91-170 relative to methyl 
testosterone, when taken orally.
11 
 
Gestrinone and tretrahydrogestrinone (THG) are both estratrienes, with an ethyl group 
attached at the 13-position and a beta-hydroxyl group at the 17-position. They only differ 
by the saturation of the ethynyl (gestrinone) or ethyl (THG) group attached to the 17-
position. It is these alkyl functional groups that have been introduced to generate steric 
hindrance, thus preventing their efficient derivatisation. As with Xtren and trenazone, the 
locations of the unsaturated bonds in the fused rings of gestrinone and THG mean that they 
are not aromatising, resulting in their non-estrogenic effect. THG has an anabolic activity 
ten times greater than that of nandrolone or trenbalone, which will also result in lean 
muscle mass, and comes with potential side effects such as infertility, acne and hirsutism. It 
may also suppress the immune system.
12,13
     
Based on the late elution of 1,4-androstadiene-3,17-dione (Boldione) in the prohormone 
study, it is hypothesised that these multiple saturated species will also be retained 
significantly by the combination of stationary phases selected.      
Methyltestosterone, the 17 alpha-epimer of testosterone, is to be used as an internal 
standard in this study. The methylation of testosterone at the 17-position has the advantage 
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of making it orally administrable, as this prevents its digestion. Unfortunately, this small 
modification has also made it one of the most toxic steroids produced, in particular its 
toxicity in the liver, both short- and long- term are a major drawback.
14
 In addition, it will 
aromatise to estrogen and be converted to dihydrotestosterone, with all the inherent side-
effects associated with both. Other side effects include influencing thyroid hormone 
production and an increased level of aggression.
15
 Of the oral designer steroids, the extreme 
side effects make it one of the least attractive options.  
WADA accredited methods specify the detection of specific steroids at a given minimum 
required performance levels (MRPL). The MRPL is an analytical parameter of technical 
performance that the laboratories shall comply with when testing for the presence of a 
particular prohibited substance, its metabolite(s) or marker(s).  In 2010, the MRPL was set 
at 10 ng/mL for exogenous anabolic androgenous steroids; in 2012 this was reduced to 5 
ng/mL.
16,17
 Specific exceptions include dehydrochlormethyltestosterone, methandienone, 
methyltestosterone and stanozolol, all of which have a MRPL of 2 ng/mL. 
4.2. Results and Discussion 
4.2.1. Further validation of the GCxGC-MS method 
As a consequence of different projects requiring different column configurations, it was 
necessary to reconfigure the system prior to analysis. In practice, this meant using the same 
first dimension column, but introducing a new second dimension column. As the shorter,   
2 m column, is cut from a longer 10 m column, it is unlikely that the stationary phase 
coverage will be exactly the same. To ensure that the new configuration was appropriate for 
the evaluation of the MIPS method, a series of studies were first conducted with steroid 
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standards to re-characterise the performance of the GCxGC-MS system, both for the new 
cohort of designer steroids listed earlier and the original cohort of prohormones.   
Section 2.2.10, described how the standard mixtures used in this study were prepared. A 
summary of the composition of each of the solutions is provided in Table 4.1.  
Table 4.1.      Summary of the concentrations of the steroids present in the mixed designer 
and prohormone standards used during the characterization studies 
 
Standard 
name 
 
Designer Steroid 
Concentration 
(ng/mL) 
 
Prohormone 
Concentration 
(ng/mL) 
 
Internal  
Standard 
Concentration 
(ng/mL) 
DS#1 500 - - 
DSP#1 250 250 - 
DSPI#1 100 100 167 
DSPI#2 50 50 167 
DSPI#3 25 25 167 
Initially, the elution characteristics of the designer steroids were evaluated in isolation from 
the prohormones and the internal standard, in order to: a) identify if they could be detected, 
b) determine the region in which they elute, and c) to evaluate any potential co-elutions 
with the known prohormone elution region.  
As can be seen in Figure 4.2, epitestosterone [13] elutes close to the testosterone retention 
time.  This is not unexpected given that it is the epimer of testosterone, with only the 
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orientation of the hydroxyl group at the 17- position being different.  Xtren [14] and 
trenazone [15] are both estradienes, and in both dimensions they elute later than the 
prohormones characterised in the previous chapters. Epistane [16], which has the bridging 
thiol group instead of a ketone or hydroxyl group at the 3-position, is retained even longer 
on both columns.  
 
Figure 4.3.    A 2D surface plot [TIC] illustrating the elution regions for the underivatised 
designer steroids (epitestosterone [13], Xtren [14], trenazone [15] and 
epistane [16]). 
Gestrinone [17] and THG [18], cannot be seen in Figure 4.3, this is because they are both 
retained even further and do not elute within the modulation time. This is not an issue, as 
can be seen in Figure 4.4, they elute off the second column in a very clean part of the 
chromatogram, prior to where the non-polar column bleed and matrix species elute. This 
effect is known as “wrap around” and can either be allowed to continue or can be removed 
through an increase in the modulation time. Whilst increasing the modulation time, from 
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the current six seconds, (maximum of ~10 s) would bring gestrinone and THG within this 
window (they would then be found to the top right of the traces) it would also increase the 
size of the slices taken of the first dimension eluent which could result in a reduction in the 
resolution of other compounds. 
 
Figure 4.4. A 2D surface plot [TIC] illustrating the elution regions for the underivatised 
designer steroids (gestrinone [17] and THG [18].  Note the retention times 
in the second dimension, which indicate they have eluted after the 
modulation period, a process known as “wrap around”. 
 
The traces in Figures 4.3 and 4.4 were obtained from a 1 L splitless injection of a mixed 
designer steroid standard solution containing 500 ng/mL of each in acetonitrile; this is 
equivalent to 500 pg (0.5 ng) of each steroid being injected splitless on to the column.  
Based on the existing extraction method and assuming complete recovery, this would be 
consistent with having an initial concentration level of 10 ng/mL of each steroid present in 
1 mL of urine, the equivalent of the detection levels required by the 2010 WADA 
Prohibitive List.    
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A better illustration of the elution regions for the designer steroids, relative to the 
prohormones, is provided in Figure 4.5. This surface plot is taken from a 1 L injection of 
the mixed prohormone and designer steroid standard (DSP#1) at a concentration of 250 
ng/mL of each. 250 pg on column being equivalent to 5 ng/mL in urine, the detection levels 
specified in the 2012 WADA Prohibitive List. 
  
Figure 4.5. A 2D surface plot [m/z 99] illustrating the elution regions for:   
i) Prohormones 
ii) Designer Steroids #1  (epitestosterone, Xtren, trenazone, epistane) 
iii) Designer Steroids #2  (gestrinone, THG)  
Figure 4.5 shows that epitestosterone, Xtren, trenazone, and epistane elute in a region that 
partially overlaps with the prohormone region. As predicted, epitestosterone elutes very 
close to testosterone. They pretty much co-elute, as will be illustrated in the following 
figures. Xtren and trenazone both have two double bonds in the fused ring structure and 
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therefore their interaction with the aromatic groups in the stationary phase of the gas 
chromatography columns is stronger than that of the prohormones that have greater 
saturation. Similarly, gestrinone and THG have three double bonds, one in each of the rings 
A, B and C and their interaction with the aromatic groups of the stationary phase are the 
greatest, and actually results in them being retained beyond the modulation period of six 
seconds. They uniquely elute in a region to the bottom right hand side of the trace. 
Figures 4.6 and 4.7 identify the individual prohormones and the four steroids in the first 
designer steroid region. In Figure 4.6, the upper, contour plot allows the relative locations 
of each of the compounds in each dimension to be identified, i.e. their elution times on each 
column. The lower, surface plot gives an indication of the relative peak abundances of each 
of the compounds. Figure 4.7, provides a series of surface plots with a different perspective 
of the closely eluting peaks. 
 All the peaks result from the same 1 L injection of a mixed standard solution, with each 
steroid present at a concentration of 250 ng/mL (as before, 250 pg being the equivalent to 
the detection levels required by the 2012 WADA Prohibitive List). Once again, as 
previously explained in the Chapter 3, the caviat is that these steroid standard are present in 
the unconjugated form. The fragment ion at m/z 99 was found to be the best ion to illustrate 
the presence of all the steroids. 
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Figure 4.6.   A 2D contour plot and surface plot [m/z = 99] identifying the prohormones 
and the designer steroids present in a 1 L injection of a mixed solution of 
steroids, each at a concentration of 250 ng/mL. 
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Figure 4.7.    Alternative perspectives of the previous 2D surface plot [m/z = 99] 
clarifying the identities and locations of the prohormones and the designer 
steroids present in a 1 L injection of a mixed solution containing each of 
the steroids at a concentration of 250 ng/mL (5 ng/mL). 
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Similar plots can be drawn for each of the steroids in each of the mixed standard solutions 
at each concentration. From these chromatograms, quantitative measurements such as the 
retention times of the peak apex, the peak areas and signal to noise can be determined to 
evaluate the analytical technique. As was shown in the previous chapter, assessing the 
chromatographic resolution and reproducibility, the limits of detection and quantitation and 
linearity of the responses for the individual steroids is best performed using diagnostic 
fragmentation ions. Ideally, these ions are selected as being unique or significantly more 
abundant in the steroid of interest and are selected from the full fragmentation pattern 
available for each data point. Proposed mechanisms for the formation of these fragments 
are provided in Appendix A1.2 and A1.3. For example, gestrinone’s fragmentation is most 
easily recognized by the loss of the D ring, resulting in a highly diagnostic ion forming at 
m/z 227. The removal of water (18 Da) from the molecular ion also results in the fragment 
at m/z 291. Homolytic cleavage at position 13, results in the formation of a fragment at m/z 
261.  
A summary of the first dimension retention times for each of the steroids, at each 
concentration, is provided in Table 4.2.  It should be noted that the modulation of the eluent 
from the first gas chromatography column onto the second column takes place every six 
seconds, effectively dividing the chromatographic trace in to a series of six second slices.  
It is possible for the modulation to take place part of the way through an eluting peak, 
which results in the peak being divided over two slices. For species that were found in more 
than one modulation, the retention time was assigned to the slice with the greatest signal to 
noise ratio. The criteria for the assignment of a peak was that the signal to noise ratio for a 
particular steroid had to be above 3. In addition to the retentions times in the first 
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dimension, the table includes the fragmentation ion selected for each steroid. As a result of 
the mixed standards prepared, the designer steroids were analysed a total of eleven times, 
the prohormones were analysed a total of ten times, whereas the internal standard was 
analysed nine times. Triplicate analyses were performed at 100, 50 and 25 pg, respectively.  
Based on the standard extraction methodology, these on column injections, assuming 100% 
recovery, would be the equivalent to the material recovered from urine samples with a 
concentration range of between 2.0 and 0.5 ng/mL, well below the detection levels required 
by WADA for steroids. The exception is the internal standard, methyl testosterone, which 
has a MRPL of 2 ng/mL. 
It is worth noting that the identification of a suspected substance by WADA is usually 
undertaken by matching chromatographic retention time between an unknown and a 
certified reference standard. Gas chromatography is coupled with MS to provide additional 
certainty for the positive identification of a suspected finding, over cheaper, non-specific 
detectors, such flame ionisation detectors (FID). However, given the detection levels 
required and the complexity of the sample matrix, scanning MS systems, such as 
quadrupole GC-MS systems, use selected ion monitoring (SIM) windows to detect and 
quantify species. With a limited number of ions available in each window, characterising 
retention time is vital in the evidence against a doping suspect. Automated chromatographic 
data systems use retention time windows to integrate and identifying suspected samples 
within an automated platform. The coupling of comprehensive chromatography with a 
time-of-flight MS, reduces the reliance on retention time matching as compounds can be 
separated chromatographically, reducing the chance of co-elution, before being identified 
using a full fragmentation patterns available from the high acquisition TOFMS.  
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Table 4.2. A summary of the first dimension retention times (s) of the prohormones, designer steroids and the internal standard 
determined throughout the linearity studies with steroid standards. 
 
Steroid  Steroid 
 
Ion m/z 500 pg 250 pg 100 pg  100 pg  100 pg  50 pg  50 pg  50 pg  25 pg  25 pg  25 pg  
No. Name (Th) 
  
(1) (2) (3) (1) (2) (3) (1) (2) (3) 
              
1 5(10)-estrene-3b,17b-diol 225 - 1268 1274 1274 1268 1268 1268 1268 1268 1268 1268 
2 4-estrene-3b,17b-diol 218 - 1274 1274 1274 1274 1274 1274 1274 1274 1274 1274 
3 5(10)-estrene-3,17-dione 215 - 1298 1298 1298 1298 1298 1298 1298 1298 1298 1298 
4 4-androstene-3b,17b-diol 220 - 1310 1310 1310 1310 1310 1310 1310 1310 1310 1310 
5 DHEA 255 - 1310 1310 1310 1310 1310 1310 1310 1310 1310 1310 
6 5(6)-androstene-3b,17b-diol 205 - 1322 1322 1322 1322 1322 1322 1322 1322 1322 1322 
7 5a-androstane-3b,17b-diol 292 - 1328 1328 1328 1328 1328 1328 1328 1328 1328 1328 
8 5a-androstane-3,17-dione 217 - 1346 1346 1346 1346 1346 1346 1346 1346 1346 1346 
9 Nandrolone 110 - 1358 1364 1352 1358 1358 1358 1358 1358 1358 1358 
10 5(6)-androstene-3,17-dione 124 - 1388 1394 1394 1388 1388 1388 1388 1388 1388 1388 
11 Testosterone 124 - 1406 1412 1406 1406 1406 1406 1406 1406 1406 1406 
12 1,4-androstadiene-3,17-dione 122 - 1412 1418 1412 1412 1412 1412 1412 1412 1412 1412 
              
13 Epitestosterone 147 1400 1400 1400 1400 1400 1400 1400 1400 1400 1400 1400 
14 Xtren 174 1412 1412 1412 1412 1406 1406 1406 1406 1406 1406 1406 
15 Trenazone 135 1436 1436 1442 1436 1436 1436 1436 1436 1436 1436 1436 
16 Epistane 255 1556 1556 1556 1556 1556 1556 - - - - - 
17 Gestrinone 129 1550 1550 1550 1550 1550 1550 - 1550 - - - 
18 THG 227 1652 1652 1664 1658 1652 1652 1652 1652 1652 - - 
              
19 Methyltestosterone 91 - - 1430 1430 1424 1424 1424 1424 1424 1424 1424 
 
 
For species that were found in more than one modulation in the first dimension the peak was assigned to the slice that had the highest apex present.   
The criterion for the assignment of a peak was that the signal to noise for any quantitation ion had to be above 3. 
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It is clear from Table 4.2 that the method is highly reproducible with the apex of the peak 
being assigned either to the same or consecutive modulations in the majority of cases. Only 
nandrolone and THG are found to be assigned in three different modulations. Eight 
analyses of nandrolone give the same retention time; the two outliers are found at one 
modulation either side. In the case of THG, seven analyses are identical with one outlier 
being one modulation away from the mean, and the second being two modulations. The 
WADA criteria for traditional GC-MS methods using selected ion monitoring, require that 
the retention time of the analyte shall not differ by more than 1% or 0.2 minutes (whichever 
is smaller) from that of the same substance in a spiked urine sample or reference  material 
analysed comtemporaneously. The assignment of the majority of the steroid species in to 
one of two slices is more than consistent with the WADA requirement and even nandrolone 
and THG are within the required 12 s window.   
It is also clear from the same table that peaks are identified (above the signal to noise 
threshold) for all the prohormones and they are assigned a retention time at all 
concentrations. This is also the case for epitestosterone, Xtren and trenazone, but not for 
epistane, gestrinone and THG. This issue will be returned to during the discussion on the 
signal to noise ratios obtained for all species. Potential mechanisms for the formation of the 
fragmentation ions for each of the prohormones and designer steroids are provided in 
Appendix A1.2 and A1.3, respectively. 
Table 4.3 summarises all the retention times determined for each of the steroids in the 
second dimension over the range of mixed standard samples analysed, whilst Table 4.4 
summarises the relative standard deviation (RSD(%)) for the second dimension retention 
times for each steroid, at each concentration.   
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Table 4.3.     A summary of the retention times(s) obtained for the prohormones, designer steroids and the internal standard in the second 
dimension, as determined throughout the linearity studies with steroid standards. 
 
Steroid  Steroid  
Ion 
m/z 
(Th) 500 pg 250 pg 100 pg  100 pg  100 pg  50 pg  50 pg  50 pg  25 pg  25 pg  25 pg  
No. Name    (1) (2) (3) (1) (2) (3) (1) (2) (3) 
              
1 5(10)-estrene-3b,17b-diol 225 - 3.045 3.300 3.2600 3.020 3.010 3.010 3.010 3.015 2.995 3.010 
2 4-estrene-3b,17b-diol 218 - 3.050 3.265 3.2400 3.020 3.025 3.015 3.025 3.025 3.030 3.030 
3 5(10)-estrene-3,17-dione 215 - 3.475 3.765 3.7100 3.450 3.435 3.455 3.455 3.460 3.440 3.470 
4 4-androstene-3b,17b-diol 220 - 3.300 3.555 3.4950 3.255 3.250 3.270 3.265 3.260 3.250 3.250 
5 DHEA 255 - 3.390 3.670 3.6050 3.350 3.345 3.365 3.360 3.365 3.350 3.355 
6 5(6)-androstene-3b,17b-diol 205 - 3.375 3.650 3.5800 3.335 3.345 3.340 3.345 3.365 3.335 3.340 
7 5a-androstane-3b,17b-diol 292 - 3.375 3.640 3.5650 3.340 3.350 3.350 3.355 3.350 3.355 3.345 
8 5a-androstane-3,17-dione 217 - 3.780 4.075 4.0000 3.750 3.755 3.765 3.760 3.750 3.750 3.745 
9 Nandrolone 110 - 3.995 4.295 4.2600 3.945 3.970 3.960 3.975 3.985 3.985 3.950 
10 5(6)-androstene-3,17-dione 124 - 4.380 4.705 4.5900 4.360 4.365 4.375 4.360 4.345 4.340 4.345 
11 Testosterone 124 - 4.335 4.655 4.5650 4.310 4.305 4.315 4.320 4.325 4.325 4.300 
12 1,4-androstadiene-3,17-dione 122 - 4.760 5.095 5.0050 4.295 4.300 4.725 4.750 4.745 4.730 4.715 
              
13 Epitestosterone 147 4.370 4.255 4.580 4.500 4.220 4.235 4.235 4.255 4.260 4.245 4.235 
14 Xtren 174 4.980 4.880 5.245 5.145 4.855 4.850 4.870 4.870 4.870 4.860 4.860 
15 Trenazone 135 5.110 5.010 5.350 5.255 4.955 4.960 4.970 4.970 4.995 4.980 4.965 
16 Epistane 255 5.350 5.245 5.610 5.485 5.205 5.250 - - - - - 
17 Gestrinone 129 0.265 0.120 0.415 0.480 0.160 0.206 - 0.251 - - - 
18 THG 227 0.840 0.735 1.085 0.997 0.729 0.705 0.730 0.725 1.770 - - 
              
19 Methyltestosterone 91 - - 4.630 4.550 4.295 4.300 4.310 4.320 4.310 4.315 4.300 
 
For species that were found with more than one peak marker in the second dimension the peak was assigned to the marker that had the 
greater signal present.  The criterion for the assignment of a peak was that the signal to noise for any quantitation ion had to be above 3.
179 
 
Table 4.4. A summary of the relative standard deviation (RSD(%)) for the retention 
times obtained for the second dimension, as determined throughout the 
linearity studies with steroid standards. 
Steroid 
 No. 
Steroid  
Name 
RSD 
2
nd
 Dimension 
Retention 
Time 
[100 pg] 
(%) 
RSD 
2
nd
 Dimension 
Retention 
Time 
[50 pg] 
(%) 
RSD 
2
nd
 Dimension 
Retention 
Time 
[25 pg] 
(%) 
1 5(10)-estrene-3b,17b-diol 4.7 0.0 0.3 
2 4-estrene-3b,17b-diol 4.2 0.2 0.1 
3 5(10)-estrene-3,17-dione 4.6 0.3 0.4 
4 4-androstene-3b,17b-diol 4.6 0.3 0.2 
5 DHEA 4.8 0.3 0.2 
6 5(6)-androstene-3b,17b-diol 4.7 0.1 0.5 
7 5a-androstane-3b,17b-diol 4.4 0.1 0.1 
8 5a-androstane-3,17-dione 4.3 0.1 0.1 
9 Nandrolone 4.6 0.2 0.5 
10 5(6)-androstene-3,17-dione 3.9 0.2 0.1 
11 Testosterone 4.0 0.2 0.3 
12 1,4-androstadiene-3,17-dione 9.1 5.5 0.3 
13 Epitestosterone 4.3 0.3 0.3 
14 Xtren 4.0 0.2 0.1 
15 Trenazone 4.0 0.1 0.3 
16 Epistane 3.8 - - 
17 Gestrinone 48.1 - - 
18 THG 19.8 1.8 - 
19 Methyltestosterone 3.9 0.2 0.2 
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As can be seen from the preceding tables, the majority of the steroids show good 
reproducibility for the retention times in the second dimension, with the percentage relative 
standard deviation being generally less than 5 %. The greatest variation in the assignment 
of the peak marker in the second dimension occurs for all steroids during injections of 100 
pg. This may be related to the fact that it is the highest concentration under study and the 
variability is significantly greater than that seen at 50 or 25 pg. The reproducibility of the 
assignment of the apex of the peak might be improved by either: a) reducing the data 
acquisition rate from its current 200 Hz, or b) applying further data smoothing, post 
collection. Reducing the acquisition rate would also improve the signal to noise and may 
also improve the limit of detection. 
The two species that show the greatest variability in the second dimension retention times 
are gestrinone and THG. Since these are the two species that elute outside of the six second 
modulation window it isn’t suprising that they show the greatest variability. Gestrinone in 
particular is influenced by the fact that it is eluting from the second column, just as the 
modulation period terminates. Lengthening the modulation period would prevent the 
existing issues with the variability in elution times in the second dimension and would 
result in gestrinone and THG being located close to epistane, to the top right hand side of 
the 2D surface plot. An evaluation would need to be conducted in terms of the influence on 
the detection limits of other steroids, should the modulation period be increased to the ~9 
seconds necessary to elute both gestrinone and THG.   
The assignment of the retention times of each of the steroid compounds, at different 
concentrations, is dependent on the signal to noise ratio for each compound being above a 
minimum value of 3. Table 4.5 summarises the signal to noise determined for the 
quantitation ion for each steroid in each sample. 
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Table 4.5. A summary of the signal to noise values obtained for the prohormones, designer steroids and the internal standard, as 
determined throughout the linearity studies with steroid standards 
No. Steroid Name 
 
Ion 
m/z 
(Th) 
500 pg 250 pg 
100pg 
(1) 
100pg 
(2) 
100pg 
(3) 
50 pg 
(1) 
50 pg 
(2) 
50 pg 
(3) 
25 pg 
(1) 
25 pg 
(2) 
25 pg 
(3) 
              
1 5(10)-estrene-3b,17b-diol 225 - 53.0 29.4 27.5 21.2 9.3 7.0 7.9 5.9 4.3 4.5 
2 4-estrene-3b,17b-diol 218 - 153.1 40.2 37.9 39.7 14.3 17.1 10.5 9.2 10.1 8.6 
3 5(10)-estrene-3,17-dione 215 - 109.3 43.1 46.7 42.7 10.5 8.6 9.1 4.3 5.7 3.9 
4 4-androstene-3b,17b-diol 220 - 476.0 139.4 136.3 112.0 30.1 30.2 24.8 20.7 22.1 14.6 
5 DHEA 255 - 225.8 46.0 47.6 47.8 26.7 17.8 17.3 13.5 11.1 11.5 
6 5(6)-androstene-3b,17b-diol 205 - 126.3 48.1 35.9 34.4 11.6 10.9 10.3 6.8 4.3 5.0 
7 5a-androstane-3b,17b-diol 292 - 169.9 30.7 38.5 46.6 18.4 12.9 17.4 12.4 10.4 10.3 
8 5a-androstane-3,17-dione 217 - 217.9 51.2 55.0 49.3 21.6 19.6 16.9 12.6 11.7 11.7 
9 Nandrolone 110 - 307.6 199.5 198.8 142.3 65.1 63.8 53.5 33.2 34.6 31.3 
10 5(6)-androstene-3,17-dione 124 - 158.5 119.9 88.9 94.7 32.0 27.1 33.7 24.7 23.3 16.5 
11 Testosterone 124 - 964.8 276.7 259.4 272.2 131.3 100.5 99.0 81.6 80.5 73.3 
12 1,4-androstadiene-3,17-dione 122 - 2371.3 376.0 739.9 764.9 352.3 306.5 265.7 196.0 189.9 186.1 
              
13 Epitestosterone 147 85.3 73.1 16.4 18.8 24.8 10.2 8.9 9.7 7.3 4.5 6.8 
14 Xtren 174 1057 660.5 293.1 290.9 323.0 79.2 72.9 59.3 44.4 36.9 31.0 
15 Trenazone 135 136.2 108.8 39.3 27.5 42.8 14.1 13.6 10.5 7.9 7.5 8.3 
16 Epistane 255 42.8 21.9 7.2 6.4 9.5 3.0 - - - - - 
17 Gestrinone 129 30.5 18.3 8.4 18.1 12.9 3.4 - 3.9 - - - 
18 THG 227 43.5 30.2 6.6 7.9 11.8 7.1 4.6 4.7 3.4 - - 
              
19 Methyltestosterone 91 - - 51.4 46.4 35.5 33.0 26.9 24.8 35.1 35.6 33.7 
. 
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Table 4.5 lists all the values for the signal to noise determined for each steroid, at each of 
the masses injected, along with the fragmentation ion used. The signal to noise values are 
then used to determine the limit of detection and quantitation for each steroid. Steroids that 
have a signal to noise greater than 3, are assigned as being detectable, those with a signal to 
noise of greater than 5 are considered quantifiable.    
It is interesting that the limits of detection predicted for the prohormones, based on the 
replicate analyses at 50 pg reported in Chapter 3, are pretty much confirmed by the findings 
listed in the table at 25 pg. All the prohormones are detectable, above the signal noise limit, 
at 25 pg, which would be equivalent to a concentration in urine of 0.5 ng/mL. 
The designer steroids, epitestosterone, Xtren and trenazone are all detectable at 25 pg.  
Xtren, in particular, has a very strong signature at m/z 174. THG is detectable in all three 
injections at 50 pg and just detectable in one injection at 25 pg. Gestrinone is not detectable 
at 25 pg but is just detectable in two of the three injections at 50 pg. Epistane is not 
detectable at 25 pg and is only found in one of the injections at 50 pg. 
Figure 4.8, provides the confirmatory 2D surface plots for epitestosterone (m/z 147), when 
injected at 100, 50 and 25 pg. Having the same chemical composition as testosterone and 
only deviating in the orientation of the hydroxyl group at the 17- position, it is not suprising 
that it partially co-elutes with testosterone, as previously shown in Figure 4.7.  
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Figure 4.8.    2D surface plots illustrating the responses obtained for epitestosterone using 
its diagnostic fragmentation ion (m/z = 147) at 100, 50 and 25 pg, 
respectively.  
Whilst epitestosterone was predictably difficult to resolve from testosterone, other designer steroids 
were shown to be easier to identify. In particular, as can be seen in Figures 4.9 - 4.10, the 
estradienes: dienedione (Xtren) and dienolone (trenalone) are well resolved from the prohormones. 
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Figure 4.9.   2D surface plots illustrating the responses obtained for Xtren using its 
diagnostic fragmentation ion (m/z = 174). The peaks result from injections 
of 100, 50 and 25 pg of Xtren, respectively.   
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Figure 4.10.    2D surface plots illustrating the responses obtained for trenazone using its 
diagnostic fragmentation ion (m/z = 135). The peaks result from injections 
of 100, 50 and 25 pg of trenazone, respectively. 
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As shown earlier, epistane is well retained by both columns and elutes after both Xtren and 
trenalone. As can be seen in Figures 4.11, the epistane peak is clearly identifiable at 100 pg.  
In contrast, at 50 and 25 pg, whilst the elution region can be identified, the peak is not 
significantly above the background noise level. 
 
 
Figure 4.11.   2D surface plots illustrating the responses obtained for epistane, using its 
diagnostic fragmentation ion (m/z = 255), injected at 100, 50 and 25 pg on 
column, respectively.  
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Both Gestrinone [17] and THG [18] elute outside of the modulation window, taking more 
than 6 s to elute from the second column. The responses obtained for both gestrinone and 
THG can be seen in Figures 4.12. Gestrinone is detectable down to 100 pg, whereas THG 
can be clearly identified at 50 pg.  Neither can be seen at 25 pg. 
 
 
 
Figure 4.12 2D surface plots illustrating the responses obtained for gestrinone [17] and 
THG [18] using m/z = 227. The peaks result from injection of 100, 50 and 
25 pg of each on column, respectively.  
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Utilising the proprietary instrument software, areas have been determined for all the steroid 
peaks identified in the previous tables with a signal to noise ratio of greater than three (S/N 
> 3) for their quantitation ion. These peak areas have then been plotted against the mass of 
steroid injected and used to determine the equations and the squared correlation coefficients 
for the linear least square fit over the mass range of 25 to 250 pg for the prohormones and 
over the mass range of 25 to 500 pg for the designer steroids.   
The plots of the peak areas obtained for the quantitation ion for each of the steroids are 
provided in Figure A3.1 in Appendix A3. All the peak areas for the prohormones are shown 
to be linearly correlated with the mass injected in to the mass spectrometer, over the mass 
range of 25 to 250 pg. The regression equations and the squared correlation coefficients for 
each of the prohormones are provided in Table 4.6.  
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Table 4.6. The equations and the squared correlation coefficients for the linear least 
square fit corresponding to peak areas obtained for each of the prohormones, 
for injections over the mass range of 25 to 250 pg. 
 
 
 
Steroid 
Number 
 
 
Steroid Name 
 
Regression Equation  
 
R
2
 
1 5(10)-estrene-3b,17b-diol y = 28.013x + 44.024 0.8503 
2 4-estrene-3b,17b-diol y = 72.241x - 1843.6 0.969 
3 5(10)-estrene-3,17-dione y = 58.133x - 1104.1 0.9599 
4 4-androstene-3b,17b-diol y = 256.38x - 7032.6 0.9822 
5 DHEA y = 120x - 3257.6 0.9502 
6 5(6)-androstene-3b,17b-diol y = 84.616x - 2213.3 0.9884 
7 5a-androstane-3b,17b-diol y = 83.622x - 1958 0.9644 
8 5a-androstane-3,17-dione y = 125.2x - 3154.1 0.9751 
9 Nandrolone y = 245.4x + 1421 0.8864 
10 5(6)-androstene-3,17-dione y = 116.2x + 897.65 0.8787 
11 Testosterone y = 665.57x - 12489 0.9781 
12 1,4-androstadiene-3,17-dione y = 1830.2x - 32682 0.9516 
The squared correlation coefficients range between 0.8503 for 5(10)-estrene-3b,17b-diol 
and 0.9884 for 5(6)-androstene-3b,17b-diol. The plots for both these prohormones are 
provided for illustrative purposes in Figure 4.13. 
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Figure 4.13.   Plots of the peak areas obtained for 5(10)-androstene-3b,17b-diol [1] and 
5(6)-androstene-3b,17b-diol [6], over the mass range of 25 to 250 pg. 
The plots for the ratio of the peak area obtained for the quantitation ion for each of the 
prohormones versus the peak area obtained for the internal standard (methyltestosterone, 
m/z 91), over the mass range of 25 to 100 pg, are to be found in Figure A3.2 in Appendix 
A3. The regression equation and the squared correlation coefficients for the ratio of the 
peak areas of the prohormones relative to the internal standard are provided in Table 4.7. 
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Table 4.7. The equations and the squared correlation coefficients for the linear least 
square fit corresponding to the ratio of the peak areas obtained for each of 
the prohormones relative to the internal standard, for injections over the 
mass range of 25 to 100 pg. 
 
 
 
Steroid 
Number 
 
 
Steroid Name 
 
Regression Equation  
 
R
2
 
1 5(10)-estrene-3b,17b-diol y = 0.0028x - 0.037 0.9031 
2 4-estrene-3b,17b-diol y = 0.0027x + 0.007 0.8952 
3 5(10)-estrene-3,17-dione y = 0.0043x - 0.0874 0.9608 
4 4-androstene-3b,17b-diol y = 0.0122x - 0.1764 0.9822 
5 DHEA y = 0.0035x + 0.0533 0.9385 
6 5(6)-androstene-3b,17b-diol y = 0.0045x - 0.079 0.9895 
7 5a-androstane-3b,17b-diol y = 0.0029x + 0.036 0.807 
8 5a-androstane-3,17-dione y = 0.005x - 0.0057 0.9921 
9 Nandrolone y = 0.022x - 0.096 0.969 
10 5(6)-androstene-3,17-dione y = 0.0101x - 0.0084 0.9683 
11 Testosterone y = 0.0263x + 0.3471 0.952 
12 1,4-androstadiene-3,17-dione y = 0.0632x + 1.7405 0.5973 
 
The squared regression coefficient (R
2
) varies between 0.807 for 5a-androstane-3b,17b-diol 
and 0.9921 for 5a-androstane-3,17-dione, indicating that there is a good correlation 
between the mass of steroid injected and the ratio of the peak area of the steroid relative to 
the peak area of the internal standard.  As expected, the squared regression coefficients (R
2
) 
has generally improved over the values obtained from straight area measurement, as this 
enables any slight variation in the experimental method to be accounted for.   The obvious 
exception to this is the result obtained for 1,4-androstadiene-3,17-dione, which surprisingly 
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indicates that there is no significant correlation, with an R
2
 of 0.5973.   On studying the 
graph, shown in Figure 4.14, it appears that one of the data points at 100 pg is much lower 
than the other two, and may be producing the anomalous value. If this point were to be 
removed then the equation becomes y = 0.0885x + 0.8556 and R
2 
= 0.9285, indicating that 
there is a good correlation with the mass of steroid injected. However, given the limited 
number of data points available (9), it is difficult to justify any statistically robust approach 
that would justify the removal of the data point. It is acknowledged that, in hind sight, this 
compound should have been re-analysed and that this result should be considered in any 
future study. However, it should also be noted that as a different approach is to be used for 
calculating the recovery of steroids using MIPS, then this anomalous result has no 
significant bearing on the rest of the chapter.  
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Figure 4.14.   A plot of the ratio of the peak areas obtained for 1,4-androstadiene-3,17-
dione [12] and the internal standard over the mass range of 25 to 100 pg.   
Having established that the peak areas measured for the prohormones could be linearly 
correlated with the mass of steroid injected (with the exception of 1,4-androstadiene-3,17-
dione), the attention turned to evaluating the peak areas for the designer steroids. Table 4.8, 
summarises the equations and squared correlation coefficients for the linear least square fit 
for the peak areas for injections over the mass range of 25 to 500 pg.  
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Table 4.8. The equations and the squared correlation coefficients for the linear least 
square fit corresponding to the peak areas obtained for each of the designer 
steroids, for injections over the mass range of 25 to 500 pg. 
 
Steroid 
Number 
 
 
Steroid Name 
 
Regression Equation  
 
R
2
 
13 Epitestosterone y = 49.935x - 158.14 0.9110 
14 Xtren y = 405.06x + 1348.8 0.9604 
15 Trenazone y = 78.661x - 631.98 0.9319 
16 Epistane y = 19.691x - 699.01 0.9845 
17 Gestrinone y = 14.904x + 288.69 0.9086 
18 THG y = 17.612x - 256.14 0.9171 
The squared correlation coefficients range between 0.9086 for gestrinone and 0.9845 for 
epistane, although it should be noted that due to higher detection limits (S/N >3) there are 
fewer data points than for the prohormones.  As previously reported, epistane had only one 
peak above the limit of detection at 50 pg and no peaks were attributable at 25 pg.  
Gestrinone had only two peaks above the limit of detection at 50 pg and no peaks were 
attributable at 25 pg whereas THG had no peaks attributable above the limit of detection, at 
25 pg. 
The linearity plots for the designer steroids can be found below, in Figures 4.15 and 4.16 
and also in Figure A3.3 in Appendix A3. 
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Steroid #14 y = 405.06x + 1348.8
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Steroid #15 y = 78.661x - 631.98
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Figure 4.15    Plots of the peak areas obtained for the quantitation ion for each of the 
designer steroids: epitestosterone [13], Xtren [14] and trenazone [15], over 
the mass range 25 to 500 pg. 
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Steroid #17 y = 14.904x + 288.69
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Steroid #18 y = 17.612x - 256.14
R2 = 0.9171
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Figure 4.16.    Plots of the peak areas obtained for the quantitation ion for each of the 
designer steroids: epistane [16], gestrinone [17] & THG [18], over the 
mass range 25 to 500 pg. 
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The linearity plots for two of the designer steroids (epitestosterone and trenazone) may be 
being influenced by the single data point at 250 pg. As previously stated, with the limited 
number of data points there is no statistically robust reason or any apparent systematic 
experimental error to justify removing these values. The squared correlation coefficients for 
these two compounds are also acceptable. Most tests for outliers (e.g. Grubb Test or Dixon 
Q Test) assume a Gaussian distribution, requiring more data than available. The experiment 
would have been improved if triplicate measurements had been taken at 250 and 500 pg 
and this approach will be applied in future. As with 1,4-androstadiene-3,17-dione, it should 
also be noted that a different approach is to be used for calculating the recovery of steroids 
using MIPS. These results therefore have no significant bearing on the rest of the chapter.   
A detailed summary of the conclusions of this part of the study will be provided in the 
conclusion section of this chapter (Section 4.3). For now it is suffice to say that based on 
the above findings it was decided to evaluate the molecular imprinted polymer method, 
utilising urine standards containing designer steroids (spiked at the 10 ng/mL level)  in the 
presence of prohormones (spiked at the 2-10 ng/mL level) and the internal standard 
(methyltestosterone, spiked at the 500 ng/mL level). 
4.2.2. Analysis of designer steroids following extraction from synthetic urine using 
molecularly imprinted polymers. 
Spiked urine standards were prepared as previously described in Section 2.2.11. and the 
subsequent extractions were performed as per the method described in the same section.   
Three cartridges of both M6 and M5, as used in the Chapter 3 study, were re-used 
following washing with 1 mL of water, acetonitrile and then methanol. 
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It should also be noted that the starting temperature of the gas chromatography ramp was 
increased slightly from 50 C in the above standard study to 65 C in this study. This step 
was taken to reduce the overall duty cycle for the cooling of the primary and secondary 
ovens between runs. It was not thought to have a significant bearing on the chromatography 
of the steroids, except that they would elute ~1 minute earlier than previously (given the 15 
C/min ramp rate). 
Figure 4.17 to 4.20 provide representative surface plots for each of the designer steroids 
obtained by extraction, by molecular imprinted polymers (M6 or M5), from 1 mL of 
synthetic urine (spiked at 10 ng/mL). Except for epistane, each of the designer steroids is 
clearly detectable at the 10 ng/mL level in the reconstituted eluent from each of the M6 
cartridges. 
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Figure 4.17. 2D surface plots obtained for Xtren [14], using its diagnostic fragmentation 
ion (m/z = 174).  The peaks result from the extraction of the designer steroid 
from 1 mL of synthetic urine, spiked at the 10 ng/mL level, using the 
molecular imprinted polymer, M6.  The extractions were conducted in 
triplicate on three separate cartridges.  Virtually identical plots were 
obtained using the M5 cartridges. 
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Figure 4.18. 2D surface plots obtained for trenazone [15], using its diagnostic 
fragmentation ion (m/z = 135).  The peaks result from the extraction of the 
designer steroid from 1 mL of synthetic urine, spiked at the 10 ng/mL level, 
using the molecular imprinted polymer, M6.  The extractions were 
conducted in triplicate on three separate cartridges.  Virtually identical plots 
were obtained using the M5 cartridges. 
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Figure 4.19. 2D surface plots obtained for epistane [16], using its diagnostic 
fragmentation ion (m/z = 255).  The peaks result from the extraction of the 
designer steroid from 1 mL of synthetic urine, spiked at the 10 ng/mL level, 
using the molecular imprinted polymer, M6.  The extractions were 
conducted in triplicate on three separate cartridges.  Virtually identical plots 
were obtained using the M5 cartridges. 
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Figure 4.20. 2D surface plots obtained for gestrinone [17] and THG [18], using their 
diagnostic fragmentation ion (m/z = 227).  The peaks result from the 
extraction of the designer steroid from 1 mL of synthetic urine, spiked at the 
10 ng/mL level, using the molecular imprinted polymer, M5.  The extractions 
were conducted in triplicate on three separate cartridges.  Virtually identical 
plots were obtained using the M6 cartridges (except for M6(3)). 
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Table 4.9 summarises the percentage recovery obtained on each of the M6 molecular 
imprinted polymer cartridges, for each of the designer steroids. These values were derived 
by dividing the peak area for the quantitation ion for each steroid by the peak area 
determined for the internal standard in each sample. This ratio was then further divided by 
the average of the same ratios determined for the two bracketed standards. Multiplying by 
100 gave the percentage recovery.   
Table 4.9. The percentage recovery determined for each of the designer steroids in each 
of the M6 molecular imprinted polymers cartridges, relative to the average 
areas obtained from bracketed standards.  1 mL of synthetic urine spiked at 
10 ng/mL. 
 
Steroid 
Number 
 
Steroid Name 
Recovery 
M6 (1) 
(%) 
Recovery 
M6 (2) 
(%) 
Recovery 
M6 (3) 
(%) 
Average 
Recovery 
(%)  
 
Recovery 
Standard 
Deviation 
(%)  
 
13 Epitestosterone 30.1 15.5 33.0 26.2 9.4 
14 Xtren 35.3 35.1 38.2 36.2 1.7 
15 Trenazone 30.2 16.5 20.6 22.4 7.0 
16 Epistane 0 0 0 0 0 
17 Gestrinone 1.0 1.1 7.4 3.2 3.6 
18 THG 145.8 72.6 100.7 106.3 36.9 
Table 4.10 summarises the percentage recovery obtained on each of the M5 molecular 
imprinted polymer cartridges, for each of the designer steroids. The values were derived in 
the same way as for M6. 
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Table 4.10. The percentage recovery determined for each of the designer steroids in each 
of the M5 molecular imprinted polymers cartridge, relative on the average 
areas obtained from bracketed standards.  1 mL of synthetic urine spiked at 
10 ng/mL. 
 
Steroid 
Number 
 
Steroid Name 
Recovery 
M5 (1) 
(%) 
Recovery 
M5 (2) 
(%) 
Recovery 
M5 (3) 
(%) 
Average 
Recovery 
(% ) 
Recovery 
Standard 
Deviation 
(%) 
13 Epitestosterone 31.3 23.7 15.0 23.4 8.2 
14 Xtren 32.4 37.7 57.7 42.6 13.3 
15 Trenazone 31.0 32.0 26.6 29.9 2.9 
16 Epistane 0 0 0 0 0 
17 Gestrinone 1.4 5.2 6.7 4.4 2.7 
18 THG 165.0 130.4 98.4 131.3 33.3 
From the above tables we are able to conclude that the average percentage recoveries 
determined for the M5 cartridges are highly consistent with those determined for M6. In 
addition, the recoveries of individual designer steroids are highly reproducible between the 
replicate cartridges. 
It is also clear, with the exception of THG, that the percentage recovery of each of the 
designer steroids is much lower than was achieved for the prohormones.    
THG had the highest recovery on all six of the MIPs cartridges, with an average percentage 
recovery of 106.3 % on M6 and 131.3 % on M5 cartridges, respectively. 
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Gestrinone had very low recovery on all six of the MIPs cartridges, with an average 
percentage recovery of 3.2 % on the M6 cartridges and 4.4 % on the M5 cartridges, 
respectively. 
Suprisingly, the average percentage recovery of epitestosterone was only 26.2 % on M6 
and 23.4 % on M5. This would not have been expected in terms of its similarity to the 
testosterone molecule; however, the very close chromatographic proximity (co-elution) to 
testosterone made it difficult to determine accurate peak areas. 
Xtren and trenazone had very similar recoveries to epitestosterone, with the average 
percentage recovery of Xtren being 36.2 % on M6 and 42.6 % on M5 and the average 
percentage recovery of trenazone being 22.4 % on M6 and 29.9 % on M5, respectively. 
The failure to detect epistane in any of the cartridges, despite having been detected at lower 
concentration level in the previous validation study would indicate that the unique 
conformation of epistane, with its bridging sulphur group, means that it is either not being 
extracted from the urine or it is being retained within the MIPs. The former is more likely 
and is an additional piece of evidence that the MIPs material has developed cavities that 
were templated around the testosterone molecule. 
It is not clear if the presence of the full cohort of the prohormones in the urine samples, 
ranging in concentration from 2-10 ng/mL, has significantly influenced the performance of 
the MIPs for the designer steroids. It may be possible that there is competition for the 
cavities and that the prohormones are being selectively trapped. There is no clear evidence 
of this being the case and therefore this would need to be evaluated in further studies.    
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Despite the lower recoveries all the designer steroids, all except epistane, are clearly visible 
in the 2D surface plots provided in Figures 4.16 to 4.19.   
At this stage, the performance of the cartridges are acceptable, despite the low percentage 
recovery. They are very reproducible and have been shown to be viable for the detection of 
most of the designer steroids present in synthetic urine at 10 ng/mL. Further studies will be 
necessary to determine batch-to-batch variability and how the cartridges perform if they are 
re-used and if they are used on urine samples at lower concentrations.  
4.3. Conclusions 
In addition to naming specific banned substances, the WADA Prohibited Lists also carry 
the caveat of “other substances with a similar chemical structure or similar biological 
effect(s) are also prohibited”. Designer steroids fit firmly into this category. With 
derivatisation methods shown to be highly compound specific, and other sensitive tests 
developed for LC/MS (MS) also being highly specific, there is no suitable “family-wide” 
protocol available for the screening of known, and unknown, prohormones or designer 
steroids. Therefore, by targeting the native state of the steroids and utilising the power of 
comprehensive gas chromatography and molecular imprinted polymers (MIPs) we have 
developed a screening method for a family of prohormones and designer steroids that share 
the testosterone nucleus.   
Based on the findings of the above studies to evaluate the suitability of the previously 
developed comprehensive chromatography method to resolve, detect and quantify a cohort 
of designer steroids in the presence of the original prohormones, it can be concluded that: 
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i. Most of the cohort of six designer steroids elute in different regions to that of the 
prohormones; 
ii. The exception is epitestosterone, the 17 alpha-epimer of testosterone. As  
anticipated, epitestosterone and testosterone partially co-elute making them difficult 
to quantify as they also have the same fragmentation pattern; 
iii. Xtren and trenazone, having a similar estradiene configuration, elute in a similar 
area and are retained longer than the prohormones; 
iv. Epistane, with its bridging sulphur group, is retained on both columns for longer 
than either Xtren or trenazone. It also elutes later than gestrinone in the first 
dimension yet interestingly it elutes earlier on the second dimension column, which 
has a greater level of aromatic substituents; 
v. Gestrinone and THG, being estratrienes have the longest elution times on the 
second dimension, taking longer to elute than the current modulation time allows.  
As a result of this ‘wrap around’ they are found in their own distinct region of the 
surface plot.  Their greater retention is due to the fact that their three conjugated 
carbon-carbon double bonds and the ketone group at the 3-position have the greatest 
interaction with the aromatic substituents in the stationary phases; 
vi. Retention times are consistent in the first dimension; however, due to modulation, 
small changes in the second dimension retention time are possible.  The one 
exception is gestrinone which elutes from the second dimension column at around 
the time the modulator switches, which can result in significant changes in its 
second dimension retention time.  This does not tend to cause an issue as the full 
mass range of ions (m/z 50 to 521) are available and the compound can be identified 
by comparison of its fragmentation pattern with library values;  
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vii. The use of underivatised steroids produces high spectral similarity between the 
library fragmentation patterns and those found for the steroids in the samples, as it 
prevents ambiguous identification due to derivatisation issue.  As expected, the 
similarity increases when the concentrations of the steroid increases, as the 
background noise becomes less significant; 
viii. The areas measured for the individual quantitation ions for each of the prohormones 
and designer steroids has been shown to be correlated with the amount of steroid 
injected; 
ix. Not all of the designer steroids were detectable above background noise, in all the 
standard solutions injected: 
a. Xtren and trenazone were detectable at 25 pg 
b. Epistane was only detectable down to 100 pg 
c. THG was detectable at 50 pg but not at 25 pg  
d. Gestrinone was only detectable down to 100 pg  
Based on the extraction method employed throughout the thesis, 0.25 pg on column 
would be equivalent to a concentration of 0.5 ng/mL in urine; similarly 50 pg would 
be equivalent to 1.0 ng/mL in urine and 100 pg equivalent to 2.0 ng/mL.  Once 
again the caviat is that these figures are for unconjugated steroid standards and they 
were not extracted from synthetic urine; 
x) The average percentage recovery of the designer steroids, on triplicate M6 
cartidges, ranged between 0 - 106.3 % when extracted from 1 mL of synthetic urine 
spiked at 10 ng/mL; 
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xi) The average percentage recovery of the designer steroids, on triplicate M5 
cartidges, ranged between 0 - 131.3 % when extracted from 1 mL of synthetic urine 
spiked at 10 ng/mL. 
a. THG had the highest recovery on all six of the MIPs cartridges, with an 
average percentage recovery of 106.3 % on M6 and 131.3 % on M5, 
respectively; 
b. Gestrinone had very low recovery on all six of the MIPs cartridges, with an 
average percentage recovery of 3.2 % on the M6 cartridges and 4.4 % on the 
M5 cartridges, respectively; 
c. Suprisingly, the average percentage recovery of epitestosterone was only 
26.2 % on M6 and 23.4 % on M5.  This would not have been expected in 
terms of its similarity to the testosterone molecule; however, the very close 
chromatographic proximity (co-elution) to testosterone made it difficult to 
determine accurate peak areas; 
d. Xtren and trenazone had very similar recoveries to epitestosterone, with the 
average percentage recovery of Xtren being 36.2 % on M6 and 42.6 % on 
M5 and the average percentage recovery of trenazone being 22.4 % on M6 
and 29.9 % on M5, respectively; 
e. Epistane was not detected in any of the eluents from the MIPs cartridges, 
suggesting that was not extracted from the urine.  The most likely 
explanation is that this is due to it not sharing the same conformation as 
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testosterone and therefore it does not bind efficiently in the templated 
cavities; 
xii) It is not clear if the presence of the prohormones significantly impacted the 
performance of the method and this should be explored further in the future; 
xiii) Further evaluation will be required to determine if there is any significant influence 
on the performance of the MIPs when analysing real, as opposed to synthetic urine.  
Whilst the average percentage recoveries for all the designer steroids, except for THG, 
were lower than those obtained for the prohormones, the recoveries were consistent and 
reproducible. Further studies will be necessary to determine batch-to-batch variability and 
to observe how the cartridges perform if they are re-used, and also to assess the potential 
influence in moving from synthetic to human urine samples and towards conjugated 
steroids. The availability of conjugated steroids was beyond the scope of this thesis. 
It is clear that not all the designer steroids are compatible with the method developed and 
further work is required to fully characterise their performance for a range of compounds.  
The screening capability is determined by both the response factor of the designer steroid in 
the GCxGC/MS and the recovery from the MIPs. Both epistane and gestrinone have very 
low recoveries from the MIPs and have the highest detection levels (100 pg on column for 
standards, equivalence of 2 ng/mL in urine). MIPs templated with testosterone are not 
applicable to the extraction of epistane and it is highly unlikely to be applicable in sports 
testing for gestrinone. Xtren, trenazone and THG have acceptable recoveries and better 
response factors (equivalence of 0.5 ng/mL, 0.5 ng/mL and 1.0 ng/mL, respectively). When 
taking this and the percentage recovery by the MIPs in to consideration, then they should be 
able to be detected at the 5 ng/mL level in urine. However, as stated previously, this test is 
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currently for unconjugated steroids and therefore will require the urine sample to be 
processed, prior to extraction, especially with the lower MRPL levels now required by 
WADA since 2012.  
Despite this draw back, the MIPs method has been shown to remove matrix components 
and the power of comprehensive chromatography coupled to TOFMS, reduces the 
probability of co-elution of the target compounds with system blanks, matrix compounds, 
masking agents, reducing the likelihood of obtaining false positive and false negative 
results.  The resolving power of comprehensive gas chromatography coupled with the high 
acquisition rate of the TOFMS also makes it an ideal tool for the screening of unknown 
compounds. Capturing the full mass spectrum also allows for retrospective analysis, should 
new compounds emerge and co-elute.  
 211 
 
References 
1. Anabolic Androgenic Research  (accessed August 2014) available from: 
http://www.anabolicandrogenicresearch.com/pro-hormone-compound-info.html *** 
2. Impurities in New Drug Substances, Q3A(R2), Current Step 4 Version, International 
Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use, 25 October 2006, (accessed August 2014) available from: 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3A_R2
/Step4/Q3A_R2__Guideline.pdf 
3. Catlin D. H., M. H. Sekera,. B.D. Ahrens, B. Starcevic, Y.-C. Chang, C.K. Hatton, 
Tetrahydrogestrinone: discovery, synthesis, and detection in urine, Rapid Communications 
in Mass Spectrometry, 2004, 18, 1245–049. 
4. Shipley A., Mario Jones admits to steroid use, The Washington Post, 5 October 2007 
(accessed August 2014) available from: 
http://mspriorhealthpe.cmswiki.wikispaces.net/file/view/Marion+Jones+Admits+to+Steroid
+Use.pdf *** 
5. BALCO Investigation Timeline - USATODAY.com  (last accessed April 2013) 
http://usatoday30.usatoday.com/sports/balco-timeline.html *** 
6. Tetrahydrogestrinone, Material Safety Data Sheet (accessed August 2014) available from: 
http://www.cerilliant.com/ShopOnline/MSDS.aspx?itemno=c06bfa9c-9908-4015-862f-
06069f82f75f  *** 
7. Gomes R.L., W. Meredith, C.E. Snape, and M.A. Sephton, Analysis of conjugated steroid 
androgens: deconjugation, derivatisation and associated issues, Journal of Pharmaceutical 
and Biomedical Analysis, 2009, vol. 49, no. 5, pp. 1133–40. 
8. Trenazone (30 mL) Product Review, Anteus Labs (accessed August 2014) available from: 
https://www.musclecharge.com/store/muscle-gain/prohormones/trenbolone-precursor *** 
9. Dienolone (Trenazone) Bible, posted by Khysong on February 10, 2012 (accessed August 
2014) avaliable from: http://tunedsports.com/?s=tren *** 
10. Pro- Hormone/ Designer Steroid & Supplement Info (accessed August 2014) available 
from: http://www.anabolicandrpgeniocresearch.com-pro-hormone-compound-info.html *** 
11. What is epistane?  Provided by Russian Star (accessed August 2014) avaliable from: 
http://www.evolutionary.org/what-is-epistane/ *** 
12. Moon H.Y., S.H. Kim, S.H. Ryu, and P.G. Suh, The androgenic anabolic steroid 
tetrahydrogestrinone produces dioxin-like effects via the aryl hydrocarbon receptor, Toxicol 
In Vitro, 2012, 26(7), 1129-33 
 212 
 
13. Death A. K., K.C.Y. McGrath, R. Kazlauskas, D.J. Handelsman, Tetrahydrogestrinone is a 
potent androgen and progestin, J. Clin. Endocrinol. Metab., 2004, 89, 2498–2500. 
14. George A.J. and D.R. Mottram, Anabolic agents. In: Drugs in Sport, eds. D.R. Mottram, 
Routledge Taylor Francis, Fourth Edition, 2005, pp 41-81. 
15. Methyltestosterone steroid use, drug info and side effects, dosage (accessed August 2014) 
available from: http://www.steroiduse.org/methyltestosterone-steroid.html *** 
16. WADA, Minimum required performance levels for detection and identification of non-
threshold substances, WADA Technical Document – TD2010MRPL, 2010. 
17. WADA, Minimum required performance levels for detection and identification of non-
threshold substances, WADA Technical Document – TD2013MRPL, 2013.  
 
NB  References marked with *** at the end are non-peer reviewed articles on Designer Steroids 
 
 213 
 
5.  A pilot study evaluating the potential of aptamer coated 
magnetic beads for the extraction of estradiol prior to 
analysis by mass spectrometry 
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5.1. Introduction  
The previous chapters have shown that molecular imprinted polymers (MIPS), when 
coupled with comprehensive gas chromatography and mass spectrometry, can enhance the 
existing portfolio of techniques currently available to the analyst. However, the analysis of 
steroids is not limited to the sports testing arena, clinical applications also have similar 
requirements.  In addition, the extraction of steroids from biological matrices is not limited 
to the application of molecular imprinted polymers or solid phase extraction. Other 
analytical approaches, such as magnetic beads coated with aptamers, may also provide an 
alternative, as summarised in Section 1.2.6. 
This chapter presents a pilot study exploring the potential of an aptamer, coated on to 
magnetic beads, as a clean-up and extraction procedure for estradiol, prior to analysis by 
mass spectrometry.  This work actually pre-dated the MIPs studies and the selection of 
estradiol as the target steroid was driven by: 
i) the lack of a suitable aptamer for testosterone,  
ii) estradiol is a compound with significant clinical relevance. 
Estradiol (E2) is a small molecule, containing just 18 carbon atoms and has a molecular 
weight of 272.4 Da.  In mammals its synthesis occurs mainly in the ovaries; smaller 
amounts are synthesized by the adrenal cortex and by the testes.  The development of 
secondary sexual characteristics in women is triggered by estradiol production, produced by 
the corpus luteum.  Estradiol levels vary according to age and menstrual cycle. During the 
menstrual cycle, in pre-menopausal women, E2 serum levels will vary over a range from 41 
to 272 pg/mL, and decrease to about 4–14 pg/mL after the menopause.1   
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A determination of the amount of E2 in a biological matrix is often needed in investigative 
and clinical analysis, for example: during pregnancy, amenorrhea (including menstrual 
disorders), estrogen-secreting tumours, testicular function and gonadal agenesis.  It has also 
been shown that elevated amounts of estradiol, or its metabolites, can activate the rapid 
growth of cancer cells.
2
  Gynecomastia is linked to oestrogens formed in the adipose tissue 
and can cause obesity in men.
3
  Due to the strong link between estradiol and endocrine and 
gynaecological diseases, its monitoring and quantification remains an important aspect in 
clinical diagnosis.
2-3
 
Given the low concentration of E2 in post-menopausal women and the high concentration 
levels of a large number of structurally related steroids present in the sample, the accuracy 
of E2 measurements can be affected. Assays developed for estradiol therefore require high 
sensitivity and selectivity. 
5.2. Results and Discussion 
The aptamer was bound to the magnetic beads using the materials and apparatus described 
in Sections 2.4.1 and 2.4.2 and the method reported in Section 2.4.7, respectively.  The 
binding process was confirmed by measuring a drop in the UV absorbance, at a wavelength 
of 260 nm, after exposure to the beads.   
The scanning electron microscope images in Figure 5.1, confirm that the spherical, super 
paramagnetic beads (Dynabeads M-280, coated with streptavidin) provided a consistent and 
uniform surface for conjugation with the chosen DNA aptamer (5-Biotin 
GCTTCCAGCTTATTGAATTACACGCAGAGGGTAGCGGCTCTGCGCATTCAATTG
CTGCGCGCTGAAGCGCGGAAGC-3). During the study, the beads rapidly separated 
from the rest of the sample on the application of an external magnetic field, allowing the 
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matrix to be easily decanted, and they fully returned to solution when the external magnet 
was removed.  This confirmed the manufacturer’s claim that the beads would exhibit no 
residual magnetism once removed from the magnetic field.
 4
 
   
Figure 5.1. Scanning electron microscope images showing the aptamer attached to the 
magnetic beads following implementation of the binding procedure 
described in Section 2.4.3.   The right hand image is a X3 magnification of 
the left hand image. 
5.2.1. Evaluating the GC/MS response to different quantities of derivatised estradiol 
present in standard solutions 
Prior to the evaluation of the aptamer performance, the response of the GC/MS to a range 
of derivatised estradiol (E2) standards was studied using the parameters described in 
Section 2.3.4.  The derivatised estradiol standards were prepared as described in Section 
2.3.3.   
Estradiol, following derivatisation with MTBSTFA (1% TBDMCS), was shown to elute at 
10.18 minutes and its identity was further confirmed using its full fragmentation pattern 
and a secondary ion (m/z 500).  As shown in Figure 5.2, the peak areas are linear over the 
range 14,286 - 0.143 g/mL, with a squared coefficient of regression of 0.9977.  A spurious 
data point at 14.3 g/mL has been removed, as the area measured was of the same 
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magnitude as the value determined at 143 g/mL, suggesting an error in the preparation of 
that solution.   
 
Figure 5.2.   Showing the peak areas measured for serial dilutions of derivatised estradiol 
standards in methanol, from 1 L injections over the concentration range of 
14,286-0.143 g/mL.  
With a 1 L splitless injection utilised throughout, this equates to between 14.3 g and 
0.143 ng of estradiol being injected in to the mass spectrometer.  The signal to noise 
determined for the lowest concentration injection was 104, suggesting that the limit of 
quantitation (LOQ) achievable by GC-MS, by this method is in the tens of pg of estradiol.  
When the above data was re-plotted over the reduced concentration range of 1,429-0.143 
g/mL (equating to injections of between 1.43 g and 143 pg of estradiol) a slightly lower 
slope was obtained (y = 1E+6x + 4E+7) with a squared correlation coefficient of 0.9962.    
5.2.2. Evaluating the binding efficiencies and the recovery of estradiol from the 
aptamer coated magnetic beads by GC/MS  
Samples were prepared for analysis as described in Section 2.4.9.  Analysis of the Hormone 
Binding Buffer, before and after addition to the aptamer coated magnetic beads, showed 
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that estradiol was not detectable above background noise in the second solution, suggesting 
that it had been efficiently trapped.  The GC/MS trace obtained from the original solution is 
shown in Figure 5.3; whereas, the chromatogram obtained for the solution after vortexing 
with the aptamer is provided in Figure 5.4.  
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Figure 5.3.  Chromatograms and mass fragmentation patterns showing the peak 
obtained for estradiol from the original Hormone Binding Buffer. 
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Figure 5.4  Showing the chromatograms obtained for the Hormone Binding Buffer after 
vortexing with the aptamer coated magnetic beads.  Estradiol was not 
detected above the background noise.   
Whilst the trapping of estradiol on to the aptamer appears efficient, the eventual percentage 
recovery of estradiol in the original Elution Buffer (40 mM Tris-HCl, 10 mM (EDTA), 3.5 
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mM urea), was found to be only 31.2 %.  A comparison of the peak areas obtained for both 
solutions, processed in the same manner, is provided in Figure 5.5. 
 
Figure 5.5.   A comparison of the peak areas determined for estradiol in the Hormone 
Binding Buffer, as added to the aptamer coated beads, and in the original 
Elution Buffer supernatant. 
A much higher recovery of estradiol (53.8 %) was obtained when the original Elution 
Buffer solution was replaced with 10 % sodium dodecyl sulphate (SDS).  This higher 
recovery with SDS is illustrated in Figure 5.6 and as a result, SDS was deemed a more 
suitable elution buffer for estradiol, when analysed in its derivatised form by GC/MS. 
 
Figure 5.6. A comparison of the peak areas obtained for estradiol in the Hormone 
Binding Buffer added to the beads, and that obtained in the SDS Elution 
Buffer supernatant.                                                                    
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It should be noted that the pictorial representation of the method in Figure 2.1 of Chapter 2, 
for the selective extraction and elution of estradiol from an aptamer, is not the full story.  
As reported in Section 2.4.9, additional steps are required prior to analysis of the estradiol 
by GC/MS.  These included liquid–liquid extraction of the estradiol from the Elution 
Buffer using hexane, followed by evaporative drying and derivatisation.   
The limit of quantification for the analysis of derivatised estradiol by GC/MS was shown in 
Section 5.2.1 to fall in the middle of the range of material that might be expected to be 
obtained from 1 mL of serum.  The high salt content in the buffers used was also thought to 
have a negative influence on the derivatisation procedure.  It was thus deemed necessary to 
explore LC/MS/MS as alternative analysis tool, as this would eliminate the derivatisation 
and drying procedure as well as having lower levels of quantitation than GC/MS.    
5.2.3. Evaluating the LC/MS/MS response to different quantities of estradiol present 
in standard solutions 
Prior to analysing the serial dilutions of estradiol, the mobile phase conditions were 
optimised. The most suitable mobile phase conditions, which gave the lowest baseline 
noise, most consistent retention times and peak shapes on a XBridge C18 (2.5 µm, 2.1 x 50 
mm) column, was achieved by using a 5 % to 90 % gradient of methanol in water, at a flow 
rate of 0.2 mL/min.  The method started with the methanol concentration held at 5 % for 2 
minutes. The methanol concentration was then ramped up to 90 % over 12 minutes. It was 
maintained at this concentration for 3 minutes before finally being returned to the initial 
conditions in preparation for the next sample. 
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As reported in Section 2.4.6, E2 was serially diluted in the mobile phase solution (5 % 
MeOH / 95 % deionised water) at concentrations of 100, 10, 1 and 0.1 ng/mL, respectively. 
Data acquisition was performed in negative ion mode and the peak area response was 
determined for 10 L injections of underivatised E2 standards, over the range of 
concentrations reported above, using the parameters summarised in Section 2.4.5. 
As can be seen in Figure 5.7, the peak areas obtained for E2 showed good linearity for a 
four point calibration, with a squared correlation coefficient of 0.9999.  10 L injections of 
the above standard solutions equate to 1000, 100, 10 and 1 pg being injected in to the mass 
spectrometer.  The signal to noise determined at 1 pg was 14, indicating that a 1 pg 
injection is at the limit of quantitation, under the conditions used. 
 
Figure 5.7.   Showing the peak areas measured for 10 L injections of estradiol by 
LC/MS/MS over a concentration range of 100 ng/mL - 0.1 ng/mL   
5.2.4. Optimisation of the solvent for extraction from the Elution Buffer prior to 
LC/MS/MS analysis 
Prior to utilising the LC/MS/MS to evaluate the performance of the aptamer coated 
magnetic beads, the optimum solvent for the extraction of estradiol from the SDS Elution 
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Buffer was determined.  Hexane and tert-butyl ether (TBE) were both evaluated as 
described in Section 2.4.12 and the chromatograms obtained are provided in Figure 5.8. 
In brief, estradiol was spiked at the 1 g/mL level in 100 L of the Elution Buffer.  This 
solution was then diluted to 1 mL, with de-ionised water, before being extracted with the 
same volume of solvent (hexane or TBE).  Once the extraction was complete the solvent 
was dried and reconstituted in 100 L of the mobile phase of the LC/MS/MS (5 % MeOH, 
95 % deionised water).  10 L of the final solution was then injected, potentially equating 
to a 10 ng injection into the mass spectrometer. 
 
 
Figure 5.8.    Example chromatograms obtained for estradiol following its extraction from 
the Elution Buffer in a) hexane and b) tert-butyl ether (TBE).   Estradiol 
elutes at a) 8.43 and b) 8.44 minutes, respectively. 
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The analyses were repeated in triplicate for both solvents.  The peak areas obtained for each 
extractions are shown in Figure 5.9. 
 
(a)                                                                           (b) 
Figure 5.9. Peak areas obtained by LC/MS/MS for triplicate extractions of estradiol in:   
a) hexane and b) TBE. 
As can be seen in Figure 5.9, when 100 L of the Elution Buffer is spiked at 1 g/mL, the 
average peak area obtained from extraction with hexane (828,353 +/- 235,058) is almost the 
double of that obtained when extraction is performed in to tertiary-butyl ether (432,192 +/-  
74,689).   Despite the greater repeatability of TBE, the higher recovery of hexane meant 
that the latter was used in the remainder of the study. 
5.2.5. Evaluation of the aptamer extraction process using LC/MS/MS 
The efficacy of the aptamer binding processes, as initially investigated by the GC/MS, was 
repeated using the LC/MS/MS.  A number of different solutions were prepared for the 
evaluation and the peak areas were determined for the following solutions: 
i) 100 l of LC/MS/MS mobile phase (5% MeOH in deionized water) was spiked with 
estradiol at 1 ng/mL,  
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ii) Hormone Binding Buffer was spiked with estradiol at 1 ng/mL,  
iii) Supernatant of the Hormone Binding Buffer, spiked with estradiol at 1 ng/mL, 
following vortexing with aptamer coated magnetic beads for 1 hour, 
iv) Supernatant of an additional washing step using 100 L of the Hormone Binding 
Buffer, following vortexing for 2 minutes  
v) Supernatant of the Elution Buffer. 
In contrast to the method illustrated in Figure 2.1, an additional wash step was introduced 
prior to the addition of the Elution Buffer.  This step used 100 L of the Hormone Binding 
Buffer to evaluate if there was any non-specific binding of estradiol on the aptamers. 
Apart from the initial mobile phase solution, the above solutions were prepared for analysis 
by LC/MS/MS, as described in Section 2.3.10.   The supernatants were removed from the 
aptamer vial and diluted to 1 mL with dionised water. The estradiol was then extracted in to 
1 mL of hexane, the hexane was dried and reconstituted in to 100 L of the mobile phase 
for analysis. Table 5.1 summarises the peak areas obtained for estradiol from each of the 
above solutions.  It also relates the areas obtained for each of the solutions to the peak area 
obtained from spiking 100 L of the mobile phase with 1 ng/mL of estradiol. 
 226 
 
Table 5.1 A summary of the peak areas measured for estradiol in each of the solutions 
and supernatants and their percentage recovery relative to a sample of the 
mobile phase spiked with 1 ng/mL of estradiol. 
Spiked Solutions / Supernatants 
 
 
Peak area of 
estradiol 
(arbitrary 
units) 
 
Percent recovery of 
estradiol relative to 
mobile phase 
(%) 
Mobile Phase   27770 - 
Hormone Binding Buffer (before beads)  7338 26.4 
Hormone Binding Buffer (after beads)  129 0.46 
Washing Step   1088 3.9 
Elution Buffer  8859 31.9 
 
The results in Table 5.1 raise a number of questions. The peak area measured for the 
Hormone Binding Buffer, without exposure to the aptamer, is only 26.4 % of that 
determined from the direct spiking of the mobile phase with estradiol.  This would suggest 
that either: 
i) the extraction of estradiol from the buffer in to the mobile phase is not complete,  or 
ii) the process results in the transfer of species which can then influence the 
measurement of the target species in the LC/MS/MS.   
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A reduction in the anticipated peak area is not limited to the Hormone Binding Buffer, it is 
also found for the SDS Elution Buffer.   This interesting finding will be returned to once 
the primary question for the experiment has been explored.  The influence of the aptamer 
coated magnetic bead on the estradiol concentration will now need to be evaluated by 
considering the peak areas for each stage relative to the peak area determined for the spiked 
Hormone Binding Buffer that wasn’t exposed to the aptamers.  The relative percentage 
recovery determined for each step is summarised in Table 5.2. 
 Table 5.2 A summary of the peak areas measured for estradiol in each of the 
supernatants and their percentage recovery relative to the Hormone Binding 
Buffer. 
Spiked Solutions / Supernatants 
 
 
Peak area of 
estradiol 
(arbitrary 
units) 
 
Percent recovery of 
estradiol relative to 
Hormone Binding 
Buffer (no beads) 
(%) 
Hormone Binding Buffer (before beads)  7338 - 
Hormone Binding Buffer (after beads)  129 1.8 
Wash Step   1088 14.7 
Elution Buffer  8859 120.7 
The relative peak areas summarized in Table 5.2, provide an interesting insight in to the 
influence of the aptamer on the spiked solution of estradiol.   The supernatant generated 
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following sixty minutes of vortexing of the spiked Hormone Binding Buffer with aptamer 
coated magnetic beads generated a signal that was less than 2% of that found in an 
equivalent volume of the spiked buffer.  This result confirms the findings from the GC/MS 
study, though the lower detection limit of the LC/MS/MS has allowed the determination 
that the extraction is not totally complete.  The signal to noise for the estradiol peak in this 
first supernatant is only 18, and so is approaching the limit of the level of quantitation.  
The extra wash step was introduced as it was thought that it might be useful in the future to 
remove any matrix species that were non-selectively adsorbed during the first extraction. It 
was also introduced at this stage to evaluate whether any of the estradiol was not securely 
bound to the aptamer.  Vortexing of the aptamer with 100 L of fresh Hormone Binding 
Buffer for 2 minutes resulted in the removal of approximately 15% of the estradiol.  The 
loss of estradiol during this process will need to be further investigated and the 
reproducibility of this loss will need to be determined as it will influence the quantitative 
nature of the process.  The loss of estradiol in this step will need to be considered against 
the benefits of the removal of matrix species and depending on the trade-off it may, or may 
not, be utilized. 
Aptamers bind to their target due to shape-shape/hydrophobic/Van der Waals and ionic 
interactions.
5
  In some instances, as in this study, the binding can be very strong and is 
dependent on the buffer system used to select for the target.  Aptamers are strongly 
influenced by the buffer system used and the binding will dictate the affinity for the target 
analyte. Each aptamer behaves uniquely taking on different structures and binding to their 
target by adopting various configurations. As in this study, these interactions can result in 
good affinity and specificity. Again this is largely due to shape-shape interactions i.e. 
surface complementarity and the structure the aptamer adopts is down to the buffer it is in - 
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salts such as NaCl, MgCl2 and KCl, as used in the Hormone Binding Buffer, facilitate 
aptamers in adopting secondary structures that enhance the interactions with the target 
species. 
The SDS Elution Buffer, which has a different composition to the Hormone Binding 
Buffer, provided a peak area for estradiol that was comparable to that found in the initial 
spiked buffer.  Indeed the recovery was determined as being 121%.  This slightly high 
percentage recovery may simply be a result of experimental error, but also it may have been 
a result of the influence that different buffers appear to have on the extraction of estradiol 
into hexane and subsequently the mobile phase introduced into the LC/MS/MS.  The result 
obtained for the SDS supernatant would appear to be consistent with the earlier findings 
that indicated that there is significant loss in the estradiol signal from the introduction of the 
buffer solutions and the liquid-liquid extraction process.  
As previously discussed, despite the high selectivity of LC/MS/MS, interferences from co-
eluting endogenous compounds, or species introduced during the extraction process, can 
affect the quantitative analysis with electrospray ionization (ESI) as they can cause ion-
suppression or enhancement.
6,7  
In this study, the latter appears to be more important; 
however if the method is transferred to clinical samples then the former will become more 
important. The response for an analyte in ESI-MS can be strongly inﬂuenced by the 
existence of other electrolytes in the solution that enters the electrospray and may provide a 
mechanism to explain the loss in the estradiol signal on moving from the spiked mobile 
phase to the buffer solutions.   
In ESI, an analyte is already in the ionized form and transferred into the gas phase as a 
charged molecule, therefore the process that leads to the formation of gas phase ions can be 
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easily disrupted by the presence of matrix components.  Charge can also be lost through 
neutralization or charge transfer reactions due to the presence of interfering compounds.
6
  
Co-extracted matrix components may compete for the available charges surrounding the 
molecule and the entrance to the droplet surface between the analyte and the matrix 
components. The subsequent droplets formed require charged analyte trapped inside the 
droplets to escape the surface and enter into the MS orifice.  
High analyte concentrations can also limit the charge available on the ESI droplets. 
Furthermore endogenous compounds with very high surface activities at high concentration 
can increase the viscosity and the surface tension of the droplets to change the efﬁciency of 
their formation and evaporation, which, in turn, affects the amount of charged ions in the 
gas phase that are separated and detected by the mass analyser.
6,7
 
The use of aptamers with magnetic beads is a comparatively new technique. The number of 
publications that involve aptamer and magnetic beads coupled to mass spectroscopy 
detection method are very few and far between.  A review of the literature revealed very 
few publications that have dealt with the coupling of aptamers and mass spectroscopy, 
especially for small molecules detection.
8,9,10,11  
Most of the publications have developed 
bead-based methods for larger molecules such as proteins in peanuts and insulin.
8,9
    
The literature search revealed 925 publications on the application of aptamers with 
thrombin.  The success of HD-1, the aptamer for thrombin, has been widely attributed to 
the short sequence that results in higher yield and lower cost of this aptamer. HD-1 was the 
first aptamer selected toward a protein target and is extensively used as a model for 
aptamer-based sensor approaches. 
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Perhaps the most comparable work to this study is that by Huy et al.
12 
 The authors used a  
Shimadzu HPLC  with UV detection at 275 nm, for the detection of estradiol extracted and 
eluted using a specific aptamer (50-NH2 GCTTCCAGCTTATTGAATT 
ACACGCAGAGGGTAGCGGCTCTGCGCATTCAATTGCTGCGCGCTGAAGCGCGG
AAGC-30; random ssDNA: 50-NH2-T12TGGAGTAGATTGGCCAACCCTTTT-30).  A 
wavelength of 275 nm was selected as it is a wavelength which is above the UV cut-off 
value for most commonly used solvent including methanol and acetontrile.
13
 Furthermore, 
SDS and Buffer salts are compatible with HPLC UV detection and are used as ion pair 
reagents to improve the peak shape of basic compounds that interact with residual silanol 
groups in HPLC columns.   
Another important aspect of Huy’s work was that the samples analysed were spiked river 
waters and the wash step was comparatively mild, as it used MilliQ water. Furthermore, 
comparatively milder elution conditions of 40 mM Tris–HCl, 10 mM EDTA, 3.5 mM urea, 
and 0.02 % Tween20 at a pH 8.0 were used.  However, this method provided low 
percentage recovery of between 28.1-20.4 % over the range of 5-50 M.   
The addition, extraction and efficient elution of estradiol from aptamers requires the 
application of harsh conditions including the use of urea (original Elution Buffer), 
chaotropic salts or detergents (SDS).  As neither SDS nor the original Elution Buffer are 
suitable for LC/MS/MS analysis, the liquid-liquid extraction used in this study was a 
necessity, even though it introduces issues that will need to be characterised.  As no HPLC-
UV detector was available at the time of the study, it was not possible to apply this to our 
work. 
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Perhaps one major advantage of Huy’s elution conditions is the potential to reuse the 
aptamers. SDS is particularly harsh and it is difficult to remove from the aptamers, a soapy 
residue was seen to remain on our beads.  Therefore, in this context, despite the lower 
recovery, their work may be a better compromise as it enables the beads to be re-used.  
Since this study was conducted, methods have been developed that use magnetic beads but 
with alternative agents to aptamers.  Quotient Research published work describing the 
addition of monoclonal and polyclonal antibodies (raised against SXN101959) to tosyl-
activated magnetic beads.
14
 The attachment was confirmed by tryptic digestion and 
monitoring antibody specific tryptic peptides by LC/MS-MS/MS.
14
 Similarly, attaching 
C18 moieties to magnetic beads would be useful.  In such a case, optimised solvent 
conditions could then be used without any of the issues of denaturing the aptamer or the 
requirement for aptamer compatible methods.  
In 2007, Kim et al., had described a cost-effective, electrochemical detection method for 
estradiol using a DNA aptamer immobilized on to a gold electrode chip.
15
 Single-stranded 
DNA aptamers that speciﬁcally bound to estradiol were selected by the SELEX (Systematic 
Evolution of Ligands by EXponential enrichment) method and isolated for use. The 
isolated DNA aptamer was then immobilised on to the gold electrode, using the avidin–
biotin interaction.  Cyclic voltammetry (CV) and square wave voltammetry (SWV) were 
used to evaluate the level of binding of estradiol to the aptamer. Binding of estradiol with 
the aptamer caused the current to decrease and the magnitude of this drop was shown to be 
proportional to the level of binding.   
The authors described the approach as cost-effective because it did not require expensive 
dyes and instruments. The authors also concluded that a streptavidin-modiﬁed gold surface 
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provided better surface coverage than using avidin–biotin interaction.  A surface plasmon 
resonance (SPR) system was then used to conﬁrm and optimize the conditions for the 
DNA-aptamer immobilization on the gold surface.  
The SPR analysis was performed on the immobilized gold chips with various 
concentrations (0.1, 1 and 4 M) of the aptamer. The SPR responses increased as the 
aptamer concentration was increased. No response was seen from the DNA aptamer-
immobilized SPR chip when 1 M of estradiol was added. The authors went on to conclude 
that mass-dependant detection methods such as SPR were not actually suitable for the 
detection and quantitation of small organic chemicals.   
Other issues also arose in the study.  In assessing the speciﬁcity of this biosensor system for 
estradiol, the authors chose to use 2-methoxynaphthalene and 1-aminoanthraquinone as 
negative controls, owing to their structural similarity to estradiol. However, given these 
compound are not steroids, more precise cross-reactivity studies with structurally similar 
steroid such as testosterone, should have been conducted. 
Non-speciﬁc absorption was also highlighted as the cause for high background signal 
caused by the binding buffer on the gold electrode. The authors also suggest optimising the 
concentration of aptamers since a lower concentration of aptamer may not be enough to 
produce an efﬁcient electrochemical signal.  Conversely too high a concentration of 
aptamers may dampen the electrochemical signal.  
Prior to both these studies, Kim et al. had reported on a new approach for analysing the 
hormonal activity of estrogens, by binding a yellow fluorescence, protein-fused human 
estrogen receptor on to glass slides.
16
  Avidin was covalently immobilized on an amine-
modified glass slide. A biotinylated DNA probe was then immobilized through the avidin-
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biotin binding interaction. The estrogens were incubated at 37˚C for 30 minutes and the 
fluorescence was directly read with a micro-plate reader. The intensity was shown to be 
estrogen-dependent and enabled the identification and quantification of the hormonal 
activities of diethylstilbestrol, 17b-estradiol, ethynylestradiol, 4-hydroxy tamoxifen and 
clomiphene. The method provided estrogen-dependent sensitivity ~10
-13
 M for estradiol. 
Xin et al., have described the use of a magnetic particle-based chemiluminescence 
immunoassay (CLIA) for the detection of estradiol in human sera.
17
 The assay was 
designed to specifically recognise E2 in the presence of estrone (E1), estriol (E3), 
dihydrotestosterone (DHT), androstenedione, and testosterone.  
Sodium trichloracetate (Na-TCA) was specifically mentioned as a blocking agent for direct 
analysis of E2 in human serum, without extraction. The method had a detection limit of 
2.51 pg/mL with a larger working range of 15–1000 pg/mL.  High recoveries of 93.3, 106 
and 101 % and low coefficients of variation (<15%) were also reported. This method was 
then applied to the determination of E2 in 105 human sera and compared with commercial 
radioimmunoassay (RIA) kit, with a correlative coefficient of 0.9892. the authors proposed 
that the method could be used as a diagnostic kit for clinical analysis of E2 in human 
serum. 
A recently published study reported on the application of covalently immobilized 
recombinant human sex hormone binding globulin (rhSHBG) on paramagnetic beads for 
the screening and identification of androgenic and estrogenic designer steroids in dietary 
supplements.
18    
Testosterone and estradiol circulate in the bloodstream, bound mostly to the sex hormone 
binding globulin (SHBG) and to a lesser extent to serum albumin and corticosteroid-
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binding globulin (CBG).  Only 1-2% are unbound and are thus able to enter a cell and 
activate the relevant receptor.  SHBG inhibits the function of these hormones, albeit 
providing a mode of transport due to the hydrophobic nature of steroids.  
The binding affinity of SHBG is strongest for dihydrotestosterone (DHT)  followed by 
testosterone, androstenediol and then  estradiol.
19
  The binding affinity for other 
prohormones,  studied in the previous chapters, can be significantly different, for example  
DHEA is weakly bound to SHBG, whilst androstenedione does not bind.
20
  
The assay was performed in a 96-well plate and combined with the fast LC-MS, 96 
measurements could be performed within 4 h. The concentration-dependent inhibition of 
the label by steroids in buffer and dietary supplements was demonstrated.  
Impressively, the designer steroid tetrahydrogestrinone was identified in a spiked 
supplement. The author claims that the steroid-binding assay can be used for high-
throughput screening of androgens, estrogens, and gestagens in dietary supplements. One 
point of note was the lack of detection of androst-4-ene-3β-17β-diol in sample. This 
compound was not found by the targeted LC-MS/MS method, because the MRM 
transitions for this compound were not acquired. 
5.3. Conclusions 
The preliminary data from the pilot study reported in this chapter set out to evaluate the 
potential of aptamer-coated magnetized beads as a simple, high affinity, highly selective, 
high specificity, low cost method for the analysis of estradiol prior to its detection and 
quantification by mass spectrometry. 
The study revealed the following: 
 236 
 
 The peak areas determined by GC/MS for derivatised estradiol show a linear 
correlation with the concentration of estradiol standard introduced, though the limit 
of quantification is not sufficient to enable this method to be used for the range of 
concentrations found in clinical samples, in particular post-menopausal women. 
 The peak areas determined by LC/MS/MS for underivatised estradiol show a linear 
correlation with the concentration of estradiol standard introduced, the limit of 
quantification is sufficient to enable this method to be used for the range of 
concentrations found in clinical samples. 
 Based on the percentage recovery of estradiol, as determined by GC/MS, SDS was 
preferred over the original Elution Buffer solution. 
 In contrast to HPLC UV, prior to analysis by mass spectrometry estradiol had to be 
removed from the buffer solutions through extraction with an organic solvent, this 
was then dried and reconstituted in to the starting mobile (LC/MS) or derivatising 
agent (GC/MS).  This essential step added complexity and introduced issues, in 
terms of quantitation. 
 Hexane was shown to result in higher recovery than tertiary-butyl ether (TBE), 
when extracting estradiol from the SDS Elution Buffer. 
 The peak area measured for the Hormone Binding Buffer, without exposure to the 
aptamer, was only 26.4 % of that determined from the direct spiking of the mobile 
phase with estradiol.  A similar reduction in the anticipated peak area was also 
found for the SDS Elution Buffer.  This would suggest that either: 
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o the extraction of estradiol from the buffer in to the mobile phase is not complete,  
or  
o the process results in the transfer of species which can then influence the 
measurement of the target species in the LC/MS/MS.   
 The supernatant generated following sixty minutes of vortexing of the spiked 
Hormone Binding Buffer (1 ng/mL) with aptamer coated magnetic beads generated 
a signal that was less than 2% of that found in an equivalent volume of the spiked 
buffer, indicating a high affinity of the aptamer for estradiol. 
 Vortexing of the aptamer with 100 L of fresh Hormone Binding Buffer for 2 
minutes resulted in the removal of approximately 15% of the estradiol. The benefits 
of adding a wash step in terms of cleaning up the sample of matrix species will need 
to be evaluated against the knowledge that estradiol can be lost through its 
implementation. 
 The percentage recovery of estradiol in the Elution Buffer was determined as being 
121%, relative to the peak area measured in the Hormone Binding Buffer.   
 The use of a surfactant (SDS) as the Ellution Buffer was not without its issues, with 
a visible residue being left behind on the magnetic beads, limiting its multiple re-
use, thus increasing the cost. 
The proposed strategy was twofold: 
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i) to use aptamer coated magnetic beads as a vehicle to develop a simple technique 
that did not require skilled operatives and procedures that could be potentially 
be used for high throughput; 
ii) to use mass spectrometry as the detection device for its high specificity 
iii) a publication   
In reality, coupling of the magnetic beads coated with aptamers and mass spectrometry 
necessitated additional steps that added complexity and were not without issue. The buffer 
conditions required to bind and then elute estradiol from the aptamer were not consistent 
with mass spectrometry. 
Since conducting the study, other methods have been developed, most notably the recently 
published study reporting on the application of covalently immobilized recombinant human 
sex hormone binding globulin (rhSHBG) on paramagnetic beads for the screening and 
identification of androgenic and estrogenic designer steroids in dietary supplements.  This 
would suggest that the approach was valid; however the selection of the aptamer material 
could have been better. 
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6. Conclusions and Future Work  
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6.1. Introduction 
Steroids are a large family of organic compounds that are highly important biological 
molecules that play significant parts in the functioning of many living organisms. Several 
hundred steroids are known to exhibit bioactivity within human physiology. Many are 
produced by the human body (endogenous) but many are exogenous, produced either 
synthetically or by other organisms.  Anabolic steroids increase and muscle and bone 
production and are highly regulated and for many years they have been one of the most 
detected drug classes in sports testing.  Current regulations are prepared by the World Anti-
Doping Agency (WADA) and their latest Prohibited List (2012) names 50+ compounds 
that must be closely monitored by sports testing laboratories. 
There is considerable interest in the development of high throughput multi-component, 
chromatographic methods to screen for a large range of compounds. In an attempt to 
overcome the issues associated with traditional analysis techniques, this thesis has explored 
and evaluated two complimentary approaches (aptamers and MIPs) to the extraction of a 
range of steroids prior to their separation, detection and quantification by comprehensive 
gas chromatography/mass spectrometry or liquid chromatography/mass spectrometry.  The 
steroids selected for the studies either had clinical relevance (estradiol) or are of interest in 
the context of sports testing applications (prohormones and designer steroids). 
The individual chapters have presented detailed discussions and the conclusions for each of 
the studies conducted. The aim of this chapter is to:  
i. collate and summarise these findings, 
ii. provide feedback on how the methodology could be improved, and  
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iii. provide suggestions on how the work might ultimately be applied to a wider range 
of projects, by building on the findings reported.  
6.2. A summary of the conclusions from the studies 
Taking a chronological perspective of the research activities reported in this thesis, then the 
data from the pilot study reported in Chapter 5 set out to evaluate whether aptamer-coated 
magnetized beads had the potential to provide a simple, high affinity, highly selective, high 
specificity, low cost method for the extraction of estradiol prior to its detection and 
quantification with mass spectrometry. 
In reality, the coupling of the magnetic beads coated with aptamers and mass spectrometry 
necessitated the use of additional solvent extraction steps to the standard method applied 
previously.  These additional steps added complexity and were not without issue. In 
particular the buffer conditions required to bind and then elute estradiol from the aptamer 
were not found to be consistent with analysis by mass spectrometry.  The derivatisation of 
estradiol prior to analysis by GC/MS was negatively influenced by the salts present in the 
buffers and the limit of detection was not found to be adequate for the proposed clinical 
purpose.  Even when estradiol was analysed underivatised by LC/MS/MS, the use of 
surfactants in the elution buffer created issues with the analysis and even left physical 
residues on the aptamer beads, preventing their re-use. Significant effort would have been 
required to develop the extra clean-up steps. 
Having explored and discounted the use of aptamers, the attention of the research project 
turned to the development of a method for extracting unconjugated steroids from synthetic 
urine, using molecular imprinted polymers (MIPs) templated with testosterone.   
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Two variants of the MIPs were developed, using different monomers, and their 
performances evaluated against non-imprinted versions of the polymers.  Uniquely, this 
work has combined the selectivity of molecular recognition polymers with the high 
resolving power of two-dimensional gas chromatography/time-of-flight mass spectrometry 
to enable the identification and quantitation of all the prohormones without the need for 
derivatisation. 
Based on the initial findings in Chapter 3, it was possible to draw the following 
conclusions: 
 The identification and quantification of the cohort of twelve prohormones by GC-
MS, following derivatisation, is very difficult due to poor chromatographic 
resolution and the wide range of compounds generated during the derivatisation 
process. This confirmed the findings reported by others and this remained the case 
when the derivatised species were analysed using comprehensive chromatography. 
 In contrast, the majority of the underivatised unconjugated prohormones in a mixed 
standard solution, were resolved using two-dimensional comprehensive 
chromatography. Whilst a few of the prohormones co-eluted in the total ion 
chromatogram; all of these species could be resolved and quantified using their 
individual pattern of fragmentation ions, which were diagnostic. All the 
prohormones were also significantly resolved from the matrix compounds and 
column bleed.  The level of matrix compounds present was also much lower than 
those found in samples following derivatisation.  
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 The elution characteristics of the individual prohormones could be grouped based 
on which of the functional groups were present, especially those at the 3- and 17- 
positions.   
 The peak areas measured for each unconjugated prohormone were linear over the 
range of 50 to 500 pg injected. This range is equivalent to a quantity of material that 
could be recovered from 1 mL of urine samples spiked at 1 to 10 ng/mL, using the 
extraction method developed in this thesis. This range all covers the minimum 
required performance limit (MRPL) levels of the two latest WADA Prohibitive 
Lists.   
 It was also calculated that each of the twelve prohormones was likely to be 
detectable below ~30 pg on column, and quantitation should be possible below 
~100 pg on column.  All the prohormones should therefore be detectable well below 
the MRPL of 10 ng/mL, as defined by WADA in 2010 and reduced to 5 ng/mL in 
2012. It is accepted that whilst the sensitivity of the method could be improved 
further it is likely that any analysis of urines samples will require the hydrolysis of 
conjugated steroids in real world samples. 
 The imprinting of a polymer with testosterone, using methacrylic acid (MAA) as the 
momoner, did not result in a significant increase in the percentage recovery of the 
prohormones over the non-imprinted polymer; when used to extract the cohort of 
prohormones from 1 mL of synthetic urine spiked at 10 ng/mL.  
 The imprinting of a polymer with testosterone, using 4-vinyl pyridine (4-VP) as the 
monomer, did result in a significant increase in the percentage recovery for all the 
prohormones when compared with the non-imprinted polymer.  The difference was 
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interpreted as being as a result of the steroids having greater non-specific 
interactions with MAA and more specific interactions with the unsaturated groups 
of 4-VP.  
When the same comprehensive chromatography method was then applied to designer 
steroid standards in Chapter 4, the following was concluded: 
 Most of the cohort of six designer steroids elute in different regions to the 
prohormones. The exception is epitestosterone, the 17 alpha-epimer of testosterone.  
a. Xtren and trenazone, having a similar estradiene configuration, elute in a 
similar area and are retained longer than the prohormones. 
b. Epistane, with its bridging sulphur group, is retained on both columns for 
longer than either Xtren or trenazone. It also elutes later than gestrinone in 
the first dimension yet interestingly it elutes earlier on the second dimension 
column, which has a greater level of aromatic substituents. 
c. Gestrinone and THG, being estratrienes have the longest elution times on 
the second dimension, taking longer to elute than the current modulation 
time allows.  As a result of this ‘wrap around’, they are found in their own 
distinct region of the surface plot.  Their greater retention is due to the fact 
that their three conjugated carbon-carbon double bonds and the ketone group 
at the 3-position have the greatest interaction with the aromatic substituents 
in the stationary phases. 
 Retention times are consistent in the first dimension; however, due to modulation, 
small changes in the second dimension retention time are possible.  The one 
 247 
 
exception is gestrinone which elutes from the second dimension column at around 
the time the modulator switches, which can result in significant changes in its 
second dimension retention time.  This does not tend to cause an issue as the full 
mass range of ions (m/z 50 to 521) are available and the compound can be identified 
by comparison of its fragmentation pattern with library values.  
 The use of underivatised steroids produces high spectral similarity between the 
library fragmentation patterns and those found for the steroids in the samples, as it 
prevents ambiguous identification due to derivatisation issue.  As expected, the 
similarity increases when the concentrations of the steroid increases, as the 
background noise becomes less significant. 
 The areas measured for the individual quantitation ions for each of the prohormones 
and designer steroids has been shown to be correlated with the amount of steroid 
injected. 
 Not all of the designer steroids were detectable above background noise, in all the 
standard solutions injected: 
 Xtren and trenazone were detectable at 25 pg. 
 Epistane was only detectable down to 100 pg. 
 THG was detectable at 50 pg but not at 25 pg  
 Gestrinone was only detectable down to 100 pg 
When the same method was then applied to the extraction of the designer steroid standards 
from 1 mL of synthetic urine spiked at the 10 ng/mL level, the following was concluded: 
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 Whilst the average percentage recoveries for all the designer steroids, except for 
THG, were much lower than those obtained for the prohormones, the recoveries 
were consistent and reproducible.  
 Epistane was not detected in any of the eluents from the MIPs cartridges, suggesting 
that it was not extracted from the urine.  The most likely explanation is that this is 
due to it not sharing the same conformation as testosterone and therefore it does not 
bind efficiently in the templated cavities. 
 Further studies will be necessary to determine batch-to-batch variability and to 
observe how the cartridges perform if they are re-used, and also to assess the 
potential influence in moving from synthetic to human urine samples and towards 
conjugated steroids. The availability of conjugated steroids was beyond the scope of 
this thesis. 
It is clear that not all the designer steroids are compatible with the method developed and 
further work is required to fully characterise their performance for a range of compounds.  
The viability of the screening capability is determined by the response factor of the 
designer steroid in the MS and the recovery from the MIPs.  Both epistane and gestrinone 
have very low recoveries from the MIPs and have the highest detection levels (100 pg on 
column for standards, equivalence of 2 ng/mL in urine). MIPs templated with testosterone 
are not applicable to epistane and it is highly unlikely to be applicable in sports testing for 
gestrinone.   Xtren, trenazone and THG have acceptable recoveries and better response 
factors (equivalence of 0.5 ng/mL, 0.5 ng/mL and 1.0 ng/mL, respectively). When taking 
both in to consideration they should be able to be detected at the 5 ng/mL level in urine. 
However, as stated previously, this test is currently for unconjugated steroids and therefore 
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will require the urine sample to be processed, prior to extraction, especially with the lower 
MRPL levels now required by WADA since 2012.  
Despite this draw back, the MIPs method removes matrix components and the power of 
comprehensive chromatography coupled to TOFMS, reduces the probability of co-elution 
of the target compounds with system blanks, matrix compounds, masking agents or thus, 
reducing the likelihood of obtaining false positive and false negative results.  The resolving 
power of comprehensive gas chromatography coupled with the high acquisition rate of the 
TOFMS also makes it an ideal tool for the screening of unknown compounds. Capturing of 
the full mass spectrum also allows for retrospective analysis, should new compounds 
emerge and co-elute. 
6.3. Suggested Improvements 
Data management and quantitation of species using Leco Pegasus IV GC×GC/TOFMS 
have posed significant challenges in this study.  Whilst qualitative production of surface 
plots that enable the location of specific peaks to be identified and visualised is very 
intuitive, quantitative data processing is particularly labour intensive.  Better data handling 
functions within the ChromaTOF software, that accompanies the LECO Pegasus 
GCxGC/TOFMS systems, will be required if this method is ever to be used routinely.  The 
data-processing features require better search capabilities and functionality for library 
matching to species that are unique to the analysis. For example, the manual input of 
diagnostic ion so that the relevant mass spectrum and peak position can be pin pointed 
within the two dimension chromatogram.  The automated data-processing capabilities 
leaves much to yearn for and the similarity of the steroids has definitely challenged the 
software capabilities.  Despite this, the use of the ‘Region Classification’ function was 
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much appreciated, as prior to data processing, a specific region of the surface plot (e.g. the 
prohormone or designer steroid region) can be assigned for data processing, greatly 
reducing the time taken to process a sample if this were not performed.  
One way of improving the chromatographic resolution of the compounds would be to look 
at alternative modulators to the one used in this thesis.  It has been shown, by colleagues, 
that the Zoex cryogenic modulator reduces tailing in the second dimension, improving peak 
shapes and the ability to resolve closely eluting compounds.   Newer designs for the time of 
flight mass spectrometer are also becoming available, such as the BenchTOF-HD and 
BenchTOF-Select systems now sold by ALMSCO, a subsidiary of Markes International 
Ltd.   The BenchTOF-Select allows the energy of the electrons in the ionisation source to 
be modified thus providing even greater selectivity. 
Extending the modulation period would resolve the issues with gestrinone eluting at the 
point when the modulator switches from one process to another.  Careful consideration will 
need to be given to what influence this has on all the steroids, as extending the modulation 
period will result in larger slices of the first dimension eluent being collected together. 
An alternative approach to comprehensive chromatography would be to utilise high 
resolution/accurate mass MS systems that are becoming increasingly affordable. A high 
resolution/accurate mass system coupled to molecular imprinted polymers, could provide 
an opportunity to build on this study for steroid analysis. The specificity would result from 
accurate mass measurement of the molecular ions.   
It should be noted that since conducting these experiments the WADA specifications for 
anabolic androgenic steroids have changed. It changed from a level of 10 ng/mL in 2010 to 
5 ng/mL in 2012.  It is therefore recommended that studies with prohormones and designer 
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steroids be replicated with the knowledge of this lower threshold value and that the method 
is evaluated by spiking urine samples obtained from humans. 
6.4. Future Work  
The results presented in this thesis and the publication to be found in Appendix A4 have 
illustrated that the coupling of MIPs (tailored to the target family of compounds of interest) 
with comprehensive gas chromatography/mass spectrometry provides a method that is 
capable of extracting, resolving and quantifying a cohort of unconjugated, underivatised 
steroids (prohormones and designer steroids) from synthetic urine, at concentrations that 
are appropriate for sports testing.  The key to the successful application of this method will 
be its coupling with a method that hydrolyses conjugated steroids making them available 
for MIPs extraction and separation by GCxGC/TOFMS. It is understood that this work will 
form the basis of future application to WADA by the co-authors of the publication. 
The ability to screen and resolve a wide range of very similar steroids has the potential to 
be applied in fields well beyond those explored during this thesis.   For example, the results 
generated in this thesis have already formed the basis of: 
i.       an application to BBSRC, to investigate the level of stress hormones released by 
fish.  In partnership with the University of West of Scotland and the University 
of Bath the bid has been reviewed and was deemed “excellent and fundable” 
and the applicants await the decision of the funding panel. The bid title was 
“Trace detection of steroidal compounds in the aqueous environment using 
molecularly imprinted polymers and comprehensive GCxGC and LCxLC 
detection.” 
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ii.       discussions with Prof. Malcolm Mason (Cardiff University / Cancer Bank 
Wales) with the view to a joint application to the Cancer Research UK 
Biomarker Project Panel, in November, to evaluate the performance of the 
method developed in this thesis for screening urine samples for prostate cancer. 
The projects named above are probably just the beginning of the journey for MIPs coupled 
with comprehensive chromatography. Indeed, feedback already received on the publication 
has indicated that there may be a significant range of applications in environmental 
monitoring. In addition, as intimated in the introduction to the thesis, the method developed 
could also be adapted to have applications in nutritional supplement testing. 
Whilst the Leco Pegasus IV has provided the analytical basis of the studies reported in this 
thesis, its high cost and use of liquid nitrogen in the cryo-modulator will tend to preclude its 
adoption in mainstream laboratories.  In contrast, add-on systems such as the Capillary 
Flow Technologies developed by Agilent or the Zoex cryo-modulator and associated 
software enable existing laboratory GC-MS systems to be effectively upgraded.  These are 
not without limitations, but should be explored as they will provide niche solutions in 
specific application areas at a lower cost.  
6.5. Summary 
In summary, the thesis has described the development of a screening method capable of 
detecting multiple, unconjugated prohormones, steroids and designer steroids in urine that 
are structurally similar and commercially relevant at concentration levels that are applicable 
to sports testing.  A molecularly imprinted solid phase extraction clean-up step was 
employed prior to injection on a GCxGC/MS. Significant improvements over commercial 
C-18 material were observed. The nature of this study also removes the need for sample 
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derivatisation, which speeds up the screening process. However, as the method is based on 
the extraction and separation of unconjugated steroids, for the technique to be adopted by 
the sports testing community and for it to meet the requirements of the WADA MRPL it 
will either require a suitable hydrolysis method to be developed or the sensitivity of the 
method will need to be further improved.  Potential improvements have been suggested.  
It is interesting to ponder whether THG would potentially have been detected sooner, if the 
technique developed here had been available along with a suitable hydrolysis method?  
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Appendix A1.1   
Mechanisms proposed for the formation of the major fragment 
ions for the derivatised prohormones. 
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2.  4-estrene-3b,17b-diol, bis-(O-tert.-butyldimethylsilyl)- 
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3.   5(10)-estrene-3b,17-dione,bis-(O-tert.-butyldimethylsilyl)- 
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4.   4-androstene-3b,17b-diol, bis-(O-tert.-butyldimethylsilyl)- 
H3C
H3C
O
Si
H3C
H3C
O
Si
H3C
O
Si
H3C
H3C
H
O
O
Si
Si
H3C
H3C
O
Si
m/z= 384
m/z= 384
m/z= 386
m/z= 386
H3C
H3C
O
Si
m/z= 327
rearangement
H
m/z= 518
H3C
H3C
H
O
O
Si
Si H3C
H3C
H
O
O
Si
Si
+
m/z= 461
- H2
H
H
Resononce 
stabilisation
of carbocation
m/z= 518
H3C
O
Si
m/z=369
CH3
H3C
CH3
O
Si
H
H
H
H
m/z=249
H
H H
CH3
m/z=231
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5.   5(6)-androstene-3b,17b-diol, bis-(O-tert.-butyldimethylsilyl)- 
H3C
H3C
O
Si
H3C
H3C
H
O
Si
H3C
H
H
O
Si
H3C
H3C
H
O
O
Si
Si
Si+
H3C
H3C
O
Si
m/z= 385
m/z= 385
m/z= 387
m/z= 387
H
H3C
H3C
O
Si
m/z= 329
H
+ rearangement
m/z=56
m/z= 131
H3C
H3C
OH
Si
H
H
m/z=253
m/z=75
H
+
m/z= 518
O
H3C
H3C
H
O
O
Si
Si H3C
H3C
H
O
O
Si
Si
+
m/z= 461
- H2
H3C
H3C
O
Si
m/z= 385
- H2
H
H
Resononce 
stabilisation
of carbocation
m/z= 518
H
H
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6.   5a-androstane-3b,17b-diol, bis-(O-tert.-butyldimethylsilyl)- 
H3C
H3C
O
Si
H3C
H3C
H
O
Si
H3C
H
H
O
Si
H3C
H3C
H
O
O
Si
Si
Si+
H3C
H3C
O
Si
m/z= 387
m/z= 387
m/z= 389
m/z= 389
H
H3C
H3C
O
Si
m/z= 331
H
+ rearangement
m/z=56
m/z= 131
H3C
H3C
OH
Si
H
H
m/z=255
m/z=75
H
+
m/z= 518
O
H3C
H3C
H
O
O
Si
Si H3C
H3C
H
O
O
Si
Si
+
m/z= 463
- H2
H3C
H3C
O
Si
m/z= 387
- H2
H
H
H
H
Resononce 
stabilisation
of carbocation
m/z= 520
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7.   Nandrolone, bis-(O-tert.-butyldimethylsilyl)- 
H3C
O
O
Si
Si
m/z=  504
H
H
HH
- H2
H3C
O
Si
H
H
m/z=  502
H3C
O
O
Si
Si
+
m/z=  445
H3C
O
O
Si
Si
+m/z=  371
H3C
O
SiH
H3C
O
Si
- H2
- H2
m/z=  369
m/z=  369
H
H
H
H3C
O
Si
H
+
m/z=  313
H3C
O
SiH
+
m/z=  313
H
H
Resononce 
stabilisation
of carbocation
H
O Si
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8.  Testosterone, bis-(O-tert.-butyldimethylsilyl)- 
H3C
H3C
O
Si
H3C
H3C
O
Si
H3C
H
O
Si
H3C
H3C
H
O
O
Si
Si
Si+
H3C
H3C
O
Si
m/z= 383
m/z= 383
m/z= 385
m/z= 385
H
H3C
H3C
O
Si
m/z= 327
H
+ rearangement
m/z=56
m/z= 131
H
m/z= 518
O
H3C
H3C
H
O
O
Si
Si H3C
H3C
O
O
Si
Si
+
m/z= 459
- H2
H3C
H3C
O
Si
m/z= 383
- H2
H
H
H
Resononce 
stabilisation
of carbocation
m/z= 518
H
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Appendix A1.2   
Mechanisms proposed for the formation of the major fragment 
ions for underivatised prohormones 
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 1.  5(10)-estrene-3b,17b-diol  
O
HO
C18H28O2
Exact Mass: 276.21
Mol. Wt.: 276.41
HO
.
H
H
C18H26O
Exact Mass: 258.2
Mol. Wt.: 258.4
-H2O
C18H24
Exact Mass: 240.19
Mol. Wt.: 240.38
-H2O
. .
CH3
C17H21
•+
Exact Mass: 225.16
Mol. Wt.: 225.35
HO
C15H19
•+
Exact Mass: 199.15
Mol. Wt.: 199.31
first step .CH3
second step 
retro diels alder
m/z=276 m/z=258
m/z=240 m/z=225
m/z=199
 
 
2.   4-estrene-3b,17b-diol 
O
HO
H
H
HO
H
C15H22O
Exact Mass: 218.17
Mol. Wt.: 218.33
C15H20
Exact Mass: 200.16
Mol. Wt.: 200.32
-H2O
C14H17
+
Exact Mass: 185.13
Mol. Wt.: 185.28
. .
.
C18H28O2
Exact Mass: 276.21
Mol. Wt.: 276.41
m/z=276 m/z=218
m/z=200
m/z=185
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3.   5(10)-estrene-3b,17-dione 
O
O
5(10)-estrene-3b,17b-dione
C18H24O2
Exact Mass: 272.18
Mol. Wt.: 272.38
O
C15H20O
Exact Mass: 216.15
Mol. Wt.: 216.32
O
-H.
H
C15H19O
+
Exact Mass: 215.14
Mol. Wt.: 215.31
.
m/z=272
m/z=216
m/z=215
 
 
4.    4-androstene-3b,17b-diol 
HO
OH
4-androstene-3b,17b-diol
OH
-H2O
OH
H
OH
C15H24O
Exact Mass: 220.18
Mol. Wt.: 220.35
C19H28O
Exact Mass: 272.21
Mol. Wt.: 272.43
C18H25O
+
Exact Mass: 257.19
Mol. Wt.: 257.39
C19H30O2
Exact Mass: 290.22
Mol. Wt.: 290.44
- H2O
C15H22
Exact Mass: 202.17
Mol. Wt.: 202.34
C14H19
+
Exact Mass: 187.15
Mol. Wt.: 187.3
m/z=290
m/z=272 m/z=257
m/z=220 m/z=202 m/z=187
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5.   DHEA  
HO
O
DHEA
HO
O O
O
-H2O
-H2O
C18H25O2
+
Exact Mass: 273.18
Mol. Wt.: 273.39
C18H23O
+
Exact Mass: 255.17
Mol. Wt.: 255.37
C19H26O
Exact Mass: 270.2
Mol. Wt.: 270.41
O
C18H23O
+
Exact Mass: 255.17
Mol. Wt.: 255.37
O
H
H
H
C17H17O
+
Exact Mass: 237.13
Mol. Wt.: 237.32
C19H28O2
Exact Mass: 288.21
Mol. Wt.: 288.42
1) -CH4
2) -H2
O
C16H22
Exact Mass: 214.17
Mol. Wt.: 214.35
m/z= 270
m/z=255 m/z=237
m/z=214
H
C16H21
+
Exact Mass: 213.16
Mol. Wt.: 213.34
m/z=213
- H
m/z= 288
m/z= 273
m/z= 255
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6.   5(6)-androstene-3b,17b-diol 
HO
OH
5(6)-androstene-3b,17b-diol
m/z=290
OH
-H2O
OH
-H2O
HO
C19H28O
•+
Exact Mass: 272.21
Mol. Wt.: 272.42
C18H25O
+
Exact Mass: 257.19
Mol. Wt.: 257.39
C18H23
+
Exact Mass: 239.18
Mol. Wt.: 239.37
C16H24O
•+
Exact Mass: 232.18
Mol. Wt.: 232.36
C16H20
•+
Exact Mass: 212.16
Mol. Wt.: 212.33
C15H25
+
Exact Mass: 205.2
Mol. Wt.: 205.36
m/z=272 m/z=257
m/z=239
m/z=232
m/z=212
m/z=205
 
7.   5a-androstane-3b,17-diol  
-H2O
HO
OH
5a-androstane-3b,17b-diol
m/z=292
HO
m/z= 274
HO
m/z= 259
-H2O
m/z= 241
HO
m/z=234 m/z=215
HO
m/z=233
-H2O
C16H25O
+
Exact Mass: 233.19
Mol. Wt.: 233.37
C19H30O
Exact Mass: 274.23
Mol. Wt.: 274.44
C18H27O
+
Exact Mass: 259.21
Mol. Wt.: 259.41
C18H25
+
Exact Mass: 241.2
Mol. Wt.: 241.39
C16H26O
Exact Mass: 234.2
Mol. Wt.: 234.38
C16H23
+
Exact Mass: 215.18
Mol. Wt.: 215.35
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8.   5a-androstane-3,17-dione 
O
O
5a-androstane-3,17-dione
m/z= 288
O
O
+
O
C16H24O
•+
Exact Mass: 232.18
Mol. Wt.: 232.36
C15H21O
+
Exact Mass: 217.16
Mol. Wt.: 217.33
C12H18
Exact Mass: 162.14
Mol. Wt.: 162.27
C11H15
+
Exact Mass: 147.12
Mol. Wt.: 147.24
m/z=232
m/z=217
m/z=162 m/z=147
 
9. Nandrolone 
O
OH
C18H26O2
Exact Mass: 274.19
Mol. Wt.: 274.4
-H2O
O
C18H24O
Exact Mass: 256.18
Mol. Wt.: 256.38
O
H
-H.
O
C15H19O
+
Exact Mass: 215.14
Mol. Wt.: 215.31
O
H
H
O
H
H
O
H
H
O
Tautomery
m/z=274 m/z=256
m/z=215
m/z=110
HO
C7H10O
Exact Mass: 110.07
Mol. Wt.: 110.15
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10.    5(6)-androstene-3,17-dione 
H3C
H3C
O
O
H3C
H3C
O
O
H3C
H3C
O
O
H
H3C
CH3
O
O H
CH3
O CH3
O
+
C8H12O
•+
Exact Mass: 124.09
Mol. Wt.: 124.18
5(6)androstene-3,17-dione
C19H26O2
Exact Mass: 286.19
Mol. Wt.: 286.41
CH3
O
H
H
CH3
O
C10H12O
Exact Mass: 148.09
Mol. Wt.: 148.2
-H2
m/z=286
m/z=124
m/z=148
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11.   Testosterone 
H3C
H3C
OH
O
C19H28O2
•+
Exact Mass: 288.21
Mol. Wt.: 288.42
H3C
H3C
OH
O
H3C
H3C
OH
O
H
H3C
CH3
OHO
C19H28O2
•+
Exact Mass: 288.21
Mol. Wt.: 288.42
H
CH3
O CH3
OH+
radical rearrangement
C8H12O
•+
Exact Mass: 124.09
Mol. Wt.: 124.18
H3C
H3C
OH
O
H OH
O
ionic fragmentation
-CH3
C18H25O2
+
Exact Mass: 273.18
Mol. Wt.: 273.39
H3C
H3C
OH
O
H
H3C
H3C
OH
H
ionic rearrangement
C17H26O
•+
Exact Mass: 246.2
Mol. Wt.: 246.39
- H2C=C=O H3C
H3C
H
H
-H2O
CH3
O
m/z=288 m/z=288
m/z=124
m/z=273
m/z=246
C17H24
•+
Exact Mass: 228.19
Mol. Wt.: 228.37
m/z=228
H
H
H3C
H3C
OH
O
H
H
H
H
H
H3C
OH
H
+
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12.   1,4-androstadiene-3,17-dione 
O
O
m/z= 284
O
O
H
O
O
O
m/z= 160
O
m/z=  159
O
m/z=  145
O
O O
-H2
O
H
H
m/z= 91 m/z= 77  
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Appendix A1.3   
Mechanisms proposed for the formation of the major fragment 
ions of the designer steroids 
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 1.    Epitestosterone 
H3C
H3C
OH
O
C19H28O2
•+
Exact Mass: 288.21
Mol. Wt.: 288.42
H3C
H3C
OH
O
H3C
H3C
OH
O
H
H3C
CH3
OHO
C19H28O2
•+
Exact Mass: 288.21
Mol. Wt.: 288.42
H
CH3
O CH3
OH+
radical rearrangement C8H12O
•+
Exact Mass: 124.09
Mol. Wt.: 124.18
H3C
H3C
OH
O
H OH
O
ionic fragmentation
-CH3
C18H25O2
+
Exact Mass: 273.18
Mol. Wt.: 273.39
H3C
H3C
OH
O
H
H3C
H3C
OH
H
ionic rearrangement
C17H26O
•+
Exact Mass: 246.2
Mol. Wt.: 246.39
- H2C=C=O H3C
H3C
H
H
-H2O
C
H
3
O
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2.    XTREN 
O
H
H
H
C19H26O
Exact Mass: 270.2
Mol. Wt.: 270.41
O
H
H
H
O
H
H
H
C15H17O
+
Exact Mass: 213.13
Mol. Wt.: 213.29
+
O
H
O
H
H
H
O
H H
+
C19H26O
•+
Exact Mass: 270.2
Mol. Wt.: 270.41
C19H26O
•+
Exact Mass: 270.2
Mol. Wt.: 270.41
C12H14O
•+
Exact Mass: 174.1
Mol. Wt.: 174.24
C16H20O
Exact Mass: 228.15
Mol. Wt.: 228.33
 
3.   Trenazone 
O
OH
H
H
trenazone
m/z= 272 O
H
H
m/z= 254
O
H
H
H2O
O
H
H
m/z= 214
O
H
m/z= 213 m/z= 105 m/z= 91 m/z= 77
m/z = 239
C104H124O7
•5+
Exact Mass: 1484.93
Mol. Wt.: 1486.09
C18H22O
Exact Mass: 254.17
Mol. Wt.: 254.37
C15H18O
Exact Mass: 214.14
Mol. Wt.: 214.3
 
 275 
 
4.   Epistane 
epistane
H
H
H
OH
H
S
C20H32OS
Exact Mass: 320.22
Mol. Wt.: 320.53
H
H
HS
H
-H2O
C20H30S
Exact Mass: 302.21
Mol. Wt.: 302.52
H
H
HS
C19H27S
+
Exact Mass: 287.18
Mol. Wt.: 287.48
 
 
 
5.   Gestrinone 
O
OH
H
H
gestrinone
m/z= 308 O
H
H
-H2O
O
H
H
m/z= 261
m/z=  291
HO
H
H
m/z= 227
C21H24O2
Exact Mass: 308.18
Mol. Wt.: 308.41
C21H22O
Exact Mass: 290.17
Mol. Wt.: 290.4
C19H17O
+
Exact Mass: 261.13
Mol. Wt.: 261.34
C16H19O
+
Exact Mass: 227.14
Mol. Wt.: 227.32  
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6.   THG 
C21H28O2
Exact Mass: 312.21
Mol. Wt.: 312.45
O
HO
H
H
O
H
- H2O
O
-
CH2CH3
C21H26O
Exact Mass: 294.2
Mol. Wt.: 294.43
C19H21O
+
Exact Mass: 
265.16
Mol. Wt.: 265.37
O
HO
H
H
+
H
O
HO
H
H
H H
H
O
H
H
HO
H
H
+
C17H20O
Exact Mass: 240.15
Mol. Wt.: 240.34
O
H
H
rearangement
C17H20O
Exact Mass: 240.15
Mol. Wt.: 240.34
O
H
H
C17H20O
Exact Mass: 240.15
Mol. Wt.: 240.34
O
H
H
C15H15O
+
Exact Mass: 211.11
Mol. Wt.: 211.28
C16H18O
Exact Mass: 226.14
Mol. Wt.: 226.31
O
O
H
H
H
O
O
H
H
H
H
O
HO
H
H
H
H
C16H19O
+
Exact Mass: 227.14
Mol. Wt.: 227.32
+rearangment
H
O
C14H14O
Exact Mass: 198.1
Mol. Wt.: 198.26
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7.   Methyltestosterone  
O
OH
H
H
H
C20H30O2
Exact Mass: 302.22
Mol. Wt.: 302.45
O
H
H
H
C20H28O
Exact Mass: 284.21
Mol. Wt.: 284.44
- H2O
O
OH
H
H
H
C17H24O
Exact Mass: 244.18
Mol. Wt.: 244.37
O
H
H
H
C16H21O
+
Exact Mass: 229.16
Mol. Wt.: 229.34
O
OH
H
H
H
O
OH
H
H
H
O
OH
H
HH
O
OH
HH
- H.
O
OH
HH=
O
OH
HH
H
OH
H
+
C9H14O
Exact Mass: 138.1
Mol. Wt.: 138.21
O
H
H
H
H
O
H
C8H12O
Exact Mass: 124.09
Mol. Wt.: 124.18
 - CH3
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Appendix A2    
Plots of the peak areas obtained for the quantitation ion for each 
of the prohormones over the injection msss range of 50 to 500 pg 
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Table of Contents 
Figure A2. a)-c). Plots of the peak areas obtained for the quantitation ion for each of the 
prohormones: 5(10)-estrene-3b,17b-diol, 4-estrene-3b,17b-diol, 5(10)-
estrene-3,17-dione,  over the injection mass range of 50 to 500 pg.  
Figure A2. d)-f). Plots of the peak areas obtained for the quantitation ion for each of the 
prohormones: 4-androstene-3b,17b-diol, DHEA, 5(6)-androstene-
3b,17b-diol, over the injection mass range of 50 to 500 pg.  
Figure A2. g)-i). Plots of the peak areas obtained for the quantitation ion for each of the 
prohormones: 5a-androstane-3b,17b-diol, 5a-androstane-3,17-dione, 
nandrolone, over the injection mass range of 50 to 500 pg.  
Figure A2.  j)-l). Plots of the peak areas obtained for the quantitation ion for each of the 
prohormones: 5(6)-androstene-3,17-dione, testosterone, 1,4-
androstane-3,17-dione, over the injection mass range of 50 to 500 pg.  
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Figure A2. a)-c). Plots of the peak areas obtained for the quantitation ion for each of the 
prohormones over the injection mass range of 50 to 500 pg.  
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Figure A2. d)-f).   Plots of the peak areas (arbitrary units) obtained for the quantitation ion for each 
of the prohormones, over the injection mass range of 50 to 500 pg.  
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Figure A2. g)-i)    Plots of the peak areas (arbitrary units) obtained for the quantitation ion for each 
of the prohormones, over the injection mass range of 50 to 500 pg.  
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Figure A2.  j)-l) Plots of the peak areas obtained for the quantitation ion for each of the 
prohormones, over the injection mass range of 50 to 500 pg.  
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Appendix A3   
Plots of the peak areas obtained for the quantitation ion of each 
prohormones and designer steroids over the mass range of 25 to 
250 pg 
Plots of the ratio of the peak areas obtained for the quantitation 
ion for each of the prohormones and designer steroids versus the 
internal standard, over the mass range 25 to 100 pg 
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Figure A3.1  a)-c)   Plots of the peak areas obtained for the quantitation ion for each of the 
prohormones: 5(10)-estrene-3b,17b-diol [1], 4-estrene-3b,17b-diol 
[2], 5(10)-estrene-3,17-dione [3], over the mass range 25 to 250 pg. 
Figure A3.1  d)-f)    Plots of the peak areas obtained for the quantitation ion for each of the 
prohormones: 4-androstene-3b,17b-diol [4], DHEA [5], 5(6)-
androstene-3b,17b-diol [6], over the mass range of 25 to 250 pg. 
Figure A3.1  g)-i) Plots of the peak areas obtained for the quantitation ion for each of the 
prohormones: 5a-androstane-3b,17b-diol [7], 5a-androstane-3,17-
dione [8], nandrolone [9] over the mass range of 25 to 250 pg. 
Figure A3.1  j)-l) Plots of the peak areas obtained for the quantitation ion for each of the 
prohormones: 5(6)-androstene-3,17-dione [10], testosterone [11], 1,4-
androstane-3,17-dione [12] over the mass range of 25 to 250 pg. 
Figure A3.2. a)-c) Plots of the ratio of the peak areas obtained for the quantitation ion 
for each of the prohormones: 5(10)-estrene-3b,17b-diol [1], 4-estrene-
3b,17b-diol [2], 5(10)-estrene-3,17-dione [3], versus the internal 
standard, over the mass range 25 to 100 pg. 
Figure A3.2  d)-f) Plots of the ratio of the peak areas obtained for the quantitation ion 
for each of the prohormones:  4-androstene-3b,17b-diol [4], DHEA 
[5], 5(6)-androstene-3b,17b-diol [6], versus the internal standard, 
over the mass range of 25 to 100 pg. 
Figure A3.2 g)-i) Plots of the ratio of the peak areas obtained for the quantitation ion 
for each of the prohormones:  5a-androstane-3b,17b-diol [7], 5a-
androstane-3,17-dione [8], nandrolone [9], versus the internal 
standard, over the mass range of 25 to 100 pg. 
Figure A3.2  j)-l) Plots of the ratio of the peak areas obtained for the quantitation ion 
for each of the prohormones: 5(6)-androstene-3,17-dione [10], 
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testosterone [11], 1,4-androstane-3,17-dione [12], versus the internal 
standard,  over the mass range of 25 to 100 pg. 
Figure A3.3   a)-c) Plots of the peak areas obtained for the quantitation ion for each of the 
designer steroids:  epitestosterone, Xtren and trenazone, over the mass 
range 25 to 500 pg. 
Figure A3.3   a)-c) Plots of the peak areas obtained for the quantitation ion for each of the 
designer steroids:  epistane, gestrinone and THG, over the mass range 
25 to 500 pg. 
Figure A3.4   a)-c) Plots of the peak areas obtained for the quantitation ion for each of the 
designer steroids:  epitestosterone, Xtren and trenazone, over the mass 
range 25 to 500 pg (data point at 250 pg has been removed). 
Figure A3.4  a)-c) Plots of the ratio of the peak areas obtained for the quantitation ion 
for each of the designer steroids: epistane [16],  gestrinone [17],  
THG [18], versus the internal standard,  over the mass range of 25 to 
100 pg. 
Figure A3.4  d)-f) Plots of the ratio of the peak areas obtained for the quantitation ion 
for each of the designer steroids : epitestosterone [13], Xtren [14], 
trenazone [15], versus the internal standard,  over the mass range of 
25 to 100 pg. 
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Figure A3.1  a)-c)    Plots of the  peak areas obtained for the quantitation ion for each of the 
prohormones:  5(10)-estrene-3b,17b-diol [1], 4-estrene-3b,17b-diol [2], 
5(10)-estrene-3,17-dione [3], over the mass range 25 to 250 pg. 
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Figure A3.1  d)-f)    Plots of the peak areas obtained for the quantitation ion for each of the 
prohormones:  4-androstene-3b,17b-diol [4], DHEA [5], 5(6)-androstene-
3b,17b-diol [6], over the mass range of 25 to 250 pg. 
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Figure A3.1  g)-i) Plots of the peak areas obtained for the quantitation ion for each of the 
prohormones: 5a-androstane-3b,17b-diol [7], 5a-androstane-3,17-dione [8], 
nandrolone [9] over the mass range of 25 to 250 pg. 
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Figure A3.1  j)-l) Plots of the peak areas obtained for the quantitation ion for each of the 
prohormones: 5(6)-androstene-3,17-dione [10], testosterone [11], 1,4-
androstane-3,17-dione [12] over the mass range of 25 to 250 pg. 
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Figure A3.2. a)-c) Plots of the ratio of the peak areas obtained for the quantitation ion for each 
of the prohormones:  5(10)-estrene-3b,17b-diol [1], 4-estrene-3b,17b-diol 
[2], 5(10)-estrene-3,17-dione [3], versus the internal standard, over the mass 
range 25 to 100 pg. 
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Figure A3.2  d)-f) Plots of the ratio of the peak areas obtained for the quantitation ion for each 
of the prohormones:  4-androstene-3b,17b-diol [4], DHEA [5], 5(6)-
androstene-3b,17b-diol [6], versus the internal standard, over the mass 
range of 25 to 100 pg. 
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Figure A3.2 g)-i) Plots of the ratio of the peak areas obtained for the quantitation ion for each 
of the prohormones: 5a-androstane-3b,17b-diol [7], 5a-androstane-3,17-
dione [8], nandrolone [9], versus the internal standard, over the mass range 
of 25 to 100 pg. 
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Figure A3.2  j)-l) Plots of the ratio of the  peak areas obtained for the quantitation ion for each 
of the prohormones: 5(6)-androstene-3,17-dione [10], testosterone [11], 1,4-
androstane-3,17-dione [12], versus the internal standard,  over the mass 
range of 25 to 100 pg. 
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Figure A3.3   a)-c) Plots of the peak areas obtained for the quantitation ion for each of the 
designer steroids: epitestosterone [13], Xtren [14] and trenazone [15], over 
the mass range 25 to 500 pg. 
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Figure A3.3   d)-f) Plots of the peak areas obtained for the quantitation ion for each of the 
designer steroids: epistane[16], gestrinone [17] & THG [18], over the mass 
range 25 to 500 pg. 
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Figure A3.4  a)-c) Plots of the ratio of the peak areas obtained for the quantitation ion for each 
of the designer steroids : epitestosterone [13], Xtren [14], trenazone [15], 
versus the internal standard,  over the mass range of 25 to 100 pg. 
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Figure A3.4  d)-f) Plots of the ratio of the peak areas obtained for the quantitation ion for each 
of the designer steroids: epistane [16],  gestrinone [17],  THG [18], versus 
the internal standard,  over the mass range of 25 to 100 pg. 
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